sample_name	library_ID	title	library_strategy	library_source	library_selection	library_layout	platform	instrument_model	design_description	filetype	filename
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_01_100_1_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_01_100_1_1_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Belinostat (PXD101)	E1504_01_100_1_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_01_100_1_1_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Danusertib (PHA-739358)	E1504_01_100_1_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_01_100_1_1_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SNS-314 Mesylate	E1504_01_100_1_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_01_100_1_1_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM JNJ-7706621	E1504_01_100_1_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_01_100_1_1_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT129202	E1504_01_100_1_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_01_100_1_1_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-14361	E1504_01_100_1_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_01_100_1_1_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A HCl	E1504_01_100_1_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_01_100_1_1_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-907	E1504_01_100_1_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_01_100_1_1_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CI994 (Tacedinaline)	E1504_01_100_1_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_01_100_1_1_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entacapone	E1504_01_100_1_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_01_100_1_1_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_01_100_1_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_01_100_1_1_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_01_100_1_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_01_100_1_1_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Iniparib (BSI-201)	E1504_01_100_1_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_01_100_1_1_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Mocetinostat (MGCD0103)	E1504_01_100_1_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_01_100_1_1_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid sodium salt (Sodium valproate)	E1504_01_100_1_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_01_100_1_1_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Ruxolitinib (INCB018424)	E1504_01_100_1_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_01_100_1_1_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Hesperadin	E1504_01_100_1_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_01_100_1_1_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM LY2784544	E1504_01_100_1_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_01_100_1_1_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NVP-BSK805 2HCl	E1504_01_100_1_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_01_100_1_1_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MK-5108 (VX-689)	E1504_01_100_1_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_01_100_1_1_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG108	E1504_01_100_1_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_01_100_1_1_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sodium Phenylbutyrate	E1504_01_100_1_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_01_100_1_1_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_01_100_1_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_01_100_1_1_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_01_100_1_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_01_100_1_1_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-24781 (Abexinostat)	E1504_01_100_1_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_01_100_1_1_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SRT1720	E1504_01_100_1_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_01_100_1_1_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYC116	E1504_01_100_1_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_01_100_1_1_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resveratrol	E1504_01_100_1_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_01_100_1_1_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EX 527 (Selisistat)	E1504_01_100_1_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_01_100_1_1_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1776 free base	E1504_01_100_1_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_01_100_1_1_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101209	E1504_01_100_1_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_01_100_1_1_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM M344	E1504_01_100_1_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_01_100_1_1_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Baricitinib (LY3009104, INCB028050)	E1504_01_100_1_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_01_100_1_1_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine (2-PCPA) HCl	E1504_01_100_1_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_01_100_1_1_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_01_100_1_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_01_100_1_1_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_01_100_1_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_01_100_1_1_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM LAQ824 (Dacinostat)	E1504_01_100_1_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_01_100_1_1_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM INO-1001	E1504_01_100_1_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_01_100_1_1_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ENMD-2076	E1504_01_100_1_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_01_100_1_1_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Droxinostat	E1504_01_100_1_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_01_100_1_1_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Azacitidine	E1504_01_100_1_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_01_100_1_1_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZ 960	E1504_01_100_1_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_01_100_1_1_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resminostat	E1504_01_100_1_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_01_100_1_1_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET151 (GSK1210151A)	E1504_01_100_1_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_01_100_1_1_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM WHI-P154	E1504_01_100_1_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_01_100_1_1_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Aminobenzamide	E1504_01_100_1_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_01_100_1_1_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_01_100_1_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_01_100_1_1_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_01_100_1_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_01_100_1_1_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quisinostat (JNJ-26481585)	E1504_01_100_1_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_01_100_1_1_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Alisertib (MLN8237)	E1504_01_100_1_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_01_100_1_1_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-101	E1504_01_100_1_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_01_100_1_1_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aurora A Inhibitor I	E1504_01_100_1_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_01_100_1_1_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-34051	E1504_01_100_1_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_01_100_1_1_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYT387	E1504_01_100_1_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_01_100_1_1_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TAK-901	E1504_01_100_1_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_01_100_1_1_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550,Tasocitinib)	E1504_01_100_1_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_01_100_1_1_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34	E1504_01_100_1_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_01_100_1_1_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Procainamide HCl	E1504_01_100_1_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_01_100_1_1_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_01_100_1_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_01_100_1_1_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_01_100_1_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_01_100_1_1_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rucaparib (AG-014699,PF-01367338)	E1504_01_100_1_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_01_100_1_1_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AT9283	E1504_01_100_1_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_01_100_1_1_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Decitabine	E1504_01_100_1_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_01_100_1_1_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PHA-680632	E1504_01_100_1_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_01_100_1_1_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM KW-2449	E1504_01_100_1_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_01_100_1_1_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubacin	E1504_01_100_1_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_01_100_1_1_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AMG-900	E1504_01_100_1_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_01_100_1_1_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM WP1066	E1504_01_100_1_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_01_100_1_1_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM S-Ruxolitinib (INCB018424)	E1504_01_100_1_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_01_100_1_1_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550) Citrate	E1504_01_100_1_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_01_100_1_1_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_01_100_1_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_01_100_1_1_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_01_100_1_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_01_100_1_1_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MLN8054	E1504_01_100_1_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_01_100_1_1_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-490 (Tyrphostin B42)	E1504_01_100_1_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_01_100_1_1_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PFI-1 (PF-6405761)	E1504_01_100_1_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_01_100_1_1_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC1568	E1504_01_100_1_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_01_100_1_1_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1480	E1504_01_100_1_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_01_100_1_1_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AR-42	E1504_01_100_1_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_01_100_1_1_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101348 (SAR302503)	E1504_01_100_1_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_01_100_1_1_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sirtinol	E1504_01_100_1_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_01_100_1_1_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX2	E1504_01_100_1_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_01_100_1_1_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD2461	E1504_01_100_1_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_01_100_1_1_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_01_100_1_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_01_100_1_1_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_01_100_1_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_01_100_1_1_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 447439	E1504_01_100_1_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_01_100_1_1_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Barasertib (AZD1152-HQPA)	E1504_01_100_1_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_01_100_1_1_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2-Methoxyestradiol (2-MeOE2)	E1504_01_100_1_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_01_100_1_1_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pracinostat (SB939)	E1504_01_100_1_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_01_100_1_1_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Givinostat (ITF2357)	E1504_01_100_1_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_01_100_1_1_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quercetin	E1504_01_100_1_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_01_100_1_1_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT137690	E1504_01_100_1_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_01_100_1_1_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CEP-33779	E1504_01_100_1_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_01_100_1_1_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Romidepsin (FK228, Depsipeptide)	E1504_01_100_1_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_01_100_1_1_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM XL019	E1504_01_100_1_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_01_100_1_1_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_01_100_1_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_01_100_1_1_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_02_100_1_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_02_100_1_2_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Zebularine	E1504_02_100_1_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_02_100_1_2_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM OG-L002	E1504_02_100_1_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_02_100_1_2_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TMP269	E1504_02_100_1_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_02_100_1_2_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 39923 HCl	E1504_02_100_1_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_02_100_1_2_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Veliparib (ABT-888)	E1504_02_100_1_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_02_100_1_2_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CX-6258 HCl	E1504_02_100_1_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_02_100_1_2_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2,4-Pyridinedicarboxylic Acid	E1504_02_100_1_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_02_100_1_2_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ITSA-1	E1504_02_100_1_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_02_100_1_2_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AGK2	E1504_02_100_1_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_02_100_1_2_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Oxamflatin	E1504_02_100_1_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_02_100_1_2_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_02_100_1_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_02_100_1_2_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_02_100_1_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_02_100_1_2_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Deazaneplanocin A (DZNeP)	E1504_02_100_1_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_02_100_1_2_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC-CBP30	E1504_02_100_1_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_02_100_1_2_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ004777	E1504_02_100_1_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_02_100_1_2_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SMI-4a	E1504_02_100_1_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_02_100_1_2_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM FG-4592	E1504_02_100_1_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_02_100_1_2_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BMN 673	E1504_02_100_1_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_02_100_1_2_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Garcinol	E1504_02_100_1_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_02_100_1_2_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine hemisulfate	E1504_02_100_1_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_02_100_1_2_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Salermide	E1504_02_100_1_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_02_100_1_2_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suramin 6Na	E1504_02_100_1_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_02_100_1_2_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_02_100_1_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_02_100_1_2_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_02_100_1_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_02_100_1_2_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ-6438	E1504_02_100_1_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_02_100_1_2_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MM-102	E1504_02_100_1_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_02_100_1_2_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM OTX015	E1504_02_100_1_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_02_100_1_2_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX 01294	E1504_02_100_1_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_02_100_1_2_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Panobinostat (LBH589)	E1504_02_100_1_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_02_100_1_2_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ5676	E1504_02_100_1_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_02_100_1_2_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Splitomicin	E1504_02_100_1_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_02_100_1_2_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid	E1504_02_100_1_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_02_100_1_2_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC-1293	E1504_02_100_1_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_02_100_1_2_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-278	E1504_02_100_1_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_02_100_1_2_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_02_100_1_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_02_100_1_2_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_02_100_1_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_02_100_1_2_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM C646	E1504_02_100_1_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_02_100_1_2_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1027	E1504_02_100_1_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_02_100_1_2_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC669	E1504_02_100_1_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_02_100_1_2_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UPF 1069	E1504_02_100_1_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_02_100_1_2_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Trichostatin A (TSA)	E1504_02_100_1_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_02_100_1_2_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM GSK J4 HCl	E1504_02_100_1_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_02_100_1_2_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-210	E1504_02_100_1_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_02_100_1_2_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nicotinamide	E1504_02_100_1_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_02_100_1_2_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Anacardic acid	E1504_02_100_1_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_02_100_1_2_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NCH-51	E1504_02_100_1_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_02_100_1_2_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_02_100_1_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_02_100_1_2_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_02_100_1_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_02_100_1_2_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET-762	E1504_02_100_1_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_02_100_1_2_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG2833 (RGFP109)	E1504_02_100_1_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_02_100_1_2_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ME0328	E1504_02_100_1_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_02_100_1_2_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Scriptaid	E1504_02_100_1_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_02_100_1_2_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Vorinostat (SAHA, MK0683)	E1504_02_100_1_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_02_100_1_2_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC 0946	E1504_02_100_1_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_02_100_1_2_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Apicidin	E1504_02_100_1_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_02_100_1_2_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-266	E1504_02_100_1_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_02_100_1_2_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM B2	E1504_02_100_1_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_02_100_1_2_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NSC-3852	E1504_02_100_1_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_02_100_1_2_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_02_100_1_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_02_100_1_2_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_02_100_1_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_02_100_1_2_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RGFP966	E1504_02_100_1_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_02_100_1_2_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RVX-208	E1504_02_100_1_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_02_100_1_2_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nexturastat A	E1504_02_100_1_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_02_100_1_2_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A	E1504_02_100_1_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_02_100_1_2_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM VX-680 (Tozasertib, MK-0457)	E1504_02_100_1_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_02_100_1_2_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC1215	E1504_02_100_1_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_02_100_1_2_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suberoyl bis-hydroxamic acid	E1504_02_100_1_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_02_100_1_2_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Piceatannol	E1504_02_100_1_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_02_100_1_2_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX-01294 3HCl	E1504_02_100_1_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_02_100_1_2_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aminoresveratrol sulfate	E1504_02_100_1_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_02_100_1_2_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_02_100_1_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_02_100_1_2_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_02_100_1_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_02_100_1_2_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Bromosporine	E1504_02_100_1_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_02_100_1_2_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34 HCl	E1504_02_100_1_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_02_100_1_2_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Filgotinib (GLPG0634)	E1504_02_100_1_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_02_100_1_2_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Lomeguatrib	E1504_02_100_1_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_02_100_1_2_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entinostat (MS-275)	E1504_02_100_1_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_02_100_1_2_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1208	E1504_02_100_1_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_02_100_1_2_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nullscript	E1504_02_100_1_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_02_100_1_2_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Fluoro-SAHA	E1504_02_100_1_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_02_100_1_2_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Butyrolactone 3	E1504_02_100_1_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_02_100_1_2_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-281	E1504_02_100_1_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_02_100_1_2_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_02_100_1_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_02_100_1_2_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_02_100_1_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_02_100_1_2_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX1	E1504_02_100_1_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_02_100_1_2_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CPI-203	E1504_02_100_1_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_02_100_1_2_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rocilinostat (ACY-1215)	E1504_02_100_1_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_02_100_1_2_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pacritinib (SB1518)	E1504_02_100_1_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_02_100_1_2_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Olaparib (AZD2281, Ku-0059436)	E1504_02_100_1_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_02_100_1_2_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM (+)-JQ1	E1504_02_100_1_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_02_100_1_2_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Isonicotinamide	E1504_02_100_1_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_02_100_1_2_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid hydroxamate	E1504_02_100_1_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_02_100_1_2_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CTPB	E1504_02_100_1_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_02_100_1_2_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Triacetylresveratrol	E1504_02_100_1_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_02_100_1_2_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_02_100_1_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_02_100_1_2_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_03_100_2_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_03_100_2_1_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Belinostat (PXD101)	E1504_03_100_2_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_03_100_2_1_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Danusertib (PHA-739358)	E1504_03_100_2_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_03_100_2_1_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SNS-314 Mesylate	E1504_03_100_2_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_03_100_2_1_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM JNJ-7706621	E1504_03_100_2_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_03_100_2_1_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT129202	E1504_03_100_2_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_03_100_2_1_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-14361	E1504_03_100_2_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_03_100_2_1_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A HCl	E1504_03_100_2_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_03_100_2_1_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-907	E1504_03_100_2_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_03_100_2_1_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CI994 (Tacedinaline)	E1504_03_100_2_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_03_100_2_1_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entacapone	E1504_03_100_2_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_03_100_2_1_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_03_100_2_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_03_100_2_1_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_03_100_2_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_03_100_2_1_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Iniparib (BSI-201)	E1504_03_100_2_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_03_100_2_1_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Mocetinostat (MGCD0103)	E1504_03_100_2_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_03_100_2_1_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid sodium salt (Sodium valproate)	E1504_03_100_2_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_03_100_2_1_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Ruxolitinib (INCB018424)	E1504_03_100_2_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_03_100_2_1_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Hesperadin	E1504_03_100_2_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_03_100_2_1_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM LY2784544	E1504_03_100_2_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_03_100_2_1_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NVP-BSK805 2HCl	E1504_03_100_2_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_03_100_2_1_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MK-5108 (VX-689)	E1504_03_100_2_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_03_100_2_1_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG108	E1504_03_100_2_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_03_100_2_1_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sodium Phenylbutyrate	E1504_03_100_2_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_03_100_2_1_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_03_100_2_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_03_100_2_1_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_03_100_2_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_03_100_2_1_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-24781 (Abexinostat)	E1504_03_100_2_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_03_100_2_1_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SRT1720	E1504_03_100_2_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_03_100_2_1_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYC116	E1504_03_100_2_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_03_100_2_1_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resveratrol	E1504_03_100_2_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_03_100_2_1_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EX 527 (Selisistat)	E1504_03_100_2_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_03_100_2_1_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1776 free base	E1504_03_100_2_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_03_100_2_1_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101209	E1504_03_100_2_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_03_100_2_1_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM M344	E1504_03_100_2_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_03_100_2_1_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Baricitinib (LY3009104, INCB028050)	E1504_03_100_2_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_03_100_2_1_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine (2-PCPA) HCl	E1504_03_100_2_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_03_100_2_1_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_03_100_2_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_03_100_2_1_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_03_100_2_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_03_100_2_1_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM LAQ824 (Dacinostat)	E1504_03_100_2_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_03_100_2_1_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM INO-1001	E1504_03_100_2_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_03_100_2_1_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ENMD-2076	E1504_03_100_2_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_03_100_2_1_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Droxinostat	E1504_03_100_2_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_03_100_2_1_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Azacitidine	E1504_03_100_2_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_03_100_2_1_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZ 960	E1504_03_100_2_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_03_100_2_1_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resminostat	E1504_03_100_2_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_03_100_2_1_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET151 (GSK1210151A)	E1504_03_100_2_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_03_100_2_1_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM WHI-P154	E1504_03_100_2_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_03_100_2_1_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Aminobenzamide	E1504_03_100_2_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_03_100_2_1_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_03_100_2_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_03_100_2_1_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_03_100_2_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_03_100_2_1_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quisinostat (JNJ-26481585)	E1504_03_100_2_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_03_100_2_1_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Alisertib (MLN8237)	E1504_03_100_2_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_03_100_2_1_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-101	E1504_03_100_2_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_03_100_2_1_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aurora A Inhibitor I	E1504_03_100_2_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_03_100_2_1_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-34051	E1504_03_100_2_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_03_100_2_1_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYT387	E1504_03_100_2_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_03_100_2_1_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TAK-901	E1504_03_100_2_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_03_100_2_1_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550,Tasocitinib)	E1504_03_100_2_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_03_100_2_1_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34	E1504_03_100_2_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_03_100_2_1_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Procainamide HCl	E1504_03_100_2_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_03_100_2_1_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_03_100_2_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_03_100_2_1_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_03_100_2_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_03_100_2_1_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rucaparib (AG-014699,PF-01367338)	E1504_03_100_2_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_03_100_2_1_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AT9283	E1504_03_100_2_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_03_100_2_1_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Decitabine	E1504_03_100_2_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_03_100_2_1_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PHA-680632	E1504_03_100_2_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_03_100_2_1_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM KW-2449	E1504_03_100_2_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_03_100_2_1_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubacin	E1504_03_100_2_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_03_100_2_1_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AMG-900	E1504_03_100_2_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_03_100_2_1_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM WP1066	E1504_03_100_2_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_03_100_2_1_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM S-Ruxolitinib (INCB018424)	E1504_03_100_2_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_03_100_2_1_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550) Citrate	E1504_03_100_2_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_03_100_2_1_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_03_100_2_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_03_100_2_1_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_03_100_2_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_03_100_2_1_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MLN8054	E1504_03_100_2_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_03_100_2_1_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-490 (Tyrphostin B42)	E1504_03_100_2_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_03_100_2_1_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PFI-1 (PF-6405761)	E1504_03_100_2_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_03_100_2_1_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC1568	E1504_03_100_2_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_03_100_2_1_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1480	E1504_03_100_2_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_03_100_2_1_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AR-42	E1504_03_100_2_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_03_100_2_1_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101348 (SAR302503)	E1504_03_100_2_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_03_100_2_1_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sirtinol	E1504_03_100_2_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_03_100_2_1_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX2	E1504_03_100_2_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_03_100_2_1_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD2461	E1504_03_100_2_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_03_100_2_1_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_03_100_2_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_03_100_2_1_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_03_100_2_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_03_100_2_1_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 447439	E1504_03_100_2_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_03_100_2_1_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Barasertib (AZD1152-HQPA)	E1504_03_100_2_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_03_100_2_1_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2-Methoxyestradiol (2-MeOE2)	E1504_03_100_2_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_03_100_2_1_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pracinostat (SB939)	E1504_03_100_2_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_03_100_2_1_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Givinostat (ITF2357)	E1504_03_100_2_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_03_100_2_1_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quercetin	E1504_03_100_2_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_03_100_2_1_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT137690	E1504_03_100_2_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_03_100_2_1_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CEP-33779	E1504_03_100_2_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_03_100_2_1_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Romidepsin (FK228, Depsipeptide)	E1504_03_100_2_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_03_100_2_1_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM XL019	E1504_03_100_2_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_03_100_2_1_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_03_100_2_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_03_100_2_1_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_04_100_2_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_04_100_2_2_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Zebularine	E1504_04_100_2_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_04_100_2_2_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM OG-L002	E1504_04_100_2_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_04_100_2_2_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TMP269	E1504_04_100_2_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_04_100_2_2_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 39923 HCl	E1504_04_100_2_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_04_100_2_2_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Veliparib (ABT-888)	E1504_04_100_2_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_04_100_2_2_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CX-6258 HCl	E1504_04_100_2_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_04_100_2_2_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2,4-Pyridinedicarboxylic Acid	E1504_04_100_2_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_04_100_2_2_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ITSA-1	E1504_04_100_2_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_04_100_2_2_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AGK2	E1504_04_100_2_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_04_100_2_2_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Oxamflatin	E1504_04_100_2_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_04_100_2_2_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_04_100_2_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_04_100_2_2_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_04_100_2_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_04_100_2_2_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Deazaneplanocin A (DZNeP)	E1504_04_100_2_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_04_100_2_2_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC-CBP30	E1504_04_100_2_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_04_100_2_2_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ004777	E1504_04_100_2_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_04_100_2_2_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SMI-4a	E1504_04_100_2_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_04_100_2_2_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM FG-4592	E1504_04_100_2_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_04_100_2_2_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BMN 673	E1504_04_100_2_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_04_100_2_2_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Garcinol	E1504_04_100_2_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_04_100_2_2_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine hemisulfate	E1504_04_100_2_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_04_100_2_2_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Salermide	E1504_04_100_2_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_04_100_2_2_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suramin 6Na	E1504_04_100_2_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_04_100_2_2_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_04_100_2_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_04_100_2_2_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_04_100_2_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_04_100_2_2_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ-6438	E1504_04_100_2_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_04_100_2_2_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MM-102	E1504_04_100_2_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_04_100_2_2_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM OTX015	E1504_04_100_2_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_04_100_2_2_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX 01294	E1504_04_100_2_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_04_100_2_2_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Panobinostat (LBH589)	E1504_04_100_2_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_04_100_2_2_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ5676	E1504_04_100_2_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_04_100_2_2_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Splitomicin	E1504_04_100_2_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_04_100_2_2_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid	E1504_04_100_2_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_04_100_2_2_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC-1293	E1504_04_100_2_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_04_100_2_2_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-278	E1504_04_100_2_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_04_100_2_2_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_04_100_2_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_04_100_2_2_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_04_100_2_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_04_100_2_2_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM C646	E1504_04_100_2_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_04_100_2_2_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1027	E1504_04_100_2_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_04_100_2_2_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC669	E1504_04_100_2_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_04_100_2_2_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UPF 1069	E1504_04_100_2_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_04_100_2_2_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Trichostatin A (TSA)	E1504_04_100_2_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_04_100_2_2_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM GSK J4 HCl	E1504_04_100_2_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_04_100_2_2_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-210	E1504_04_100_2_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_04_100_2_2_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nicotinamide	E1504_04_100_2_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_04_100_2_2_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Anacardic acid	E1504_04_100_2_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_04_100_2_2_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NCH-51	E1504_04_100_2_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_04_100_2_2_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_04_100_2_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_04_100_2_2_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_04_100_2_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_04_100_2_2_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET-762	E1504_04_100_2_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_04_100_2_2_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG2833 (RGFP109)	E1504_04_100_2_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_04_100_2_2_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ME0328	E1504_04_100_2_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_04_100_2_2_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Scriptaid	E1504_04_100_2_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_04_100_2_2_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Vorinostat (SAHA, MK0683)	E1504_04_100_2_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_04_100_2_2_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC 0946	E1504_04_100_2_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_04_100_2_2_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Apicidin	E1504_04_100_2_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_04_100_2_2_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-266	E1504_04_100_2_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_04_100_2_2_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM B2	E1504_04_100_2_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_04_100_2_2_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NSC-3852	E1504_04_100_2_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_04_100_2_2_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_04_100_2_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_04_100_2_2_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_04_100_2_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_04_100_2_2_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RGFP966	E1504_04_100_2_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_04_100_2_2_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RVX-208	E1504_04_100_2_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_04_100_2_2_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nexturastat A	E1504_04_100_2_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_04_100_2_2_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A	E1504_04_100_2_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_04_100_2_2_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM VX-680 (Tozasertib, MK-0457)	E1504_04_100_2_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_04_100_2_2_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC1215	E1504_04_100_2_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_04_100_2_2_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suberoyl bis-hydroxamic acid	E1504_04_100_2_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_04_100_2_2_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Piceatannol	E1504_04_100_2_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_04_100_2_2_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX-01294 3HCl	E1504_04_100_2_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_04_100_2_2_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aminoresveratrol sulfate	E1504_04_100_2_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_04_100_2_2_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_04_100_2_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_04_100_2_2_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_04_100_2_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_04_100_2_2_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Bromosporine	E1504_04_100_2_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_04_100_2_2_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34 HCl	E1504_04_100_2_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_04_100_2_2_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Filgotinib (GLPG0634)	E1504_04_100_2_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_04_100_2_2_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Lomeguatrib	E1504_04_100_2_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_04_100_2_2_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entinostat (MS-275)	E1504_04_100_2_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_04_100_2_2_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1208	E1504_04_100_2_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_04_100_2_2_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nullscript	E1504_04_100_2_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_04_100_2_2_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Fluoro-SAHA	E1504_04_100_2_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_04_100_2_2_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Butyrolactone 3	E1504_04_100_2_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_04_100_2_2_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-281	E1504_04_100_2_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_04_100_2_2_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_04_100_2_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_04_100_2_2_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_04_100_2_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_04_100_2_2_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX1	E1504_04_100_2_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_04_100_2_2_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CPI-203	E1504_04_100_2_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_04_100_2_2_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rocilinostat (ACY-1215)	E1504_04_100_2_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_04_100_2_2_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pacritinib (SB1518)	E1504_04_100_2_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_04_100_2_2_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Olaparib (AZD2281, Ku-0059436)	E1504_04_100_2_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_04_100_2_2_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM (+)-JQ1	E1504_04_100_2_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_04_100_2_2_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Isonicotinamide	E1504_04_100_2_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_04_100_2_2_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid hydroxamate	E1504_04_100_2_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_04_100_2_2_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CTPB	E1504_04_100_2_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_04_100_2_2_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Triacetylresveratrol	E1504_04_100_2_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_04_100_2_2_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_04_100_2_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_04_100_2_2_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_05_100_3_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_05_100_3_1_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Belinostat (PXD101)	E1504_05_100_3_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_05_100_3_1_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Danusertib (PHA-739358)	E1504_05_100_3_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_05_100_3_1_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SNS-314 Mesylate	E1504_05_100_3_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_05_100_3_1_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM JNJ-7706621	E1504_05_100_3_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_05_100_3_1_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT129202	E1504_05_100_3_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_05_100_3_1_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-14361	E1504_05_100_3_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_05_100_3_1_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A HCl	E1504_05_100_3_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_05_100_3_1_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-907	E1504_05_100_3_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_05_100_3_1_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CI994 (Tacedinaline)	E1504_05_100_3_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_05_100_3_1_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entacapone	E1504_05_100_3_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_05_100_3_1_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_05_100_3_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_05_100_3_1_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_05_100_3_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_05_100_3_1_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Iniparib (BSI-201)	E1504_05_100_3_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_05_100_3_1_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Mocetinostat (MGCD0103)	E1504_05_100_3_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_05_100_3_1_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid sodium salt (Sodium valproate)	E1504_05_100_3_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_05_100_3_1_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Ruxolitinib (INCB018424)	E1504_05_100_3_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_05_100_3_1_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Hesperadin	E1504_05_100_3_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_05_100_3_1_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM LY2784544	E1504_05_100_3_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_05_100_3_1_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NVP-BSK805 2HCl	E1504_05_100_3_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_05_100_3_1_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MK-5108 (VX-689)	E1504_05_100_3_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_05_100_3_1_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG108	E1504_05_100_3_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_05_100_3_1_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sodium Phenylbutyrate	E1504_05_100_3_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_05_100_3_1_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_05_100_3_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_05_100_3_1_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_05_100_3_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_05_100_3_1_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-24781 (Abexinostat)	E1504_05_100_3_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_05_100_3_1_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SRT1720	E1504_05_100_3_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_05_100_3_1_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYC116	E1504_05_100_3_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_05_100_3_1_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resveratrol	E1504_05_100_3_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_05_100_3_1_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EX 527 (Selisistat)	E1504_05_100_3_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_05_100_3_1_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1776 free base	E1504_05_100_3_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_05_100_3_1_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101209	E1504_05_100_3_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_05_100_3_1_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM M344	E1504_05_100_3_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_05_100_3_1_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Baricitinib (LY3009104, INCB028050)	E1504_05_100_3_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_05_100_3_1_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine (2-PCPA) HCl	E1504_05_100_3_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_05_100_3_1_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_05_100_3_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_05_100_3_1_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_05_100_3_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_05_100_3_1_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM LAQ824 (Dacinostat)	E1504_05_100_3_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_05_100_3_1_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM INO-1001	E1504_05_100_3_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_05_100_3_1_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ENMD-2076	E1504_05_100_3_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_05_100_3_1_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Droxinostat	E1504_05_100_3_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_05_100_3_1_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Azacitidine	E1504_05_100_3_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_05_100_3_1_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZ 960	E1504_05_100_3_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_05_100_3_1_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resminostat	E1504_05_100_3_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_05_100_3_1_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET151 (GSK1210151A)	E1504_05_100_3_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_05_100_3_1_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM WHI-P154	E1504_05_100_3_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_05_100_3_1_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Aminobenzamide	E1504_05_100_3_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_05_100_3_1_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_05_100_3_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_05_100_3_1_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_05_100_3_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_05_100_3_1_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quisinostat (JNJ-26481585)	E1504_05_100_3_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_05_100_3_1_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Alisertib (MLN8237)	E1504_05_100_3_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_05_100_3_1_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-101	E1504_05_100_3_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_05_100_3_1_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aurora A Inhibitor I	E1504_05_100_3_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_05_100_3_1_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-34051	E1504_05_100_3_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_05_100_3_1_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYT387	E1504_05_100_3_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_05_100_3_1_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TAK-901	E1504_05_100_3_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_05_100_3_1_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550,Tasocitinib)	E1504_05_100_3_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_05_100_3_1_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34	E1504_05_100_3_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_05_100_3_1_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Procainamide HCl	E1504_05_100_3_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_05_100_3_1_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_05_100_3_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_05_100_3_1_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_05_100_3_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_05_100_3_1_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rucaparib (AG-014699,PF-01367338)	E1504_05_100_3_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_05_100_3_1_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AT9283	E1504_05_100_3_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_05_100_3_1_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Decitabine	E1504_05_100_3_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_05_100_3_1_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PHA-680632	E1504_05_100_3_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_05_100_3_1_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM KW-2449	E1504_05_100_3_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_05_100_3_1_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubacin	E1504_05_100_3_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_05_100_3_1_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AMG-900	E1504_05_100_3_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_05_100_3_1_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM WP1066	E1504_05_100_3_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_05_100_3_1_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM S-Ruxolitinib (INCB018424)	E1504_05_100_3_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_05_100_3_1_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550) Citrate	E1504_05_100_3_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_05_100_3_1_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_05_100_3_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_05_100_3_1_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_05_100_3_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_05_100_3_1_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MLN8054	E1504_05_100_3_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_05_100_3_1_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-490 (Tyrphostin B42)	E1504_05_100_3_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_05_100_3_1_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PFI-1 (PF-6405761)	E1504_05_100_3_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_05_100_3_1_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC1568	E1504_05_100_3_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_05_100_3_1_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1480	E1504_05_100_3_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_05_100_3_1_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AR-42	E1504_05_100_3_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_05_100_3_1_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101348 (SAR302503)	E1504_05_100_3_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_05_100_3_1_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sirtinol	E1504_05_100_3_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_05_100_3_1_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX2	E1504_05_100_3_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_05_100_3_1_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD2461	E1504_05_100_3_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_05_100_3_1_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_05_100_3_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_05_100_3_1_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_05_100_3_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_05_100_3_1_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 447439	E1504_05_100_3_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_05_100_3_1_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Barasertib (AZD1152-HQPA)	E1504_05_100_3_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_05_100_3_1_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2-Methoxyestradiol (2-MeOE2)	E1504_05_100_3_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_05_100_3_1_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pracinostat (SB939)	E1504_05_100_3_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_05_100_3_1_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Givinostat (ITF2357)	E1504_05_100_3_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_05_100_3_1_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quercetin	E1504_05_100_3_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_05_100_3_1_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT137690	E1504_05_100_3_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_05_100_3_1_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CEP-33779	E1504_05_100_3_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_05_100_3_1_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Romidepsin (FK228, Depsipeptide)	E1504_05_100_3_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_05_100_3_1_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM XL019	E1504_05_100_3_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_05_100_3_1_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_05_100_3_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_05_100_3_1_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_06_100_3_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_06_100_3_2_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Zebularine	E1504_06_100_3_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_06_100_3_2_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM OG-L002	E1504_06_100_3_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_06_100_3_2_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TMP269	E1504_06_100_3_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_06_100_3_2_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 39923 HCl	E1504_06_100_3_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_06_100_3_2_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Veliparib (ABT-888)	E1504_06_100_3_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_06_100_3_2_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CX-6258 HCl	E1504_06_100_3_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_06_100_3_2_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2,4-Pyridinedicarboxylic Acid	E1504_06_100_3_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_06_100_3_2_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ITSA-1	E1504_06_100_3_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_06_100_3_2_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AGK2	E1504_06_100_3_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_06_100_3_2_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Oxamflatin	E1504_06_100_3_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_06_100_3_2_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_06_100_3_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_06_100_3_2_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_06_100_3_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_06_100_3_2_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Deazaneplanocin A (DZNeP)	E1504_06_100_3_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_06_100_3_2_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC-CBP30	E1504_06_100_3_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_06_100_3_2_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ004777	E1504_06_100_3_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_06_100_3_2_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SMI-4a	E1504_06_100_3_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_06_100_3_2_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM FG-4592	E1504_06_100_3_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_06_100_3_2_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BMN 673	E1504_06_100_3_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_06_100_3_2_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Garcinol	E1504_06_100_3_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_06_100_3_2_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine hemisulfate	E1504_06_100_3_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_06_100_3_2_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Salermide	E1504_06_100_3_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_06_100_3_2_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suramin 6Na	E1504_06_100_3_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_06_100_3_2_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_06_100_3_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_06_100_3_2_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_06_100_3_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_06_100_3_2_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ-6438	E1504_06_100_3_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_06_100_3_2_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MM-102	E1504_06_100_3_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_06_100_3_2_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM OTX015	E1504_06_100_3_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_06_100_3_2_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX 01294	E1504_06_100_3_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_06_100_3_2_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Panobinostat (LBH589)	E1504_06_100_3_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_06_100_3_2_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ5676	E1504_06_100_3_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_06_100_3_2_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Splitomicin	E1504_06_100_3_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_06_100_3_2_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid	E1504_06_100_3_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_06_100_3_2_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC-1293	E1504_06_100_3_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_06_100_3_2_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-278	E1504_06_100_3_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_06_100_3_2_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_06_100_3_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_06_100_3_2_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_06_100_3_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_06_100_3_2_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM C646	E1504_06_100_3_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_06_100_3_2_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1027	E1504_06_100_3_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_06_100_3_2_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC669	E1504_06_100_3_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_06_100_3_2_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UPF 1069	E1504_06_100_3_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_06_100_3_2_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Trichostatin A (TSA)	E1504_06_100_3_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_06_100_3_2_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM GSK J4 HCl	E1504_06_100_3_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_06_100_3_2_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-210	E1504_06_100_3_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_06_100_3_2_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nicotinamide	E1504_06_100_3_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_06_100_3_2_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Anacardic acid	E1504_06_100_3_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_06_100_3_2_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NCH-51	E1504_06_100_3_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_06_100_3_2_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_06_100_3_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_06_100_3_2_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_06_100_3_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_06_100_3_2_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET-762	E1504_06_100_3_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_06_100_3_2_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG2833 (RGFP109)	E1504_06_100_3_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_06_100_3_2_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ME0328	E1504_06_100_3_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_06_100_3_2_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Scriptaid	E1504_06_100_3_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_06_100_3_2_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Vorinostat (SAHA, MK0683)	E1504_06_100_3_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_06_100_3_2_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC 0946	E1504_06_100_3_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_06_100_3_2_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Apicidin	E1504_06_100_3_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_06_100_3_2_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-266	E1504_06_100_3_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_06_100_3_2_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM B2	E1504_06_100_3_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_06_100_3_2_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NSC-3852	E1504_06_100_3_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_06_100_3_2_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_06_100_3_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_06_100_3_2_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_06_100_3_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_06_100_3_2_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RGFP966	E1504_06_100_3_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_06_100_3_2_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RVX-208	E1504_06_100_3_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_06_100_3_2_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nexturastat A	E1504_06_100_3_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_06_100_3_2_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A	E1504_06_100_3_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_06_100_3_2_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM VX-680 (Tozasertib, MK-0457)	E1504_06_100_3_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_06_100_3_2_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC1215	E1504_06_100_3_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_06_100_3_2_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suberoyl bis-hydroxamic acid	E1504_06_100_3_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_06_100_3_2_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Piceatannol	E1504_06_100_3_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_06_100_3_2_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX-01294 3HCl	E1504_06_100_3_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_06_100_3_2_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aminoresveratrol sulfate	E1504_06_100_3_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_06_100_3_2_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_06_100_3_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_06_100_3_2_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_06_100_3_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_06_100_3_2_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Bromosporine	E1504_06_100_3_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_06_100_3_2_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34 HCl	E1504_06_100_3_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_06_100_3_2_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Filgotinib (GLPG0634)	E1504_06_100_3_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_06_100_3_2_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Lomeguatrib	E1504_06_100_3_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_06_100_3_2_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entinostat (MS-275)	E1504_06_100_3_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_06_100_3_2_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1208	E1504_06_100_3_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_06_100_3_2_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nullscript	E1504_06_100_3_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_06_100_3_2_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Fluoro-SAHA	E1504_06_100_3_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_06_100_3_2_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Butyrolactone 3	E1504_06_100_3_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_06_100_3_2_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-281	E1504_06_100_3_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_06_100_3_2_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_06_100_3_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_06_100_3_2_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_06_100_3_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_06_100_3_2_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX1	E1504_06_100_3_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_06_100_3_2_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CPI-203	E1504_06_100_3_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_06_100_3_2_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rocilinostat (ACY-1215)	E1504_06_100_3_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_06_100_3_2_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pacritinib (SB1518)	E1504_06_100_3_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_06_100_3_2_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Olaparib (AZD2281, Ku-0059436)	E1504_06_100_3_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_06_100_3_2_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM (+)-JQ1	E1504_06_100_3_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_06_100_3_2_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Isonicotinamide	E1504_06_100_3_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_06_100_3_2_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid hydroxamate	E1504_06_100_3_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_06_100_3_2_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CTPB	E1504_06_100_3_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_06_100_3_2_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Triacetylresveratrol	E1504_06_100_3_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_06_100_3_2_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_06_100_3_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_06_100_3_2_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_07_1_1_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_07_1_1_1_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Belinostat (PXD101)	E1504_07_1_1_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_07_1_1_1_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Danusertib (PHA-739358)	E1504_07_1_1_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_07_1_1_1_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SNS-314 Mesylate	E1504_07_1_1_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_07_1_1_1_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM JNJ-7706621	E1504_07_1_1_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_07_1_1_1_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT129202	E1504_07_1_1_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_07_1_1_1_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-14361	E1504_07_1_1_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_07_1_1_1_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A HCl	E1504_07_1_1_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_07_1_1_1_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-907	E1504_07_1_1_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_07_1_1_1_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CI994 (Tacedinaline)	E1504_07_1_1_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_07_1_1_1_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Entacapone	E1504_07_1_1_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_07_1_1_1_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_07_1_1_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_07_1_1_1_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_07_1_1_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_07_1_1_1_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Iniparib (BSI-201)	E1504_07_1_1_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_07_1_1_1_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mocetinostat (MGCD0103)	E1504_07_1_1_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_07_1_1_1_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid sodium salt (Sodium valproate)	E1504_07_1_1_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_07_1_1_1_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Ruxolitinib (INCB018424)	E1504_07_1_1_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_07_1_1_1_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Hesperadin	E1504_07_1_1_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_07_1_1_1_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM LY2784544	E1504_07_1_1_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_07_1_1_1_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NVP-BSK805 2HCl	E1504_07_1_1_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_07_1_1_1_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MK-5108 (VX-689)	E1504_07_1_1_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_07_1_1_1_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RG108	E1504_07_1_1_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_07_1_1_1_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Sodium Phenylbutyrate	E1504_07_1_1_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_07_1_1_1_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_07_1_1_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_07_1_1_1_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_07_1_1_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_07_1_1_1_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-24781 (Abexinostat)	E1504_07_1_1_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_07_1_1_1_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SRT1720	E1504_07_1_1_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_07_1_1_1_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CYC116	E1504_07_1_1_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_07_1_1_1_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Resveratrol	E1504_07_1_1_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_07_1_1_1_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EX 527 (Selisistat)	E1504_07_1_1_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_07_1_1_1_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1776 free base	E1504_07_1_1_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_07_1_1_1_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101209	E1504_07_1_1_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_07_1_1_1_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM M344	E1504_07_1_1_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_07_1_1_1_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Baricitinib (LY3009104, INCB028050)	E1504_07_1_1_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_07_1_1_1_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine (2-PCPA) HCl	E1504_07_1_1_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_07_1_1_1_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_07_1_1_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_07_1_1_1_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_07_1_1_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_07_1_1_1_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM LAQ824 (Dacinostat)	E1504_07_1_1_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_07_1_1_1_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM INO-1001	E1504_07_1_1_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_07_1_1_1_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ENMD-2076	E1504_07_1_1_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_07_1_1_1_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Droxinostat	E1504_07_1_1_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_07_1_1_1_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Azacitidine	E1504_07_1_1_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_07_1_1_1_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZ 960	E1504_07_1_1_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_07_1_1_1_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Resminostat	E1504_07_1_1_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_07_1_1_1_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET151 (GSK1210151A)	E1504_07_1_1_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_07_1_1_1_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM WHI-P154	E1504_07_1_1_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_07_1_1_1_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Aminobenzamide	E1504_07_1_1_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_07_1_1_1_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_07_1_1_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_07_1_1_1_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_07_1_1_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_07_1_1_1_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Quisinostat (JNJ-26481585)	E1504_07_1_1_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_07_1_1_1_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Alisertib (MLN8237)	E1504_07_1_1_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_07_1_1_1_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-101	E1504_07_1_1_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_07_1_1_1_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Aurora A Inhibitor I	E1504_07_1_1_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_07_1_1_1_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-34051	E1504_07_1_1_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_07_1_1_1_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CYT387	E1504_07_1_1_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_07_1_1_1_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TAK-901	E1504_07_1_1_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_07_1_1_1_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550,Tasocitinib)	E1504_07_1_1_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_07_1_1_1_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34	E1504_07_1_1_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_07_1_1_1_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Procainamide HCl	E1504_07_1_1_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_07_1_1_1_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_07_1_1_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_07_1_1_1_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_07_1_1_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_07_1_1_1_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Rucaparib (AG-014699,PF-01367338)	E1504_07_1_1_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_07_1_1_1_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AT9283	E1504_07_1_1_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_07_1_1_1_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Decitabine	E1504_07_1_1_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_07_1_1_1_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PHA-680632	E1504_07_1_1_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_07_1_1_1_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM KW-2449	E1504_07_1_1_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_07_1_1_1_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubacin	E1504_07_1_1_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_07_1_1_1_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AMG-900	E1504_07_1_1_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_07_1_1_1_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM WP1066	E1504_07_1_1_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_07_1_1_1_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM S-Ruxolitinib (INCB018424)	E1504_07_1_1_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_07_1_1_1_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550) Citrate	E1504_07_1_1_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_07_1_1_1_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_07_1_1_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_07_1_1_1_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_07_1_1_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_07_1_1_1_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MLN8054	E1504_07_1_1_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_07_1_1_1_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-490 (Tyrphostin B42)	E1504_07_1_1_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_07_1_1_1_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PFI-1 (PF-6405761)	E1504_07_1_1_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_07_1_1_1_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MC1568	E1504_07_1_1_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_07_1_1_1_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1480	E1504_07_1_1_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_07_1_1_1_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AR-42	E1504_07_1_1_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_07_1_1_1_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101348 (SAR302503)	E1504_07_1_1_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_07_1_1_1_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Sirtinol	E1504_07_1_1_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_07_1_1_1_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX2	E1504_07_1_1_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_07_1_1_1_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD2461	E1504_07_1_1_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_07_1_1_1_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_07_1_1_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_07_1_1_1_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_07_1_1_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_07_1_1_1_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 447439	E1504_07_1_1_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_07_1_1_1_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Barasertib (AZD1152-HQPA)	E1504_07_1_1_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_07_1_1_1_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 2-Methoxyestradiol (2-MeOE2)	E1504_07_1_1_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_07_1_1_1_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Pracinostat (SB939)	E1504_07_1_1_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_07_1_1_1_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Givinostat (ITF2357)	E1504_07_1_1_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_07_1_1_1_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Quercetin	E1504_07_1_1_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_07_1_1_1_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT137690	E1504_07_1_1_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_07_1_1_1_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CEP-33779	E1504_07_1_1_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_07_1_1_1_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Romidepsin (FK228, Depsipeptide)	E1504_07_1_1_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_07_1_1_1_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM XL019	E1504_07_1_1_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_07_1_1_1_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_07_1_1_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_07_1_1_1_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_08_1_1_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_08_1_1_2_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Zebularine	E1504_08_1_1_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_08_1_1_2_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM OG-L002	E1504_08_1_1_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_08_1_1_2_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TMP269	E1504_08_1_1_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_08_1_1_2_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 39923 HCl	E1504_08_1_1_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_08_1_1_2_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Veliparib (ABT-888)	E1504_08_1_1_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_08_1_1_2_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CX-6258 HCl	E1504_08_1_1_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_08_1_1_2_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 2,4-Pyridinedicarboxylic Acid	E1504_08_1_1_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_08_1_1_2_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ITSA-1	E1504_08_1_1_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_08_1_1_2_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AGK2	E1504_08_1_1_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_08_1_1_2_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Oxamflatin	E1504_08_1_1_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_08_1_1_2_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_08_1_1_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_08_1_1_2_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_08_1_1_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_08_1_1_2_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Deazaneplanocin A (DZNeP)	E1504_08_1_1_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_08_1_1_2_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC-CBP30	E1504_08_1_1_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_08_1_1_2_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ004777	E1504_08_1_1_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_08_1_1_2_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SMI-4a	E1504_08_1_1_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_08_1_1_2_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM FG-4592	E1504_08_1_1_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_08_1_1_2_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BMN 673	E1504_08_1_1_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_08_1_1_2_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Garcinol	E1504_08_1_1_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_08_1_1_2_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine hemisulfate	E1504_08_1_1_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_08_1_1_2_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Salermide	E1504_08_1_1_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_08_1_1_2_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Suramin 6Na	E1504_08_1_1_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_08_1_1_2_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_08_1_1_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_08_1_1_2_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_08_1_1_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_08_1_1_2_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ-6438	E1504_08_1_1_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_08_1_1_2_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MM-102	E1504_08_1_1_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_08_1_1_2_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM OTX015	E1504_08_1_1_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_08_1_1_2_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX 01294	E1504_08_1_1_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_08_1_1_2_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Panobinostat (LBH589)	E1504_08_1_1_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_08_1_1_2_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ5676	E1504_08_1_1_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_08_1_1_2_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Splitomicin	E1504_08_1_1_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_08_1_1_2_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid	E1504_08_1_1_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_08_1_1_2_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MC-1293	E1504_08_1_1_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_08_1_1_2_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-278	E1504_08_1_1_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_08_1_1_2_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_08_1_1_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_08_1_1_2_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_08_1_1_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_08_1_1_2_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM C646	E1504_08_1_1_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_08_1_1_2_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1027	E1504_08_1_1_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_08_1_1_2_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC669	E1504_08_1_1_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_08_1_1_2_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UPF 1069	E1504_08_1_1_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_08_1_1_2_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Trichostatin A (TSA)	E1504_08_1_1_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_08_1_1_2_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM GSK J4 HCl	E1504_08_1_1_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_08_1_1_2_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-210	E1504_08_1_1_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_08_1_1_2_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nicotinamide	E1504_08_1_1_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_08_1_1_2_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Anacardic acid	E1504_08_1_1_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_08_1_1_2_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NCH-51	E1504_08_1_1_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_08_1_1_2_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_08_1_1_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_08_1_1_2_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_08_1_1_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_08_1_1_2_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET-762	E1504_08_1_1_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_08_1_1_2_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RG2833 (RGFP109)	E1504_08_1_1_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_08_1_1_2_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ME0328	E1504_08_1_1_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_08_1_1_2_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Scriptaid	E1504_08_1_1_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_08_1_1_2_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Vorinostat (SAHA, MK0683)	E1504_08_1_1_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_08_1_1_2_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC 0946	E1504_08_1_1_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_08_1_1_2_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Apicidin	E1504_08_1_1_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_08_1_1_2_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-266	E1504_08_1_1_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_08_1_1_2_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM B2	E1504_08_1_1_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_08_1_1_2_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NSC-3852	E1504_08_1_1_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_08_1_1_2_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_08_1_1_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_08_1_1_2_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_08_1_1_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_08_1_1_2_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RGFP966	E1504_08_1_1_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_08_1_1_2_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RVX-208	E1504_08_1_1_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_08_1_1_2_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nexturastat A	E1504_08_1_1_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_08_1_1_2_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A	E1504_08_1_1_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_08_1_1_2_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM VX-680 (Tozasertib, MK-0457)	E1504_08_1_1_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_08_1_1_2_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC1215	E1504_08_1_1_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_08_1_1_2_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Suberoyl bis-hydroxamic acid	E1504_08_1_1_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_08_1_1_2_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Piceatannol	E1504_08_1_1_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_08_1_1_2_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX-01294 3HCl	E1504_08_1_1_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_08_1_1_2_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Aminoresveratrol sulfate	E1504_08_1_1_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_08_1_1_2_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_08_1_1_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_08_1_1_2_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_08_1_1_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_08_1_1_2_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Bromosporine	E1504_08_1_1_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_08_1_1_2_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34 HCl	E1504_08_1_1_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_08_1_1_2_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Filgotinib (GLPG0634)	E1504_08_1_1_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_08_1_1_2_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Lomeguatrib	E1504_08_1_1_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_08_1_1_2_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Entinostat (MS-275)	E1504_08_1_1_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_08_1_1_2_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1208	E1504_08_1_1_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_08_1_1_2_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nullscript	E1504_08_1_1_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_08_1_1_2_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Fluoro-SAHA	E1504_08_1_1_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_08_1_1_2_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Butyrolactone 3	E1504_08_1_1_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_08_1_1_2_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-281	E1504_08_1_1_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_08_1_1_2_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_08_1_1_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_08_1_1_2_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_08_1_1_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_08_1_1_2_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX1	E1504_08_1_1_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_08_1_1_2_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CPI-203	E1504_08_1_1_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_08_1_1_2_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Rocilinostat (ACY-1215)	E1504_08_1_1_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_08_1_1_2_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Pacritinib (SB1518)	E1504_08_1_1_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_08_1_1_2_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Olaparib (AZD2281, Ku-0059436)	E1504_08_1_1_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_08_1_1_2_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM (+)-JQ1	E1504_08_1_1_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_08_1_1_2_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Isonicotinamide	E1504_08_1_1_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_08_1_1_2_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid hydroxamate	E1504_08_1_1_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_08_1_1_2_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CTPB	E1504_08_1_1_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_08_1_1_2_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Triacetylresveratrol	E1504_08_1_1_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_08_1_1_2_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_08_1_1_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_08_1_1_2_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_09_1_2_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_09_1_2_1_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Belinostat (PXD101)	E1504_09_1_2_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_09_1_2_1_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Danusertib (PHA-739358)	E1504_09_1_2_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_09_1_2_1_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SNS-314 Mesylate	E1504_09_1_2_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_09_1_2_1_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM JNJ-7706621	E1504_09_1_2_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_09_1_2_1_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT129202	E1504_09_1_2_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_09_1_2_1_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-14361	E1504_09_1_2_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_09_1_2_1_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A HCl	E1504_09_1_2_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_09_1_2_1_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-907	E1504_09_1_2_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_09_1_2_1_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CI994 (Tacedinaline)	E1504_09_1_2_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_09_1_2_1_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Entacapone	E1504_09_1_2_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_09_1_2_1_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_09_1_2_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_09_1_2_1_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_09_1_2_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_09_1_2_1_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Iniparib (BSI-201)	E1504_09_1_2_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_09_1_2_1_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mocetinostat (MGCD0103)	E1504_09_1_2_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_09_1_2_1_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid sodium salt (Sodium valproate)	E1504_09_1_2_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_09_1_2_1_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Ruxolitinib (INCB018424)	E1504_09_1_2_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_09_1_2_1_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Hesperadin	E1504_09_1_2_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_09_1_2_1_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM LY2784544	E1504_09_1_2_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_09_1_2_1_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NVP-BSK805 2HCl	E1504_09_1_2_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_09_1_2_1_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MK-5108 (VX-689)	E1504_09_1_2_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_09_1_2_1_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RG108	E1504_09_1_2_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_09_1_2_1_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Sodium Phenylbutyrate	E1504_09_1_2_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_09_1_2_1_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_09_1_2_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_09_1_2_1_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_09_1_2_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_09_1_2_1_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-24781 (Abexinostat)	E1504_09_1_2_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_09_1_2_1_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SRT1720	E1504_09_1_2_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_09_1_2_1_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CYC116	E1504_09_1_2_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_09_1_2_1_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Resveratrol	E1504_09_1_2_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_09_1_2_1_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EX 527 (Selisistat)	E1504_09_1_2_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_09_1_2_1_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1776 free base	E1504_09_1_2_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_09_1_2_1_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101209	E1504_09_1_2_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_09_1_2_1_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM M344	E1504_09_1_2_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_09_1_2_1_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Baricitinib (LY3009104, INCB028050)	E1504_09_1_2_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_09_1_2_1_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine (2-PCPA) HCl	E1504_09_1_2_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_09_1_2_1_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_09_1_2_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_09_1_2_1_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_09_1_2_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_09_1_2_1_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM LAQ824 (Dacinostat)	E1504_09_1_2_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_09_1_2_1_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM INO-1001	E1504_09_1_2_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_09_1_2_1_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ENMD-2076	E1504_09_1_2_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_09_1_2_1_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Droxinostat	E1504_09_1_2_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_09_1_2_1_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Azacitidine	E1504_09_1_2_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_09_1_2_1_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZ 960	E1504_09_1_2_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_09_1_2_1_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Resminostat	E1504_09_1_2_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_09_1_2_1_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET151 (GSK1210151A)	E1504_09_1_2_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_09_1_2_1_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM WHI-P154	E1504_09_1_2_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_09_1_2_1_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Aminobenzamide	E1504_09_1_2_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_09_1_2_1_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_09_1_2_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_09_1_2_1_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_09_1_2_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_09_1_2_1_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Quisinostat (JNJ-26481585)	E1504_09_1_2_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_09_1_2_1_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Alisertib (MLN8237)	E1504_09_1_2_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_09_1_2_1_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-101	E1504_09_1_2_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_09_1_2_1_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Aurora A Inhibitor I	E1504_09_1_2_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_09_1_2_1_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-34051	E1504_09_1_2_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_09_1_2_1_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CYT387	E1504_09_1_2_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_09_1_2_1_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TAK-901	E1504_09_1_2_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_09_1_2_1_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550,Tasocitinib)	E1504_09_1_2_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_09_1_2_1_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34	E1504_09_1_2_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_09_1_2_1_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Procainamide HCl	E1504_09_1_2_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_09_1_2_1_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_09_1_2_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_09_1_2_1_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_09_1_2_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_09_1_2_1_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Rucaparib (AG-014699,PF-01367338)	E1504_09_1_2_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_09_1_2_1_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AT9283	E1504_09_1_2_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_09_1_2_1_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Decitabine	E1504_09_1_2_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_09_1_2_1_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PHA-680632	E1504_09_1_2_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_09_1_2_1_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM KW-2449	E1504_09_1_2_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_09_1_2_1_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubacin	E1504_09_1_2_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_09_1_2_1_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AMG-900	E1504_09_1_2_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_09_1_2_1_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM WP1066	E1504_09_1_2_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_09_1_2_1_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM S-Ruxolitinib (INCB018424)	E1504_09_1_2_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_09_1_2_1_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550) Citrate	E1504_09_1_2_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_09_1_2_1_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_09_1_2_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_09_1_2_1_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_09_1_2_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_09_1_2_1_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MLN8054	E1504_09_1_2_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_09_1_2_1_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-490 (Tyrphostin B42)	E1504_09_1_2_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_09_1_2_1_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PFI-1 (PF-6405761)	E1504_09_1_2_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_09_1_2_1_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MC1568	E1504_09_1_2_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_09_1_2_1_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1480	E1504_09_1_2_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_09_1_2_1_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AR-42	E1504_09_1_2_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_09_1_2_1_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101348 (SAR302503)	E1504_09_1_2_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_09_1_2_1_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Sirtinol	E1504_09_1_2_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_09_1_2_1_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX2	E1504_09_1_2_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_09_1_2_1_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD2461	E1504_09_1_2_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_09_1_2_1_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_09_1_2_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_09_1_2_1_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_09_1_2_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_09_1_2_1_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 447439	E1504_09_1_2_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_09_1_2_1_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Barasertib (AZD1152-HQPA)	E1504_09_1_2_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_09_1_2_1_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 2-Methoxyestradiol (2-MeOE2)	E1504_09_1_2_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_09_1_2_1_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Pracinostat (SB939)	E1504_09_1_2_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_09_1_2_1_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Givinostat (ITF2357)	E1504_09_1_2_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_09_1_2_1_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Quercetin	E1504_09_1_2_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_09_1_2_1_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT137690	E1504_09_1_2_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_09_1_2_1_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CEP-33779	E1504_09_1_2_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_09_1_2_1_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Romidepsin (FK228, Depsipeptide)	E1504_09_1_2_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_09_1_2_1_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM XL019	E1504_09_1_2_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_09_1_2_1_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_09_1_2_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_09_1_2_1_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_10_1_2_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_last_E1504_10_1_2_2_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Zebularine	E1504_10_1_2_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_last_E1504_10_1_2_2_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM OG-L002	E1504_10_1_2_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_last_E1504_10_1_2_2_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TMP269	E1504_10_1_2_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_last_E1504_10_1_2_2_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 39923 HCl	E1504_10_1_2_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_last_E1504_10_1_2_2_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Veliparib (ABT-888)	E1504_10_1_2_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_last_E1504_10_1_2_2_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CX-6258 HCl	E1504_10_1_2_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_last_E1504_10_1_2_2_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 2,4-Pyridinedicarboxylic Acid	E1504_10_1_2_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_last_E1504_10_1_2_2_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ITSA-1	E1504_10_1_2_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_last_E1504_10_1_2_2_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AGK2	E1504_10_1_2_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_last_E1504_10_1_2_2_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Oxamflatin	E1504_10_1_2_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_last_E1504_10_1_2_2_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_10_1_2_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_last_E1504_10_1_2_2_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_10_1_2_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_last_E1504_10_1_2_2_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Deazaneplanocin A (DZNeP)	E1504_10_1_2_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_last_E1504_10_1_2_2_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC-CBP30	E1504_10_1_2_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_last_E1504_10_1_2_2_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ004777	E1504_10_1_2_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_last_E1504_10_1_2_2_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SMI-4a	E1504_10_1_2_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_last_E1504_10_1_2_2_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM FG-4592	E1504_10_1_2_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_last_E1504_10_1_2_2_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BMN 673	E1504_10_1_2_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_last_E1504_10_1_2_2_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Garcinol	E1504_10_1_2_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_last_E1504_10_1_2_2_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine hemisulfate	E1504_10_1_2_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_last_E1504_10_1_2_2_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Salermide	E1504_10_1_2_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_last_E1504_10_1_2_2_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Suramin 6Na	E1504_10_1_2_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_last_E1504_10_1_2_2_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_10_1_2_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_last_E1504_10_1_2_2_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_10_1_2_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_last_E1504_10_1_2_2_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ-6438	E1504_10_1_2_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_last_E1504_10_1_2_2_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MM-102	E1504_10_1_2_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_last_E1504_10_1_2_2_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM OTX015	E1504_10_1_2_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_last_E1504_10_1_2_2_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX 01294	E1504_10_1_2_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_last_E1504_10_1_2_2_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Panobinostat (LBH589)	E1504_10_1_2_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_last_E1504_10_1_2_2_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ5676	E1504_10_1_2_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_last_E1504_10_1_2_2_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Splitomicin	E1504_10_1_2_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_last_E1504_10_1_2_2_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid	E1504_10_1_2_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_last_E1504_10_1_2_2_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MC-1293	E1504_10_1_2_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_last_E1504_10_1_2_2_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-278	E1504_10_1_2_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_last_E1504_10_1_2_2_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_10_1_2_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_last_E1504_10_1_2_2_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_10_1_2_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_last_E1504_10_1_2_2_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM C646	E1504_10_1_2_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_last_E1504_10_1_2_2_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1027	E1504_10_1_2_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_last_E1504_10_1_2_2_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC669	E1504_10_1_2_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_last_E1504_10_1_2_2_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UPF 1069	E1504_10_1_2_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_last_E1504_10_1_2_2_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Trichostatin A (TSA)	E1504_10_1_2_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_last_E1504_10_1_2_2_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM GSK J4 HCl	E1504_10_1_2_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_last_E1504_10_1_2_2_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-210	E1504_10_1_2_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_last_E1504_10_1_2_2_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nicotinamide	E1504_10_1_2_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_last_E1504_10_1_2_2_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Anacardic acid	E1504_10_1_2_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_last_E1504_10_1_2_2_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NCH-51	E1504_10_1_2_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_last_E1504_10_1_2_2_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_10_1_2_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_last_E1504_10_1_2_2_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_10_1_2_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_last_E1504_10_1_2_2_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET-762	E1504_10_1_2_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_last_E1504_10_1_2_2_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RG2833 (RGFP109)	E1504_10_1_2_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_last_E1504_10_1_2_2_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ME0328	E1504_10_1_2_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_last_E1504_10_1_2_2_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Scriptaid	E1504_10_1_2_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_last_E1504_10_1_2_2_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Vorinostat (SAHA, MK0683)	E1504_10_1_2_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_last_E1504_10_1_2_2_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC 0946	E1504_10_1_2_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_last_E1504_10_1_2_2_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Apicidin	E1504_10_1_2_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_last_E1504_10_1_2_2_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-266	E1504_10_1_2_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_last_E1504_10_1_2_2_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM B2	E1504_10_1_2_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_last_E1504_10_1_2_2_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NSC-3852	E1504_10_1_2_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_last_E1504_10_1_2_2_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_10_1_2_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_last_E1504_10_1_2_2_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RGFP966	E1504_10_1_2_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_last_E1504_10_1_2_2_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RVX-208	E1504_10_1_2_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_last_E1504_10_1_2_2_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nexturastat A	E1504_10_1_2_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_last_E1504_10_1_2_2_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A	E1504_10_1_2_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_last_E1504_10_1_2_2_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM VX-680 (Tozasertib, MK-0457)	E1504_10_1_2_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_last_E1504_10_1_2_2_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC1215	E1504_10_1_2_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_last_E1504_10_1_2_2_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Suberoyl bis-hydroxamic acid	E1504_10_1_2_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_last_E1504_10_1_2_2_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Piceatannol	E1504_10_1_2_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_last_E1504_10_1_2_2_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX-01294 3HCl	E1504_10_1_2_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_last_E1504_10_1_2_2_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Aminoresveratrol sulfate	E1504_10_1_2_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_last_E1504_10_1_2_2_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_10_1_2_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_last_E1504_10_1_2_2_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_10_1_2_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_last_E1504_10_1_2_2_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Bromosporine	E1504_10_1_2_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_last_E1504_10_1_2_2_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34 HCl	E1504_10_1_2_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_last_E1504_10_1_2_2_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Filgotinib (GLPG0634)	E1504_10_1_2_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_last_E1504_10_1_2_2_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Lomeguatrib	E1504_10_1_2_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_last_E1504_10_1_2_2_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Entinostat (MS-275)	E1504_10_1_2_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_last_E1504_10_1_2_2_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1208	E1504_10_1_2_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_last_E1504_10_1_2_2_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nullscript	E1504_10_1_2_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_last_E1504_10_1_2_2_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Fluoro-SAHA	E1504_10_1_2_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_last_E1504_10_1_2_2_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Butyrolactone 3	E1504_10_1_2_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_last_E1504_10_1_2_2_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-281	E1504_10_1_2_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_last_E1504_10_1_2_2_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_10_1_2_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_last_E1504_10_1_2_2_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_10_1_2_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_last_E1504_10_1_2_2_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX1	E1504_10_1_2_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_last_E1504_10_1_2_2_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CPI-203	E1504_10_1_2_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_last_E1504_10_1_2_2_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Rocilinostat (ACY-1215)	E1504_10_1_2_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_last_E1504_10_1_2_2_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Pacritinib (SB1518)	E1504_10_1_2_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_last_E1504_10_1_2_2_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Olaparib (AZD2281, Ku-0059436)	E1504_10_1_2_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_last_E1504_10_1_2_2_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM (+)-JQ1	E1504_10_1_2_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_last_E1504_10_1_2_2_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Isonicotinamide	E1504_10_1_2_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_last_E1504_10_1_2_2_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid hydroxamate	E1504_10_1_2_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_last_E1504_10_1_2_2_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CTPB	E1504_10_1_2_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_last_E1504_10_1_2_2_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Triacetylresveratrol	E1504_10_1_2_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_last_E1504_10_1_2_2_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_10_1_2_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_last_E1504_10_1_2_2_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_11_1_3_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_11_1_3_1_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Belinostat (PXD101)	E1504_11_1_3_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_11_1_3_1_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Danusertib (PHA-739358)	E1504_11_1_3_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_11_1_3_1_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SNS-314 Mesylate	E1504_11_1_3_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_11_1_3_1_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM JNJ-7706621	E1504_11_1_3_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_11_1_3_1_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT129202	E1504_11_1_3_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_11_1_3_1_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-14361	E1504_11_1_3_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_11_1_3_1_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A HCl	E1504_11_1_3_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_11_1_3_1_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-907	E1504_11_1_3_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_11_1_3_1_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CI994 (Tacedinaline)	E1504_11_1_3_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_11_1_3_1_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Entacapone	E1504_11_1_3_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_11_1_3_1_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_11_1_3_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_11_1_3_1_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_11_1_3_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_11_1_3_1_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Iniparib (BSI-201)	E1504_11_1_3_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_11_1_3_1_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mocetinostat (MGCD0103)	E1504_11_1_3_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_11_1_3_1_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid sodium salt (Sodium valproate)	E1504_11_1_3_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_11_1_3_1_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Ruxolitinib (INCB018424)	E1504_11_1_3_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_11_1_3_1_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Hesperadin	E1504_11_1_3_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_11_1_3_1_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM LY2784544	E1504_11_1_3_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_11_1_3_1_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NVP-BSK805 2HCl	E1504_11_1_3_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_11_1_3_1_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MK-5108 (VX-689)	E1504_11_1_3_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_11_1_3_1_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RG108	E1504_11_1_3_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_11_1_3_1_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Sodium Phenylbutyrate	E1504_11_1_3_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_11_1_3_1_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_11_1_3_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_11_1_3_1_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_11_1_3_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_11_1_3_1_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-24781 (Abexinostat)	E1504_11_1_3_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_11_1_3_1_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SRT1720	E1504_11_1_3_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_11_1_3_1_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CYC116	E1504_11_1_3_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_11_1_3_1_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Resveratrol	E1504_11_1_3_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_11_1_3_1_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EX 527 (Selisistat)	E1504_11_1_3_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_11_1_3_1_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1776 free base	E1504_11_1_3_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_11_1_3_1_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101209	E1504_11_1_3_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_11_1_3_1_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM M344	E1504_11_1_3_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_11_1_3_1_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Baricitinib (LY3009104, INCB028050)	E1504_11_1_3_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_11_1_3_1_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine (2-PCPA) HCl	E1504_11_1_3_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_11_1_3_1_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_11_1_3_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_11_1_3_1_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_11_1_3_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_11_1_3_1_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM LAQ824 (Dacinostat)	E1504_11_1_3_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_11_1_3_1_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM INO-1001	E1504_11_1_3_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_11_1_3_1_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ENMD-2076	E1504_11_1_3_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_11_1_3_1_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Droxinostat	E1504_11_1_3_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_11_1_3_1_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Azacitidine	E1504_11_1_3_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_11_1_3_1_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZ 960	E1504_11_1_3_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_11_1_3_1_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Resminostat	E1504_11_1_3_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_11_1_3_1_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET151 (GSK1210151A)	E1504_11_1_3_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_11_1_3_1_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM WHI-P154	E1504_11_1_3_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_11_1_3_1_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Aminobenzamide	E1504_11_1_3_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_11_1_3_1_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_11_1_3_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_11_1_3_1_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_11_1_3_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_11_1_3_1_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Quisinostat (JNJ-26481585)	E1504_11_1_3_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_11_1_3_1_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Alisertib (MLN8237)	E1504_11_1_3_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_11_1_3_1_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-101	E1504_11_1_3_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_11_1_3_1_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Aurora A Inhibitor I	E1504_11_1_3_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_11_1_3_1_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-34051	E1504_11_1_3_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_11_1_3_1_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CYT387	E1504_11_1_3_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_11_1_3_1_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TAK-901	E1504_11_1_3_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_11_1_3_1_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550,Tasocitinib)	E1504_11_1_3_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_11_1_3_1_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34	E1504_11_1_3_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_11_1_3_1_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Procainamide HCl	E1504_11_1_3_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_11_1_3_1_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_11_1_3_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_11_1_3_1_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_11_1_3_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_11_1_3_1_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Rucaparib (AG-014699,PF-01367338)	E1504_11_1_3_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_11_1_3_1_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AT9283	E1504_11_1_3_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_11_1_3_1_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Decitabine	E1504_11_1_3_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_11_1_3_1_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PHA-680632	E1504_11_1_3_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_11_1_3_1_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM KW-2449	E1504_11_1_3_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_11_1_3_1_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubacin	E1504_11_1_3_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_11_1_3_1_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AMG-900	E1504_11_1_3_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_11_1_3_1_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM WP1066	E1504_11_1_3_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_11_1_3_1_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM S-Ruxolitinib (INCB018424)	E1504_11_1_3_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_11_1_3_1_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550) Citrate	E1504_11_1_3_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_11_1_3_1_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_11_1_3_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_11_1_3_1_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_11_1_3_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_11_1_3_1_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MLN8054	E1504_11_1_3_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_11_1_3_1_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-490 (Tyrphostin B42)	E1504_11_1_3_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_11_1_3_1_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PFI-1 (PF-6405761)	E1504_11_1_3_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_11_1_3_1_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MC1568	E1504_11_1_3_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_11_1_3_1_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1480	E1504_11_1_3_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_11_1_3_1_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AR-42	E1504_11_1_3_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_11_1_3_1_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101348 (SAR302503)	E1504_11_1_3_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_11_1_3_1_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Sirtinol	E1504_11_1_3_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_11_1_3_1_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX2	E1504_11_1_3_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_11_1_3_1_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD2461	E1504_11_1_3_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_11_1_3_1_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_11_1_3_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_11_1_3_1_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_11_1_3_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_11_1_3_1_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 447439	E1504_11_1_3_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_11_1_3_1_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Barasertib (AZD1152-HQPA)	E1504_11_1_3_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_11_1_3_1_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 2-Methoxyestradiol (2-MeOE2)	E1504_11_1_3_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_11_1_3_1_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Pracinostat (SB939)	E1504_11_1_3_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_11_1_3_1_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Givinostat (ITF2357)	E1504_11_1_3_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_11_1_3_1_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Quercetin	E1504_11_1_3_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_11_1_3_1_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT137690	E1504_11_1_3_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_11_1_3_1_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CEP-33779	E1504_11_1_3_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_11_1_3_1_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Romidepsin (FK228, Depsipeptide)	E1504_11_1_3_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_11_1_3_1_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM XL019	E1504_11_1_3_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_11_1_3_1_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_11_1_3_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_11_1_3_1_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_12_1_3_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_12_1_3_2_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Zebularine	E1504_12_1_3_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_12_1_3_2_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM OG-L002	E1504_12_1_3_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_12_1_3_2_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TMP269	E1504_12_1_3_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_12_1_3_2_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 39923 HCl	E1504_12_1_3_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_12_1_3_2_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Veliparib (ABT-888)	E1504_12_1_3_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_12_1_3_2_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CX-6258 HCl	E1504_12_1_3_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_12_1_3_2_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 2,4-Pyridinedicarboxylic Acid	E1504_12_1_3_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_12_1_3_2_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ITSA-1	E1504_12_1_3_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_12_1_3_2_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AGK2	E1504_12_1_3_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_12_1_3_2_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Oxamflatin	E1504_12_1_3_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_12_1_3_2_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_12_1_3_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_12_1_3_2_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_12_1_3_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_12_1_3_2_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Deazaneplanocin A (DZNeP)	E1504_12_1_3_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_12_1_3_2_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC-CBP30	E1504_12_1_3_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_12_1_3_2_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ004777	E1504_12_1_3_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_12_1_3_2_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SMI-4a	E1504_12_1_3_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_12_1_3_2_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM FG-4592	E1504_12_1_3_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_12_1_3_2_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BMN 673	E1504_12_1_3_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_12_1_3_2_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Garcinol	E1504_12_1_3_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_12_1_3_2_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine hemisulfate	E1504_12_1_3_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_12_1_3_2_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Salermide	E1504_12_1_3_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_12_1_3_2_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Suramin 6Na	E1504_12_1_3_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_12_1_3_2_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_12_1_3_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_12_1_3_2_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_12_1_3_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_12_1_3_2_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ-6438	E1504_12_1_3_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_12_1_3_2_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MM-102	E1504_12_1_3_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_12_1_3_2_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM OTX015	E1504_12_1_3_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_12_1_3_2_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX 01294	E1504_12_1_3_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_12_1_3_2_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Panobinostat (LBH589)	E1504_12_1_3_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_12_1_3_2_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ5676	E1504_12_1_3_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_12_1_3_2_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Splitomicin	E1504_12_1_3_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_12_1_3_2_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid	E1504_12_1_3_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_12_1_3_2_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MC-1293	E1504_12_1_3_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_12_1_3_2_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-278	E1504_12_1_3_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_12_1_3_2_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_12_1_3_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_12_1_3_2_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_12_1_3_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_12_1_3_2_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM C646	E1504_12_1_3_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_12_1_3_2_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1027	E1504_12_1_3_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_12_1_3_2_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC669	E1504_12_1_3_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_12_1_3_2_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UPF 1069	E1504_12_1_3_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_12_1_3_2_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Trichostatin A (TSA)	E1504_12_1_3_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_12_1_3_2_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM GSK J4 HCl	E1504_12_1_3_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_12_1_3_2_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-210	E1504_12_1_3_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_12_1_3_2_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nicotinamide	E1504_12_1_3_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_12_1_3_2_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Anacardic acid	E1504_12_1_3_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_12_1_3_2_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NCH-51	E1504_12_1_3_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_12_1_3_2_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_12_1_3_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_12_1_3_2_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_12_1_3_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_12_1_3_2_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET-762	E1504_12_1_3_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_12_1_3_2_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RG2833 (RGFP109)	E1504_12_1_3_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_12_1_3_2_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ME0328	E1504_12_1_3_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_12_1_3_2_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Scriptaid	E1504_12_1_3_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_12_1_3_2_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Vorinostat (SAHA, MK0683)	E1504_12_1_3_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_12_1_3_2_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC 0946	E1504_12_1_3_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_12_1_3_2_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Apicidin	E1504_12_1_3_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_12_1_3_2_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-266	E1504_12_1_3_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_12_1_3_2_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM B2	E1504_12_1_3_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_12_1_3_2_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NSC-3852	E1504_12_1_3_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_12_1_3_2_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_12_1_3_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_12_1_3_2_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_12_1_3_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_12_1_3_2_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RGFP966	E1504_12_1_3_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_12_1_3_2_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RVX-208	E1504_12_1_3_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_12_1_3_2_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nexturastat A	E1504_12_1_3_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_12_1_3_2_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A	E1504_12_1_3_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_12_1_3_2_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM VX-680 (Tozasertib, MK-0457)	E1504_12_1_3_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_12_1_3_2_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC1215	E1504_12_1_3_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_12_1_3_2_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Suberoyl bis-hydroxamic acid	E1504_12_1_3_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_12_1_3_2_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Piceatannol	E1504_12_1_3_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_12_1_3_2_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX-01294 3HCl	E1504_12_1_3_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_12_1_3_2_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Aminoresveratrol sulfate	E1504_12_1_3_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_12_1_3_2_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_12_1_3_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_12_1_3_2_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_12_1_3_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_12_1_3_2_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Bromosporine	E1504_12_1_3_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_12_1_3_2_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34 HCl	E1504_12_1_3_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_12_1_3_2_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Filgotinib (GLPG0634)	E1504_12_1_3_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_12_1_3_2_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Lomeguatrib	E1504_12_1_3_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_12_1_3_2_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Entinostat (MS-275)	E1504_12_1_3_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_12_1_3_2_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1208	E1504_12_1_3_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_12_1_3_2_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nullscript	E1504_12_1_3_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_12_1_3_2_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Fluoro-SAHA	E1504_12_1_3_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_12_1_3_2_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Butyrolactone 3	E1504_12_1_3_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_12_1_3_2_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-281	E1504_12_1_3_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_12_1_3_2_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_12_1_3_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_12_1_3_2_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_12_1_3_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_12_1_3_2_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX1	E1504_12_1_3_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_12_1_3_2_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CPI-203	E1504_12_1_3_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_12_1_3_2_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Rocilinostat (ACY-1215)	E1504_12_1_3_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_12_1_3_2_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Pacritinib (SB1518)	E1504_12_1_3_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_12_1_3_2_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Olaparib (AZD2281, Ku-0059436)	E1504_12_1_3_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_12_1_3_2_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM (+)-JQ1	E1504_12_1_3_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_12_1_3_2_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Isonicotinamide	E1504_12_1_3_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_12_1_3_2_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid hydroxamate	E1504_12_1_3_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_12_1_3_2_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CTPB	E1504_12_1_3_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_12_1_3_2_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Triacetylresveratrol	E1504_12_1_3_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_12_1_3_2_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_12_1_3_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_12_1_3_2_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_13_10_1_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_13_10_1_1_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Belinostat (PXD101)	E1504_13_10_1_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_13_10_1_1_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Danusertib (PHA-739358)	E1504_13_10_1_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_13_10_1_1_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SNS-314 Mesylate	E1504_13_10_1_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_13_10_1_1_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM JNJ-7706621	E1504_13_10_1_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_13_10_1_1_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CCT129202	E1504_13_10_1_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_13_10_1_1_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AG-14361	E1504_13_10_1_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_13_10_1_1_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubastatin A HCl	E1504_13_10_1_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_13_10_1_1_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CUDC-907	E1504_13_10_1_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_13_10_1_1_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CI994 (Tacedinaline)	E1504_13_10_1_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_13_10_1_1_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Entacapone	E1504_13_10_1_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_13_10_1_1_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_13_10_1_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_13_10_1_1_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_13_10_1_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_13_10_1_1_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Iniparib (BSI-201)	E1504_13_10_1_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_13_10_1_1_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Mocetinostat (MGCD0103)	E1504_13_10_1_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_13_10_1_1_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid sodium salt (Sodium valproate)	E1504_13_10_1_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_13_10_1_1_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Ruxolitinib (INCB018424)	E1504_13_10_1_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_13_10_1_1_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Hesperadin	E1504_13_10_1_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_13_10_1_1_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM LY2784544	E1504_13_10_1_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_13_10_1_1_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM NVP-BSK805 2HCl	E1504_13_10_1_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_13_10_1_1_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MK-5108 (VX-689)	E1504_13_10_1_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_13_10_1_1_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RG108	E1504_13_10_1_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_13_10_1_1_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Sodium Phenylbutyrate	E1504_13_10_1_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_13_10_1_1_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_13_10_1_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_13_10_1_1_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_13_10_1_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_13_10_1_1_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PCI-24781 (Abexinostat)	E1504_13_10_1_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_13_10_1_1_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SRT1720	E1504_13_10_1_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_13_10_1_1_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CYC116	E1504_13_10_1_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_13_10_1_1_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Resveratrol	E1504_13_10_1_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_13_10_1_1_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EX 527 (Selisistat)	E1504_13_10_1_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_13_10_1_1_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGI-1776 free base	E1504_13_10_1_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_13_10_1_1_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TG101209	E1504_13_10_1_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_13_10_1_1_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM M344	E1504_13_10_1_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_13_10_1_1_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Baricitinib (LY3009104, INCB028050)	E1504_13_10_1_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_13_10_1_1_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tranylcypromine (2-PCPA) HCl	E1504_13_10_1_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_13_10_1_1_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_13_10_1_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_13_10_1_1_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_13_10_1_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_13_10_1_1_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM LAQ824 (Dacinostat)	E1504_13_10_1_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_13_10_1_1_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM INO-1001	E1504_13_10_1_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_13_10_1_1_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ENMD-2076	E1504_13_10_1_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_13_10_1_1_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Droxinostat	E1504_13_10_1_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_13_10_1_1_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Azacitidine	E1504_13_10_1_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_13_10_1_1_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZ 960	E1504_13_10_1_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_13_10_1_1_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Resminostat	E1504_13_10_1_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_13_10_1_1_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM I-BET151 (GSK1210151A)	E1504_13_10_1_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_13_10_1_1_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM WHI-P154	E1504_13_10_1_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_13_10_1_1_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 3-Aminobenzamide	E1504_13_10_1_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_13_10_1_1_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_13_10_1_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_13_10_1_1_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_13_10_1_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_13_10_1_1_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Quisinostat (JNJ-26481585)	E1504_13_10_1_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_13_10_1_1_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Alisertib (MLN8237)	E1504_13_10_1_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_13_10_1_1_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CUDC-101	E1504_13_10_1_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_13_10_1_1_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Aurora A Inhibitor I	E1504_13_10_1_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_13_10_1_1_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PCI-34051	E1504_13_10_1_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_13_10_1_1_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CYT387	E1504_13_10_1_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_13_10_1_1_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TAK-901	E1504_13_10_1_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_13_10_1_1_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tofacitinib (CP-690550,Tasocitinib)	E1504_13_10_1_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_13_10_1_1_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PJ34	E1504_13_10_1_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_13_10_1_1_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Procainamide HCl	E1504_13_10_1_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_13_10_1_1_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_13_10_1_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_13_10_1_1_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_13_10_1_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_13_10_1_1_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Rucaparib (AG-014699,PF-01367338)	E1504_13_10_1_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_13_10_1_1_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AT9283	E1504_13_10_1_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_13_10_1_1_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Decitabine	E1504_13_10_1_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_13_10_1_1_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PHA-680632	E1504_13_10_1_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_13_10_1_1_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM KW-2449	E1504_13_10_1_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_13_10_1_1_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubacin	E1504_13_10_1_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_13_10_1_1_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AMG-900	E1504_13_10_1_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_13_10_1_1_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM WP1066	E1504_13_10_1_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_13_10_1_1_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM S-Ruxolitinib (INCB018424)	E1504_13_10_1_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_13_10_1_1_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tofacitinib (CP-690550) Citrate	E1504_13_10_1_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_13_10_1_1_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_13_10_1_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_13_10_1_1_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_13_10_1_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_13_10_1_1_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MLN8054	E1504_13_10_1_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_13_10_1_1_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AG-490 (Tyrphostin B42)	E1504_13_10_1_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_13_10_1_1_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PFI-1 (PF-6405761)	E1504_13_10_1_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_13_10_1_1_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MC1568	E1504_13_10_1_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_13_10_1_1_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD1480	E1504_13_10_1_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_13_10_1_1_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AR-42	E1504_13_10_1_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_13_10_1_1_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TG101348 (SAR302503)	E1504_13_10_1_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_13_10_1_1_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Sirtinol	E1504_13_10_1_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_13_10_1_1_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM IOX2	E1504_13_10_1_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_13_10_1_1_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD2461	E1504_13_10_1_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_13_10_1_1_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_13_10_1_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_13_10_1_1_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_13_10_1_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_13_10_1_1_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ZM 447439	E1504_13_10_1_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_13_10_1_1_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Barasertib (AZD1152-HQPA)	E1504_13_10_1_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_13_10_1_1_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 2-Methoxyestradiol (2-MeOE2)	E1504_13_10_1_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_13_10_1_1_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Pracinostat (SB939)	E1504_13_10_1_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_13_10_1_1_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Givinostat (ITF2357)	E1504_13_10_1_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_13_10_1_1_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Quercetin	E1504_13_10_1_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_13_10_1_1_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CCT137690	E1504_13_10_1_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_13_10_1_1_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CEP-33779	E1504_13_10_1_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_13_10_1_1_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Romidepsin (FK228, Depsipeptide)	E1504_13_10_1_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_13_10_1_1_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM XL019	E1504_13_10_1_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_13_10_1_1_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_13_10_1_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_13_10_1_1_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_14_10_1_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_14_10_1_2_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Zebularine	E1504_14_10_1_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_14_10_1_2_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM OG-L002	E1504_14_10_1_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_14_10_1_2_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TMP269	E1504_14_10_1_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_14_10_1_2_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ZM 39923 HCl	E1504_14_10_1_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_14_10_1_2_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Veliparib (ABT-888)	E1504_14_10_1_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_14_10_1_2_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CX-6258 HCl	E1504_14_10_1_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_14_10_1_2_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 2,4-Pyridinedicarboxylic Acid	E1504_14_10_1_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_14_10_1_2_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ITSA-1	E1504_14_10_1_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_14_10_1_2_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AGK2	E1504_14_10_1_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_14_10_1_2_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Oxamflatin	E1504_14_10_1_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_14_10_1_2_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_14_10_1_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_14_10_1_2_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_14_10_1_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_14_10_1_2_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 3-Deazaneplanocin A (DZNeP)	E1504_14_10_1_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_14_10_1_2_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGC-CBP30	E1504_14_10_1_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_14_10_1_2_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ004777	E1504_14_10_1_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_14_10_1_2_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SMI-4a	E1504_14_10_1_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_14_10_1_2_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM FG-4592	E1504_14_10_1_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_14_10_1_2_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BMN 673	E1504_14_10_1_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_14_10_1_2_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Garcinol	E1504_14_10_1_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_14_10_1_2_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tranylcypromine hemisulfate	E1504_14_10_1_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_14_10_1_2_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Salermide	E1504_14_10_1_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_14_10_1_2_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Suramin 6Na	E1504_14_10_1_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_14_10_1_2_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_14_10_1_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_14_10_1_2_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_14_10_1_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_14_10_1_2_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ-6438	E1504_14_10_1_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_14_10_1_2_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MM-102	E1504_14_10_1_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_14_10_1_2_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM OTX015	E1504_14_10_1_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_14_10_1_2_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BIX 01294	E1504_14_10_1_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_14_10_1_2_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Panobinostat (LBH589)	E1504_14_10_1_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_14_10_1_2_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ5676	E1504_14_10_1_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_14_10_1_2_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Splitomicin	E1504_14_10_1_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_14_10_1_2_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid	E1504_14_10_1_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_14_10_1_2_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MC-1293	E1504_14_10_1_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_14_10_1_2_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-278	E1504_14_10_1_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_14_10_1_2_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_14_10_1_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_14_10_1_2_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_14_10_1_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_14_10_1_2_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM C646	E1504_14_10_1_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_14_10_1_2_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGI-1027	E1504_14_10_1_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_14_10_1_2_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM UNC669	E1504_14_10_1_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_14_10_1_2_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM UPF 1069	E1504_14_10_1_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_14_10_1_2_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Trichostatin A (TSA)	E1504_14_10_1_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_14_10_1_2_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM GSK J4 HCl	E1504_14_10_1_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_14_10_1_2_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-210	E1504_14_10_1_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_14_10_1_2_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nicotinamide	E1504_14_10_1_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_14_10_1_2_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Anacardic acid	E1504_14_10_1_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_14_10_1_2_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM NCH-51	E1504_14_10_1_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_14_10_1_2_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_14_10_1_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_14_10_1_2_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_14_10_1_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_14_10_1_2_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM I-BET-762	E1504_14_10_1_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_14_10_1_2_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RG2833 (RGFP109)	E1504_14_10_1_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_14_10_1_2_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ME0328	E1504_14_10_1_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_14_10_1_2_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Scriptaid	E1504_14_10_1_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_14_10_1_2_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Vorinostat (SAHA, MK0683)	E1504_14_10_1_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_14_10_1_2_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGC 0946	E1504_14_10_1_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_14_10_1_2_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Apicidin	E1504_14_10_1_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_14_10_1_2_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-266	E1504_14_10_1_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_14_10_1_2_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM B2	E1504_14_10_1_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_14_10_1_2_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM NSC-3852	E1504_14_10_1_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_14_10_1_2_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_14_10_1_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_14_10_1_2_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_14_10_1_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_14_10_1_2_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RGFP966	E1504_14_10_1_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_14_10_1_2_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RVX-208	E1504_14_10_1_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_14_10_1_2_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nexturastat A	E1504_14_10_1_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_14_10_1_2_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubastatin A	E1504_14_10_1_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_14_10_1_2_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM VX-680 (Tozasertib, MK-0457)	E1504_14_10_1_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_14_10_1_2_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM UNC1215	E1504_14_10_1_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_14_10_1_2_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Suberoyl bis-hydroxamic acid	E1504_14_10_1_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_14_10_1_2_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Piceatannol	E1504_14_10_1_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_14_10_1_2_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BIX-01294 3HCl	E1504_14_10_1_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_14_10_1_2_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Aminoresveratrol sulfate	E1504_14_10_1_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_14_10_1_2_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_14_10_1_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_14_10_1_2_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_14_10_1_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_14_10_1_2_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Bromosporine	E1504_14_10_1_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_14_10_1_2_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PJ34 HCl	E1504_14_10_1_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_14_10_1_2_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Filgotinib (GLPG0634)	E1504_14_10_1_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_14_10_1_2_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Lomeguatrib	E1504_14_10_1_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_14_10_1_2_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Entinostat (MS-275)	E1504_14_10_1_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_14_10_1_2_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD1208	E1504_14_10_1_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_14_10_1_2_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nullscript	E1504_14_10_1_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_14_10_1_2_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Fluoro-SAHA	E1504_14_10_1_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_14_10_1_2_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Butyrolactone 3	E1504_14_10_1_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_14_10_1_2_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-281	E1504_14_10_1_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_14_10_1_2_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_14_10_1_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_14_10_1_2_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_14_10_1_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_14_10_1_2_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM IOX1	E1504_14_10_1_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_14_10_1_2_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CPI-203	E1504_14_10_1_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_14_10_1_2_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Rocilinostat (ACY-1215)	E1504_14_10_1_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_14_10_1_2_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Pacritinib (SB1518)	E1504_14_10_1_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_14_10_1_2_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Olaparib (AZD2281, Ku-0059436)	E1504_14_10_1_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_14_10_1_2_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM (+)-JQ1	E1504_14_10_1_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_14_10_1_2_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Isonicotinamide	E1504_14_10_1_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_14_10_1_2_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid hydroxamate	E1504_14_10_1_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_14_10_1_2_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CTPB	E1504_14_10_1_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_14_10_1_2_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Triacetylresveratrol	E1504_14_10_1_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_14_10_1_2_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_14_10_1_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_14_10_1_2_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_15_10_2_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_15_10_2_1_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Belinostat (PXD101)	E1504_15_10_2_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_15_10_2_1_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Danusertib (PHA-739358)	E1504_15_10_2_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_15_10_2_1_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SNS-314 Mesylate	E1504_15_10_2_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_15_10_2_1_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM JNJ-7706621	E1504_15_10_2_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_15_10_2_1_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CCT129202	E1504_15_10_2_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_15_10_2_1_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AG-14361	E1504_15_10_2_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_15_10_2_1_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubastatin A HCl	E1504_15_10_2_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_15_10_2_1_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CUDC-907	E1504_15_10_2_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_15_10_2_1_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CI994 (Tacedinaline)	E1504_15_10_2_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_15_10_2_1_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Entacapone	E1504_15_10_2_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_15_10_2_1_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_15_10_2_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_15_10_2_1_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_15_10_2_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_15_10_2_1_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Iniparib (BSI-201)	E1504_15_10_2_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_15_10_2_1_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Mocetinostat (MGCD0103)	E1504_15_10_2_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_15_10_2_1_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid sodium salt (Sodium valproate)	E1504_15_10_2_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_15_10_2_1_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Ruxolitinib (INCB018424)	E1504_15_10_2_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_15_10_2_1_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Hesperadin	E1504_15_10_2_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_15_10_2_1_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM LY2784544	E1504_15_10_2_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_15_10_2_1_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM NVP-BSK805 2HCl	E1504_15_10_2_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_15_10_2_1_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MK-5108 (VX-689)	E1504_15_10_2_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_15_10_2_1_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RG108	E1504_15_10_2_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_15_10_2_1_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Sodium Phenylbutyrate	E1504_15_10_2_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_15_10_2_1_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_15_10_2_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_15_10_2_1_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_15_10_2_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_15_10_2_1_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PCI-24781 (Abexinostat)	E1504_15_10_2_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_15_10_2_1_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SRT1720	E1504_15_10_2_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_15_10_2_1_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CYC116	E1504_15_10_2_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_15_10_2_1_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Resveratrol	E1504_15_10_2_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_15_10_2_1_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EX 527 (Selisistat)	E1504_15_10_2_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_15_10_2_1_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGI-1776 free base	E1504_15_10_2_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_15_10_2_1_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TG101209	E1504_15_10_2_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_15_10_2_1_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM M344	E1504_15_10_2_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_15_10_2_1_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Baricitinib (LY3009104, INCB028050)	E1504_15_10_2_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_15_10_2_1_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tranylcypromine (2-PCPA) HCl	E1504_15_10_2_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_15_10_2_1_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_15_10_2_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_15_10_2_1_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_15_10_2_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_15_10_2_1_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM LAQ824 (Dacinostat)	E1504_15_10_2_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_15_10_2_1_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM INO-1001	E1504_15_10_2_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_15_10_2_1_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ENMD-2076	E1504_15_10_2_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_15_10_2_1_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Droxinostat	E1504_15_10_2_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_15_10_2_1_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Azacitidine	E1504_15_10_2_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_15_10_2_1_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZ 960	E1504_15_10_2_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_15_10_2_1_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Resminostat	E1504_15_10_2_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_15_10_2_1_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM I-BET151 (GSK1210151A)	E1504_15_10_2_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_15_10_2_1_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM WHI-P154	E1504_15_10_2_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_15_10_2_1_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 3-Aminobenzamide	E1504_15_10_2_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_15_10_2_1_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_15_10_2_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_15_10_2_1_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_15_10_2_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_15_10_2_1_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Quisinostat (JNJ-26481585)	E1504_15_10_2_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_15_10_2_1_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Alisertib (MLN8237)	E1504_15_10_2_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_15_10_2_1_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CUDC-101	E1504_15_10_2_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_15_10_2_1_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Aurora A Inhibitor I	E1504_15_10_2_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_15_10_2_1_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PCI-34051	E1504_15_10_2_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_15_10_2_1_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CYT387	E1504_15_10_2_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_15_10_2_1_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TAK-901	E1504_15_10_2_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_15_10_2_1_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tofacitinib (CP-690550,Tasocitinib)	E1504_15_10_2_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_15_10_2_1_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PJ34	E1504_15_10_2_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_15_10_2_1_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Procainamide HCl	E1504_15_10_2_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_15_10_2_1_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_15_10_2_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_15_10_2_1_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_15_10_2_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_15_10_2_1_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Rucaparib (AG-014699,PF-01367338)	E1504_15_10_2_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_15_10_2_1_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AT9283	E1504_15_10_2_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_15_10_2_1_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Decitabine	E1504_15_10_2_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_15_10_2_1_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PHA-680632	E1504_15_10_2_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_15_10_2_1_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM KW-2449	E1504_15_10_2_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_15_10_2_1_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubacin	E1504_15_10_2_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_15_10_2_1_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AMG-900	E1504_15_10_2_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_15_10_2_1_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM WP1066	E1504_15_10_2_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_15_10_2_1_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM S-Ruxolitinib (INCB018424)	E1504_15_10_2_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_15_10_2_1_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tofacitinib (CP-690550) Citrate	E1504_15_10_2_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_15_10_2_1_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_15_10_2_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_15_10_2_1_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_15_10_2_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_15_10_2_1_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MLN8054	E1504_15_10_2_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_15_10_2_1_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AG-490 (Tyrphostin B42)	E1504_15_10_2_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_15_10_2_1_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PFI-1 (PF-6405761)	E1504_15_10_2_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_15_10_2_1_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MC1568	E1504_15_10_2_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_15_10_2_1_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD1480	E1504_15_10_2_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_15_10_2_1_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AR-42	E1504_15_10_2_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_15_10_2_1_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TG101348 (SAR302503)	E1504_15_10_2_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_15_10_2_1_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Sirtinol	E1504_15_10_2_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_15_10_2_1_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM IOX2	E1504_15_10_2_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_15_10_2_1_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD2461	E1504_15_10_2_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_15_10_2_1_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_15_10_2_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_15_10_2_1_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_15_10_2_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_15_10_2_1_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ZM 447439	E1504_15_10_2_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_15_10_2_1_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Barasertib (AZD1152-HQPA)	E1504_15_10_2_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_15_10_2_1_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 2-Methoxyestradiol (2-MeOE2)	E1504_15_10_2_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_15_10_2_1_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Pracinostat (SB939)	E1504_15_10_2_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_15_10_2_1_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Givinostat (ITF2357)	E1504_15_10_2_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_15_10_2_1_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Quercetin	E1504_15_10_2_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_15_10_2_1_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CCT137690	E1504_15_10_2_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_15_10_2_1_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CEP-33779	E1504_15_10_2_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_15_10_2_1_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Romidepsin (FK228, Depsipeptide)	E1504_15_10_2_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_15_10_2_1_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM XL019	E1504_15_10_2_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_15_10_2_1_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_15_10_2_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_15_10_2_1_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_16_10_2_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_16_10_2_2_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Zebularine	E1504_16_10_2_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_16_10_2_2_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM OG-L002	E1504_16_10_2_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_16_10_2_2_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TMP269	E1504_16_10_2_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_16_10_2_2_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ZM 39923 HCl	E1504_16_10_2_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_16_10_2_2_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Veliparib (ABT-888)	E1504_16_10_2_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_16_10_2_2_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CX-6258 HCl	E1504_16_10_2_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_16_10_2_2_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 2,4-Pyridinedicarboxylic Acid	E1504_16_10_2_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_16_10_2_2_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ITSA-1	E1504_16_10_2_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_16_10_2_2_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AGK2	E1504_16_10_2_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_16_10_2_2_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Oxamflatin	E1504_16_10_2_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_16_10_2_2_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_16_10_2_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_16_10_2_2_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_16_10_2_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_16_10_2_2_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 3-Deazaneplanocin A (DZNeP)	E1504_16_10_2_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_16_10_2_2_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGC-CBP30	E1504_16_10_2_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_16_10_2_2_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ004777	E1504_16_10_2_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_16_10_2_2_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SMI-4a	E1504_16_10_2_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_16_10_2_2_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM FG-4592	E1504_16_10_2_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_16_10_2_2_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BMN 673	E1504_16_10_2_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_16_10_2_2_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Garcinol	E1504_16_10_2_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_16_10_2_2_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tranylcypromine hemisulfate	E1504_16_10_2_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_16_10_2_2_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Salermide	E1504_16_10_2_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_16_10_2_2_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Suramin 6Na	E1504_16_10_2_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_16_10_2_2_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_16_10_2_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_16_10_2_2_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_16_10_2_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_16_10_2_2_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ-6438	E1504_16_10_2_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_16_10_2_2_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MM-102	E1504_16_10_2_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_16_10_2_2_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM OTX015	E1504_16_10_2_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_16_10_2_2_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BIX 01294	E1504_16_10_2_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_16_10_2_2_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Panobinostat (LBH589)	E1504_16_10_2_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_16_10_2_2_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ5676	E1504_16_10_2_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_16_10_2_2_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Splitomicin	E1504_16_10_2_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_16_10_2_2_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid	E1504_16_10_2_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_16_10_2_2_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MC-1293	E1504_16_10_2_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_16_10_2_2_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-278	E1504_16_10_2_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_16_10_2_2_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_16_10_2_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_16_10_2_2_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_16_10_2_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_16_10_2_2_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM C646	E1504_16_10_2_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_16_10_2_2_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGI-1027	E1504_16_10_2_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_16_10_2_2_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM UNC669	E1504_16_10_2_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_16_10_2_2_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM UPF 1069	E1504_16_10_2_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_16_10_2_2_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Trichostatin A (TSA)	E1504_16_10_2_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_16_10_2_2_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM GSK J4 HCl	E1504_16_10_2_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_16_10_2_2_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-210	E1504_16_10_2_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_16_10_2_2_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nicotinamide	E1504_16_10_2_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_16_10_2_2_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Anacardic acid	E1504_16_10_2_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_16_10_2_2_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM NCH-51	E1504_16_10_2_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_16_10_2_2_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_16_10_2_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_16_10_2_2_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_16_10_2_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_16_10_2_2_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM I-BET-762	E1504_16_10_2_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_16_10_2_2_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RG2833 (RGFP109)	E1504_16_10_2_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_16_10_2_2_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ME0328	E1504_16_10_2_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_16_10_2_2_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Scriptaid	E1504_16_10_2_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_16_10_2_2_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Vorinostat (SAHA, MK0683)	E1504_16_10_2_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_16_10_2_2_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGC 0946	E1504_16_10_2_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_16_10_2_2_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Apicidin	E1504_16_10_2_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_16_10_2_2_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-266	E1504_16_10_2_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_16_10_2_2_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM B2	E1504_16_10_2_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_16_10_2_2_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM NSC-3852	E1504_16_10_2_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_16_10_2_2_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_16_10_2_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_16_10_2_2_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_16_10_2_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_16_10_2_2_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RGFP966	E1504_16_10_2_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_16_10_2_2_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RVX-208	E1504_16_10_2_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_16_10_2_2_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nexturastat A	E1504_16_10_2_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_16_10_2_2_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubastatin A	E1504_16_10_2_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_16_10_2_2_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM VX-680 (Tozasertib, MK-0457)	E1504_16_10_2_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_16_10_2_2_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM UNC1215	E1504_16_10_2_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_16_10_2_2_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Suberoyl bis-hydroxamic acid	E1504_16_10_2_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_16_10_2_2_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Piceatannol	E1504_16_10_2_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_16_10_2_2_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BIX-01294 3HCl	E1504_16_10_2_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_16_10_2_2_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Aminoresveratrol sulfate	E1504_16_10_2_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_16_10_2_2_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_16_10_2_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_16_10_2_2_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_16_10_2_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_16_10_2_2_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Bromosporine	E1504_16_10_2_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_16_10_2_2_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PJ34 HCl	E1504_16_10_2_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_16_10_2_2_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Filgotinib (GLPG0634)	E1504_16_10_2_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_16_10_2_2_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Lomeguatrib	E1504_16_10_2_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_16_10_2_2_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Entinostat (MS-275)	E1504_16_10_2_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_16_10_2_2_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD1208	E1504_16_10_2_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_16_10_2_2_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nullscript	E1504_16_10_2_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_16_10_2_2_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Fluoro-SAHA	E1504_16_10_2_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_16_10_2_2_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Butyrolactone 3	E1504_16_10_2_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_16_10_2_2_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-281	E1504_16_10_2_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_16_10_2_2_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_16_10_2_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_16_10_2_2_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_16_10_2_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_16_10_2_2_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM IOX1	E1504_16_10_2_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_16_10_2_2_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CPI-203	E1504_16_10_2_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_16_10_2_2_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Rocilinostat (ACY-1215)	E1504_16_10_2_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_16_10_2_2_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Pacritinib (SB1518)	E1504_16_10_2_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_16_10_2_2_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Olaparib (AZD2281, Ku-0059436)	E1504_16_10_2_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_16_10_2_2_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM (+)-JQ1	E1504_16_10_2_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_16_10_2_2_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Isonicotinamide	E1504_16_10_2_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_16_10_2_2_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid hydroxamate	E1504_16_10_2_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_16_10_2_2_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CTPB	E1504_16_10_2_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_16_10_2_2_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Triacetylresveratrol	E1504_16_10_2_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_16_10_2_2_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_16_10_2_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_16_10_2_2_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_17_10_3_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_17_10_3_1_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Belinostat (PXD101)	E1504_17_10_3_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_17_10_3_1_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Danusertib (PHA-739358)	E1504_17_10_3_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_17_10_3_1_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SNS-314 Mesylate	E1504_17_10_3_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_17_10_3_1_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM JNJ-7706621	E1504_17_10_3_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_17_10_3_1_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CCT129202	E1504_17_10_3_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_17_10_3_1_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AG-14361	E1504_17_10_3_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_17_10_3_1_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubastatin A HCl	E1504_17_10_3_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_17_10_3_1_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CUDC-907	E1504_17_10_3_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_17_10_3_1_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CI994 (Tacedinaline)	E1504_17_10_3_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_17_10_3_1_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Entacapone	E1504_17_10_3_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_17_10_3_1_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_17_10_3_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_17_10_3_1_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_17_10_3_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_17_10_3_1_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Iniparib (BSI-201)	E1504_17_10_3_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_17_10_3_1_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Mocetinostat (MGCD0103)	E1504_17_10_3_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_17_10_3_1_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid sodium salt (Sodium valproate)	E1504_17_10_3_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_17_10_3_1_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Ruxolitinib (INCB018424)	E1504_17_10_3_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_17_10_3_1_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Hesperadin	E1504_17_10_3_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_17_10_3_1_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM LY2784544	E1504_17_10_3_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_17_10_3_1_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM NVP-BSK805 2HCl	E1504_17_10_3_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_17_10_3_1_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MK-5108 (VX-689)	E1504_17_10_3_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_17_10_3_1_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RG108	E1504_17_10_3_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_17_10_3_1_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Sodium Phenylbutyrate	E1504_17_10_3_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_17_10_3_1_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_17_10_3_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_17_10_3_1_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_17_10_3_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_17_10_3_1_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PCI-24781 (Abexinostat)	E1504_17_10_3_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_17_10_3_1_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SRT1720	E1504_17_10_3_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_17_10_3_1_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CYC116	E1504_17_10_3_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_17_10_3_1_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Resveratrol	E1504_17_10_3_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_17_10_3_1_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EX 527 (Selisistat)	E1504_17_10_3_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_17_10_3_1_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGI-1776 free base	E1504_17_10_3_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_17_10_3_1_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TG101209	E1504_17_10_3_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_17_10_3_1_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM M344	E1504_17_10_3_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_17_10_3_1_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Baricitinib (LY3009104, INCB028050)	E1504_17_10_3_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_17_10_3_1_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tranylcypromine (2-PCPA) HCl	E1504_17_10_3_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_17_10_3_1_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_17_10_3_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_17_10_3_1_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_17_10_3_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_17_10_3_1_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM LAQ824 (Dacinostat)	E1504_17_10_3_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_17_10_3_1_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM INO-1001	E1504_17_10_3_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_17_10_3_1_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ENMD-2076	E1504_17_10_3_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_17_10_3_1_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Droxinostat	E1504_17_10_3_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_17_10_3_1_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Azacitidine	E1504_17_10_3_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_17_10_3_1_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZ 960	E1504_17_10_3_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_17_10_3_1_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Resminostat	E1504_17_10_3_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_17_10_3_1_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM I-BET151 (GSK1210151A)	E1504_17_10_3_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_17_10_3_1_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM WHI-P154	E1504_17_10_3_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_17_10_3_1_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 3-Aminobenzamide	E1504_17_10_3_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_17_10_3_1_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_17_10_3_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_17_10_3_1_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_17_10_3_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_17_10_3_1_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Quisinostat (JNJ-26481585)	E1504_17_10_3_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_17_10_3_1_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Alisertib (MLN8237)	E1504_17_10_3_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_17_10_3_1_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CUDC-101	E1504_17_10_3_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_17_10_3_1_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Aurora A Inhibitor I	E1504_17_10_3_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_17_10_3_1_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PCI-34051	E1504_17_10_3_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_17_10_3_1_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CYT387	E1504_17_10_3_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_17_10_3_1_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TAK-901	E1504_17_10_3_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_17_10_3_1_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tofacitinib (CP-690550,Tasocitinib)	E1504_17_10_3_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_17_10_3_1_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PJ34	E1504_17_10_3_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_17_10_3_1_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Procainamide HCl	E1504_17_10_3_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_17_10_3_1_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_17_10_3_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_17_10_3_1_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_17_10_3_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_17_10_3_1_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Rucaparib (AG-014699,PF-01367338)	E1504_17_10_3_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_17_10_3_1_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AT9283	E1504_17_10_3_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_17_10_3_1_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Decitabine	E1504_17_10_3_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_17_10_3_1_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PHA-680632	E1504_17_10_3_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_17_10_3_1_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM KW-2449	E1504_17_10_3_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_17_10_3_1_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubacin	E1504_17_10_3_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_17_10_3_1_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AMG-900	E1504_17_10_3_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_17_10_3_1_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM WP1066	E1504_17_10_3_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_17_10_3_1_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM S-Ruxolitinib (INCB018424)	E1504_17_10_3_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_17_10_3_1_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tofacitinib (CP-690550) Citrate	E1504_17_10_3_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_17_10_3_1_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_17_10_3_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_17_10_3_1_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_17_10_3_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_17_10_3_1_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MLN8054	E1504_17_10_3_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_17_10_3_1_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AG-490 (Tyrphostin B42)	E1504_17_10_3_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_17_10_3_1_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PFI-1 (PF-6405761)	E1504_17_10_3_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_17_10_3_1_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MC1568	E1504_17_10_3_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_17_10_3_1_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD1480	E1504_17_10_3_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_17_10_3_1_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AR-42	E1504_17_10_3_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_17_10_3_1_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TG101348 (SAR302503)	E1504_17_10_3_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_17_10_3_1_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Sirtinol	E1504_17_10_3_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_17_10_3_1_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM IOX2	E1504_17_10_3_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_17_10_3_1_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD2461	E1504_17_10_3_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_17_10_3_1_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_17_10_3_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_17_10_3_1_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_17_10_3_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_17_10_3_1_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ZM 447439	E1504_17_10_3_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_17_10_3_1_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Barasertib (AZD1152-HQPA)	E1504_17_10_3_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_17_10_3_1_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 2-Methoxyestradiol (2-MeOE2)	E1504_17_10_3_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_17_10_3_1_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Pracinostat (SB939)	E1504_17_10_3_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_17_10_3_1_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Givinostat (ITF2357)	E1504_17_10_3_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_17_10_3_1_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Quercetin	E1504_17_10_3_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_17_10_3_1_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CCT137690	E1504_17_10_3_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_17_10_3_1_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CEP-33779	E1504_17_10_3_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_17_10_3_1_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Romidepsin (FK228, Depsipeptide)	E1504_17_10_3_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_17_10_3_1_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM XL019	E1504_17_10_3_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_17_10_3_1_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_17_10_3_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_17_10_3_1_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_18_10_3_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_18_10_3_2_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Zebularine	E1504_18_10_3_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_18_10_3_2_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM OG-L002	E1504_18_10_3_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_18_10_3_2_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TMP269	E1504_18_10_3_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_18_10_3_2_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ZM 39923 HCl	E1504_18_10_3_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_18_10_3_2_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Veliparib (ABT-888)	E1504_18_10_3_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_18_10_3_2_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CX-6258 HCl	E1504_18_10_3_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_18_10_3_2_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 2,4-Pyridinedicarboxylic Acid	E1504_18_10_3_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_18_10_3_2_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ITSA-1	E1504_18_10_3_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_18_10_3_2_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AGK2	E1504_18_10_3_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_18_10_3_2_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Oxamflatin	E1504_18_10_3_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_18_10_3_2_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_18_10_3_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_18_10_3_2_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_18_10_3_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_18_10_3_2_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 3-Deazaneplanocin A (DZNeP)	E1504_18_10_3_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_18_10_3_2_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGC-CBP30	E1504_18_10_3_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_18_10_3_2_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ004777	E1504_18_10_3_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_18_10_3_2_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SMI-4a	E1504_18_10_3_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_18_10_3_2_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM FG-4592	E1504_18_10_3_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_18_10_3_2_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BMN 673	E1504_18_10_3_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_18_10_3_2_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Garcinol	E1504_18_10_3_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_18_10_3_2_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tranylcypromine hemisulfate	E1504_18_10_3_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_18_10_3_2_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Salermide	E1504_18_10_3_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_18_10_3_2_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Suramin 6Na	E1504_18_10_3_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_18_10_3_2_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_18_10_3_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_18_10_3_2_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_18_10_3_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_18_10_3_2_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ-6438	E1504_18_10_3_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_18_10_3_2_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MM-102	E1504_18_10_3_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_18_10_3_2_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM OTX015	E1504_18_10_3_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_18_10_3_2_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BIX 01294	E1504_18_10_3_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_18_10_3_2_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Panobinostat (LBH589)	E1504_18_10_3_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_18_10_3_2_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ5676	E1504_18_10_3_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_18_10_3_2_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Splitomicin	E1504_18_10_3_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_18_10_3_2_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid	E1504_18_10_3_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_18_10_3_2_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MC-1293	E1504_18_10_3_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_18_10_3_2_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-278	E1504_18_10_3_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_18_10_3_2_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_18_10_3_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_18_10_3_2_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_18_10_3_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_18_10_3_2_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM C646	E1504_18_10_3_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_18_10_3_2_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGI-1027	E1504_18_10_3_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_18_10_3_2_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM UNC669	E1504_18_10_3_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_18_10_3_2_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM UPF 1069	E1504_18_10_3_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_18_10_3_2_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Trichostatin A (TSA)	E1504_18_10_3_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_18_10_3_2_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM GSK J4 HCl	E1504_18_10_3_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_18_10_3_2_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-210	E1504_18_10_3_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_18_10_3_2_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nicotinamide	E1504_18_10_3_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_18_10_3_2_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Anacardic acid	E1504_18_10_3_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_18_10_3_2_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM NCH-51	E1504_18_10_3_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_18_10_3_2_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_18_10_3_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_18_10_3_2_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_18_10_3_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_18_10_3_2_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM I-BET-762	E1504_18_10_3_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_18_10_3_2_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RG2833 (RGFP109)	E1504_18_10_3_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_18_10_3_2_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ME0328	E1504_18_10_3_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_18_10_3_2_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Scriptaid	E1504_18_10_3_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_18_10_3_2_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Vorinostat (SAHA, MK0683)	E1504_18_10_3_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_18_10_3_2_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGC 0946	E1504_18_10_3_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_18_10_3_2_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Apicidin	E1504_18_10_3_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_18_10_3_2_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-266	E1504_18_10_3_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_18_10_3_2_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM B2	E1504_18_10_3_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_18_10_3_2_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM NSC-3852	E1504_18_10_3_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_18_10_3_2_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_18_10_3_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_18_10_3_2_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_18_10_3_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_18_10_3_2_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RGFP966	E1504_18_10_3_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_18_10_3_2_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RVX-208	E1504_18_10_3_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_18_10_3_2_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nexturastat A	E1504_18_10_3_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_18_10_3_2_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubastatin A	E1504_18_10_3_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_18_10_3_2_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM VX-680 (Tozasertib, MK-0457)	E1504_18_10_3_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_18_10_3_2_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM UNC1215	E1504_18_10_3_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_18_10_3_2_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Suberoyl bis-hydroxamic acid	E1504_18_10_3_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_18_10_3_2_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Piceatannol	E1504_18_10_3_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_18_10_3_2_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BIX-01294 3HCl	E1504_18_10_3_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_18_10_3_2_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Aminoresveratrol sulfate	E1504_18_10_3_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_18_10_3_2_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_18_10_3_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_18_10_3_2_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_18_10_3_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_18_10_3_2_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Bromosporine	E1504_18_10_3_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_18_10_3_2_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PJ34 HCl	E1504_18_10_3_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_18_10_3_2_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Filgotinib (GLPG0634)	E1504_18_10_3_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_18_10_3_2_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Lomeguatrib	E1504_18_10_3_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_18_10_3_2_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Entinostat (MS-275)	E1504_18_10_3_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_18_10_3_2_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD1208	E1504_18_10_3_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_18_10_3_2_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nullscript	E1504_18_10_3_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_18_10_3_2_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Fluoro-SAHA	E1504_18_10_3_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_18_10_3_2_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Butyrolactone 3	E1504_18_10_3_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_18_10_3_2_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-281	E1504_18_10_3_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_18_10_3_2_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_18_10_3_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_18_10_3_2_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_18_10_3_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_18_10_3_2_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM IOX1	E1504_18_10_3_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_18_10_3_2_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CPI-203	E1504_18_10_3_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_18_10_3_2_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Rocilinostat (ACY-1215)	E1504_18_10_3_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_18_10_3_2_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Pacritinib (SB1518)	E1504_18_10_3_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_18_10_3_2_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Olaparib (AZD2281, Ku-0059436)	E1504_18_10_3_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_18_10_3_2_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM (+)-JQ1	E1504_18_10_3_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_18_10_3_2_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Isonicotinamide	E1504_18_10_3_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_18_10_3_2_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid hydroxamate	E1504_18_10_3_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_18_10_3_2_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CTPB	E1504_18_10_3_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_18_10_3_2_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Triacetylresveratrol	E1504_18_10_3_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_18_10_3_2_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_18_10_3_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_18_10_3_2_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_01_100_1_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_1_A1_ACAAGCTA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Belinostat (PXD101)	E177_01_100_1_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_2_A2_AAACATCG_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Danusertib (PHA-739358)	E177_01_100_1_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_3_A3_ACATTGGC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SNS-314 Mesylate	E177_01_100_1_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_4_A4_ACCACTGT_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM JNJ-7706621	E177_01_100_1_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_5_A5_AACGTGAT_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT129202	E177_01_100_1_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_6_A6_CGCTGATC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-14361	E177_01_100_1_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_7_A7_CAGATCTG_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A HCl	E177_01_100_1_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_8_A8_ATGCCTAA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-907	E177_01_100_1_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_9_A9_CTGTAGCC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CI994 (Tacedinaline)	E177_01_100_1_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_10_A10_AGTACAAG_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entacapone	E177_01_100_1_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_11_A11_CATCAAGT_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_01_100_1_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_12_A12_AGTGGTCA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_01_100_1_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_13_B1_AACAACCA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Iniparib (BSI-201)	E177_01_100_1_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_14_B2_AACCGAGA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Mocetinostat (MGCD0103)	E177_01_100_1_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_15_B3_AACGCTTA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid sodium salt (Sodium valproate)	E177_01_100_1_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_16_B4_AAGACGGA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Ruxolitinib (INCB018424)	E177_01_100_1_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_17_B5_AAGGTACA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Hesperadin	E177_01_100_1_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_18_B6_ACACAGAA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM LY2784544	E177_01_100_1_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_19_B7_ACAGCAGA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NVP-BSK805 2HCl	E177_01_100_1_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_20_B8_ACCTCCAA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MK-5108 (VX-689)	E177_01_100_1_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_21_B9_ACGCTCGA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG108	E177_01_100_1_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_22_B10_ACGTATCA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sodium Phenylbutyrate	E177_01_100_1_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_23_B11_ACTATGCA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_01_100_1_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_24_B12_AGAGTCAA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_01_100_1_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_25_C1_AGATCGCA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-24781 (Abexinostat)	E177_01_100_1_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_26_C2_AGCAGGAA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SRT1720	E177_01_100_1_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_27_C3_AGTCACTA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYC116	E177_01_100_1_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_28_C4_ATCCTGTA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resveratrol	E177_01_100_1_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_29_C5_ATTGAGGA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EX 527 (Selisistat)	E177_01_100_1_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_30_C6_CAACCACA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1776 free base	E177_01_100_1_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_31_C7_CAAGACTA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101209	E177_01_100_1_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_32_C8_CAATGGAA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM M344	E177_01_100_1_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_33_C9_CACTTCGA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Baricitinib (LY3009104, INCB028050)	E177_01_100_1_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_34_C10_CAGCGTTA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine (2-PCPA) HCl	E177_01_100_1_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_35_C11_CATACCAA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_01_100_1_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_36_C12_CCAGTTCA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_01_100_1_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_37_D1_CCGAAGTA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM LAQ824 (Dacinostat)	E177_01_100_1_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_38_D2_CCGTGAGA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM INO-1001	E177_01_100_1_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_39_D3_CCTCCTGA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ENMD-2076	E177_01_100_1_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_40_D4_CGAACTTA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Droxinostat	E177_01_100_1_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_41_D5_CGACTGGA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Azacitidine	E177_01_100_1_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_42_D6_CGCATACA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZ 960	E177_01_100_1_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_43_D7_CTCAATGA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resminostat	E177_01_100_1_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_44_D8_CTGAGCCA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET151 (GSK1210151A)	E177_01_100_1_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_45_D9_CTGGCATA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM WHI-P154	E177_01_100_1_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_46_D10_GAATCTGA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Aminobenzamide	E177_01_100_1_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_47_D11_GACTAGTA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_01_100_1_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_48_D12_GAGCTGAA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_01_100_1_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_49_E1_GATAGACA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quisinostat (JNJ-26481585)	E177_01_100_1_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_50_E2_GCCACATA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Alisertib (MLN8237)	E177_01_100_1_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_51_E3_GCGAGTAA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-101	E177_01_100_1_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_52_E4_GCTAACGA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aurora A Inhibitor I	E177_01_100_1_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_53_E5_GCTCGGTA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-34051	E177_01_100_1_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_54_E6_GGAGAACA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYT387	E177_01_100_1_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_55_E7_GGTGCGAA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TAK-901	E177_01_100_1_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_56_E8_GTACGCAA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550,Tasocitinib)	E177_01_100_1_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_57_E9_GTCGTAGA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34	E177_01_100_1_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_58_E10_GTCTGTCA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Procainamide HCl	E177_01_100_1_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_59_E11_GTGTTCTA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_01_100_1_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_60_E12_TAGGATGA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_01_100_1_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_61_F1_TATCAGCA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rucaparib (AG-014699,PF-01367338)	E177_01_100_1_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_62_F2_TCCGTCTA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AT9283	E177_01_100_1_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_63_F3_TCTTCACA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Decitabine	E177_01_100_1_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_64_F4_TGAAGAGA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PHA-680632	E177_01_100_1_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_65_F5_TGGAACAA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM KW-2449	E177_01_100_1_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_66_F6_TGGCTTCA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubacin	E177_01_100_1_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_67_F7_TGGTGGTA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AMG-900	E177_01_100_1_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_68_F8_TTCACGCA_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM WP1066	E177_01_100_1_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_69_F9_AACTCACC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM S-Ruxolitinib (INCB018424)	E177_01_100_1_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_70_F10_AAGAGATC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550) Citrate	E177_01_100_1_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_71_F11_AAGGACAC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_01_100_1_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_72_F12_AATCCGTC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_01_100_1_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_73_G1_AATGTTGC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MLN8054	E177_01_100_1_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_74_G2_ACACGACC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-490 (Tyrphostin B42)	E177_01_100_1_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_75_G3_ACAGATTC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PFI-1 (PF-6405761)	E177_01_100_1_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_76_G4_AGATGTAC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC1568	E177_01_100_1_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_77_G5_AGCACCTC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1480	E177_01_100_1_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_78_G6_AGCCATGC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AR-42	E177_01_100_1_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_79_G7_AGGCTAAC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101348 (SAR302503)	E177_01_100_1_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_80_G8_ATAGCGAC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sirtinol	E177_01_100_1_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_81_G9_ATCATTCC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX2	E177_01_100_1_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_82_G10_ATTGGCTC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD2461	E177_01_100_1_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_83_G11_CAAGGAGC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_01_100_1_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_84_G12_CACCTTAC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_01_100_1_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_85_H1_CCATCCTC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 447439	E177_01_100_1_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_86_H2_CCGACAAC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Barasertib (AZD1152-HQPA)	E177_01_100_1_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_87_H3_CCTAATCC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2-Methoxyestradiol (2-MeOE2)	E177_01_100_1_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_88_H4_CCTCTATC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pracinostat (SB939)	E177_01_100_1_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_89_H5_CGACACAC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Givinostat (ITF2357)	E177_01_100_1_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_90_H6_CGGATTGC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quercetin	E177_01_100_1_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_91_H7_CTAAGGTC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT137690	E177_01_100_1_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_92_H8_GAACAGGC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CEP-33779	E177_01_100_1_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_93_H9_GACAGTGC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Romidepsin (FK228, Depsipeptide)	E177_01_100_1_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_94_H10_GAGTTAGC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM XL019	E177_01_100_1_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_95_H11_GATGAATC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_01_100_1_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_96_H12_GCCAAGAC_100_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_02_100_1_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_1_A1_ACAAGCTA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Zebularine	E177_02_100_1_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_2_A2_AAACATCG_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM OG-L002	E177_02_100_1_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_3_A3_ACATTGGC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TMP269	E177_02_100_1_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_4_A4_ACCACTGT_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 39923 HCl	E177_02_100_1_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_5_A5_AACGTGAT_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Veliparib (ABT-888)	E177_02_100_1_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_6_A6_CGCTGATC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CX-6258 HCl	E177_02_100_1_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_7_A7_CAGATCTG_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2,4-Pyridinedicarboxylic Acid	E177_02_100_1_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_8_A8_ATGCCTAA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ITSA-1	E177_02_100_1_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_9_A9_CTGTAGCC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AGK2	E177_02_100_1_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_10_A10_AGTACAAG_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Oxamflatin	E177_02_100_1_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_11_A11_CATCAAGT_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_02_100_1_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_12_A12_AGTGGTCA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_02_100_1_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_13_B1_AACAACCA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Deazaneplanocin A (DZNeP)	E177_02_100_1_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_14_B2_AACCGAGA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC-CBP30	E177_02_100_1_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_15_B3_AACGCTTA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ004777	E177_02_100_1_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_16_B4_AAGACGGA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SMI-4a	E177_02_100_1_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_17_B5_AAGGTACA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM FG-4592	E177_02_100_1_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_18_B6_ACACAGAA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BMN 673	E177_02_100_1_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_19_B7_ACAGCAGA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Garcinol	E177_02_100_1_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_20_B8_ACCTCCAA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine hemisulfate	E177_02_100_1_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_21_B9_ACGCTCGA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Salermide	E177_02_100_1_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_22_B10_ACGTATCA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suramin 6Na	E177_02_100_1_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_23_B11_ACTATGCA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_02_100_1_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_24_B12_AGAGTCAA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_02_100_1_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_25_C1_AGATCGCA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ-6438	E177_02_100_1_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_26_C2_AGCAGGAA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MM-102	E177_02_100_1_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_27_C3_AGTCACTA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM OTX015	E177_02_100_1_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_28_C4_ATCCTGTA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX 01294	E177_02_100_1_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_29_C5_ATTGAGGA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Panobinostat (LBH589)	E177_02_100_1_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_30_C6_CAACCACA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ5676	E177_02_100_1_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_31_C7_CAAGACTA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Splitomicin	E177_02_100_1_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_32_C8_CAATGGAA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid	E177_02_100_1_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_33_C9_CACTTCGA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC-1293	E177_02_100_1_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_34_C10_CAGCGTTA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-278	E177_02_100_1_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_35_C11_CATACCAA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_02_100_1_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_36_C12_CCAGTTCA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_02_100_1_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_37_D1_CCGAAGTA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM C646	E177_02_100_1_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_38_D2_CCGTGAGA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1027	E177_02_100_1_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_39_D3_CCTCCTGA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC669	E177_02_100_1_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_40_D4_CGAACTTA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UPF 1069	E177_02_100_1_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_41_D5_CGACTGGA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Trichostatin A (TSA)	E177_02_100_1_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_42_D6_CGCATACA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM GSK J4 HCl	E177_02_100_1_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_43_D7_CTCAATGA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-210	E177_02_100_1_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_44_D8_CTGAGCCA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nicotinamide	E177_02_100_1_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_45_D9_CTGGCATA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Anacardic acid	E177_02_100_1_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_46_D10_GAATCTGA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NCH-51	E177_02_100_1_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_47_D11_GACTAGTA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_02_100_1_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_48_D12_GAGCTGAA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_02_100_1_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_49_E1_GATAGACA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET-762	E177_02_100_1_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_50_E2_GCCACATA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG2833 (RGFP109)	E177_02_100_1_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_51_E3_GCGAGTAA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ME0328	E177_02_100_1_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_52_E4_GCTAACGA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Scriptaid	E177_02_100_1_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_53_E5_GCTCGGTA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Vorinostat (SAHA, MK0683)	E177_02_100_1_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_54_E6_GGAGAACA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC 0946	E177_02_100_1_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_55_E7_GGTGCGAA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Apicidin	E177_02_100_1_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_56_E8_GTACGCAA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-266	E177_02_100_1_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_57_E9_GTCGTAGA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM B2	E177_02_100_1_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_58_E10_GTCTGTCA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NSC-3852	E177_02_100_1_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_59_E11_GTGTTCTA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_02_100_1_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_60_E12_TAGGATGA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_02_100_1_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_61_F1_TATCAGCA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RGFP966	E177_02_100_1_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_62_F2_TCCGTCTA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RVX-208	E177_02_100_1_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_63_F3_TCTTCACA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nexturastat A	E177_02_100_1_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_64_F4_TGAAGAGA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A	E177_02_100_1_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_65_F5_TGGAACAA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM VX-680 (Tozasertib, MK-0457)	E177_02_100_1_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_66_F6_TGGCTTCA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC1215	E177_02_100_1_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_67_F7_TGGTGGTA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suberoyl bis-hydroxamic acid	E177_02_100_1_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_68_F8_TTCACGCA_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Piceatannol	E177_02_100_1_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_69_F9_AACTCACC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX-01294 3HCl	E177_02_100_1_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_70_F10_AAGAGATC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aminoresveratrol sulfate	E177_02_100_1_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_71_F11_AAGGACAC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_02_100_1_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_72_F12_AATCCGTC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_02_100_1_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_73_G1_AATGTTGC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Bromosporine	E177_02_100_1_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_74_G2_ACACGACC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34 HCl	E177_02_100_1_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_75_G3_ACAGATTC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Filgotinib (GLPG0634)	E177_02_100_1_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_76_G4_AGATGTAC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Lomeguatrib	E177_02_100_1_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_77_G5_AGCACCTC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entinostat (MS-275)	E177_02_100_1_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_78_G6_AGCCATGC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1208	E177_02_100_1_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_79_G7_AGGCTAAC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nullscript	E177_02_100_1_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_80_G8_ATAGCGAC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Fluoro-SAHA	E177_02_100_1_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_81_G9_ATCATTCC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Butyrolactone 3	E177_02_100_1_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_82_G10_ATTGGCTC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-281	E177_02_100_1_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_83_G11_CAAGGAGC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_02_100_1_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_84_G12_CACCTTAC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_02_100_1_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_85_H1_CCATCCTC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX1	E177_02_100_1_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_86_H2_CCGACAAC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CPI-203	E177_02_100_1_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_87_H3_CCTAATCC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rocilinostat (ACY-1215)	E177_02_100_1_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_88_H4_CCTCTATC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pacritinib (SB1518)	E177_02_100_1_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_89_H5_CGACACAC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Olaparib (AZD2281, Ku-0059436)	E177_02_100_1_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_90_H6_CGGATTGC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM (+)-JQ1	E177_02_100_1_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_91_H7_CTAAGGTC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Isonicotinamide	E177_02_100_1_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_92_H8_GAACAGGC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid hydroxamate	E177_02_100_1_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_93_H9_GACAGTGC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CTPB	E177_02_100_1_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_94_H10_GAGTTAGC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Triacetylresveratrol	E177_02_100_1_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_95_H11_GATGAATC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_02_100_1_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_96_H12_GCCAAGAC_100_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_03_100_2_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_1_A1_ACAAGCTA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Belinostat (PXD101)	E177_03_100_2_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_2_A2_AAACATCG_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Danusertib (PHA-739358)	E177_03_100_2_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_3_A3_ACATTGGC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SNS-314 Mesylate	E177_03_100_2_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_4_A4_ACCACTGT_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM JNJ-7706621	E177_03_100_2_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_5_A5_AACGTGAT_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT129202	E177_03_100_2_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_6_A6_CGCTGATC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-14361	E177_03_100_2_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_7_A7_CAGATCTG_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A HCl	E177_03_100_2_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_8_A8_ATGCCTAA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-907	E177_03_100_2_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_9_A9_CTGTAGCC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CI994 (Tacedinaline)	E177_03_100_2_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_10_A10_AGTACAAG_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entacapone	E177_03_100_2_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_11_A11_CATCAAGT_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_03_100_2_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_12_A12_AGTGGTCA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_03_100_2_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_13_B1_AACAACCA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Iniparib (BSI-201)	E177_03_100_2_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_14_B2_AACCGAGA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Mocetinostat (MGCD0103)	E177_03_100_2_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_15_B3_AACGCTTA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid sodium salt (Sodium valproate)	E177_03_100_2_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_16_B4_AAGACGGA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Ruxolitinib (INCB018424)	E177_03_100_2_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_17_B5_AAGGTACA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Hesperadin	E177_03_100_2_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_18_B6_ACACAGAA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM LY2784544	E177_03_100_2_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_19_B7_ACAGCAGA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NVP-BSK805 2HCl	E177_03_100_2_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_20_B8_ACCTCCAA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MK-5108 (VX-689)	E177_03_100_2_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_21_B9_ACGCTCGA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG108	E177_03_100_2_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_22_B10_ACGTATCA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sodium Phenylbutyrate	E177_03_100_2_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_23_B11_ACTATGCA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_03_100_2_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_24_B12_AGAGTCAA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_03_100_2_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_25_C1_AGATCGCA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-24781 (Abexinostat)	E177_03_100_2_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_26_C2_AGCAGGAA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SRT1720	E177_03_100_2_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_27_C3_AGTCACTA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYC116	E177_03_100_2_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_28_C4_ATCCTGTA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resveratrol	E177_03_100_2_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_29_C5_ATTGAGGA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EX 527 (Selisistat)	E177_03_100_2_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_30_C6_CAACCACA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1776 free base	E177_03_100_2_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_31_C7_CAAGACTA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101209	E177_03_100_2_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_32_C8_CAATGGAA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM M344	E177_03_100_2_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_33_C9_CACTTCGA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Baricitinib (LY3009104, INCB028050)	E177_03_100_2_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_34_C10_CAGCGTTA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine (2-PCPA) HCl	E177_03_100_2_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_35_C11_CATACCAA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_03_100_2_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_36_C12_CCAGTTCA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_03_100_2_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_37_D1_CCGAAGTA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM LAQ824 (Dacinostat)	E177_03_100_2_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_38_D2_CCGTGAGA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM INO-1001	E177_03_100_2_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_39_D3_CCTCCTGA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ENMD-2076	E177_03_100_2_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_40_D4_CGAACTTA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Droxinostat	E177_03_100_2_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_41_D5_CGACTGGA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Azacitidine	E177_03_100_2_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_42_D6_CGCATACA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZ 960	E177_03_100_2_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_43_D7_CTCAATGA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resminostat	E177_03_100_2_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_44_D8_CTGAGCCA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET151 (GSK1210151A)	E177_03_100_2_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_45_D9_CTGGCATA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM WHI-P154	E177_03_100_2_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_46_D10_GAATCTGA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Aminobenzamide	E177_03_100_2_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_47_D11_GACTAGTA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_03_100_2_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_48_D12_GAGCTGAA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_03_100_2_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_49_E1_GATAGACA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quisinostat (JNJ-26481585)	E177_03_100_2_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_50_E2_GCCACATA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Alisertib (MLN8237)	E177_03_100_2_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_51_E3_GCGAGTAA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-101	E177_03_100_2_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_52_E4_GCTAACGA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aurora A Inhibitor I	E177_03_100_2_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_53_E5_GCTCGGTA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-34051	E177_03_100_2_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_54_E6_GGAGAACA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYT387	E177_03_100_2_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_55_E7_GGTGCGAA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TAK-901	E177_03_100_2_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_56_E8_GTACGCAA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550,Tasocitinib)	E177_03_100_2_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_57_E9_GTCGTAGA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34	E177_03_100_2_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_58_E10_GTCTGTCA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Procainamide HCl	E177_03_100_2_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_59_E11_GTGTTCTA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_03_100_2_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_60_E12_TAGGATGA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_03_100_2_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_61_F1_TATCAGCA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rucaparib (AG-014699,PF-01367338)	E177_03_100_2_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_62_F2_TCCGTCTA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AT9283	E177_03_100_2_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_63_F3_TCTTCACA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Decitabine	E177_03_100_2_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_64_F4_TGAAGAGA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PHA-680632	E177_03_100_2_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_65_F5_TGGAACAA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM KW-2449	E177_03_100_2_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_66_F6_TGGCTTCA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubacin	E177_03_100_2_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_67_F7_TGGTGGTA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AMG-900	E177_03_100_2_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_68_F8_TTCACGCA_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM WP1066	E177_03_100_2_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_69_F9_AACTCACC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM S-Ruxolitinib (INCB018424)	E177_03_100_2_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_70_F10_AAGAGATC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550) Citrate	E177_03_100_2_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_71_F11_AAGGACAC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_03_100_2_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_72_F12_AATCCGTC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_03_100_2_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_73_G1_AATGTTGC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MLN8054	E177_03_100_2_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_74_G2_ACACGACC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-490 (Tyrphostin B42)	E177_03_100_2_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_75_G3_ACAGATTC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PFI-1 (PF-6405761)	E177_03_100_2_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_76_G4_AGATGTAC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC1568	E177_03_100_2_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_77_G5_AGCACCTC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1480	E177_03_100_2_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_78_G6_AGCCATGC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AR-42	E177_03_100_2_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_79_G7_AGGCTAAC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101348 (SAR302503)	E177_03_100_2_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_80_G8_ATAGCGAC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sirtinol	E177_03_100_2_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_81_G9_ATCATTCC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX2	E177_03_100_2_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_82_G10_ATTGGCTC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD2461	E177_03_100_2_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_83_G11_CAAGGAGC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_03_100_2_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_84_G12_CACCTTAC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_03_100_2_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_85_H1_CCATCCTC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 447439	E177_03_100_2_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_86_H2_CCGACAAC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Barasertib (AZD1152-HQPA)	E177_03_100_2_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_87_H3_CCTAATCC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2-Methoxyestradiol (2-MeOE2)	E177_03_100_2_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_88_H4_CCTCTATC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pracinostat (SB939)	E177_03_100_2_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_89_H5_CGACACAC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Givinostat (ITF2357)	E177_03_100_2_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_90_H6_CGGATTGC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quercetin	E177_03_100_2_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_91_H7_CTAAGGTC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT137690	E177_03_100_2_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_92_H8_GAACAGGC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CEP-33779	E177_03_100_2_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_93_H9_GACAGTGC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Romidepsin (FK228, Depsipeptide)	E177_03_100_2_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_94_H10_GAGTTAGC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM XL019	E177_03_100_2_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_95_H11_GATGAATC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_03_100_2_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_96_H12_GCCAAGAC_100_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_04_100_2_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_1_A1_ACAAGCTA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Zebularine	E177_04_100_2_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_2_A2_AAACATCG_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM OG-L002	E177_04_100_2_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_3_A3_ACATTGGC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TMP269	E177_04_100_2_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_4_A4_ACCACTGT_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 39923 HCl	E177_04_100_2_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_5_A5_AACGTGAT_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Veliparib (ABT-888)	E177_04_100_2_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_6_A6_CGCTGATC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CX-6258 HCl	E177_04_100_2_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_7_A7_CAGATCTG_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2,4-Pyridinedicarboxylic Acid	E177_04_100_2_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_8_A8_ATGCCTAA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ITSA-1	E177_04_100_2_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_9_A9_CTGTAGCC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AGK2	E177_04_100_2_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_10_A10_AGTACAAG_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Oxamflatin	E177_04_100_2_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_11_A11_CATCAAGT_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_04_100_2_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_12_A12_AGTGGTCA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_04_100_2_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_13_B1_AACAACCA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Deazaneplanocin A (DZNeP)	E177_04_100_2_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_14_B2_AACCGAGA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC-CBP30	E177_04_100_2_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_15_B3_AACGCTTA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ004777	E177_04_100_2_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_16_B4_AAGACGGA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SMI-4a	E177_04_100_2_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_17_B5_AAGGTACA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM FG-4592	E177_04_100_2_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_18_B6_ACACAGAA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BMN 673	E177_04_100_2_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_19_B7_ACAGCAGA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Garcinol	E177_04_100_2_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_20_B8_ACCTCCAA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine hemisulfate	E177_04_100_2_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_21_B9_ACGCTCGA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Salermide	E177_04_100_2_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_22_B10_ACGTATCA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suramin 6Na	E177_04_100_2_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_23_B11_ACTATGCA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_04_100_2_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_24_B12_AGAGTCAA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_04_100_2_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_25_C1_AGATCGCA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ-6438	E177_04_100_2_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_26_C2_AGCAGGAA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MM-102	E177_04_100_2_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_27_C3_AGTCACTA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM OTX015	E177_04_100_2_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_28_C4_ATCCTGTA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX 01294	E177_04_100_2_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_29_C5_ATTGAGGA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Panobinostat (LBH589)	E177_04_100_2_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_30_C6_CAACCACA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ5676	E177_04_100_2_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_31_C7_CAAGACTA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Splitomicin	E177_04_100_2_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_32_C8_CAATGGAA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid	E177_04_100_2_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_33_C9_CACTTCGA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC-1293	E177_04_100_2_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_34_C10_CAGCGTTA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-278	E177_04_100_2_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_35_C11_CATACCAA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_04_100_2_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_36_C12_CCAGTTCA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_04_100_2_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_37_D1_CCGAAGTA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM C646	E177_04_100_2_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_38_D2_CCGTGAGA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1027	E177_04_100_2_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_39_D3_CCTCCTGA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC669	E177_04_100_2_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_40_D4_CGAACTTA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UPF 1069	E177_04_100_2_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_41_D5_CGACTGGA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Trichostatin A (TSA)	E177_04_100_2_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_42_D6_CGCATACA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM GSK J4 HCl	E177_04_100_2_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_43_D7_CTCAATGA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-210	E177_04_100_2_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_44_D8_CTGAGCCA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nicotinamide	E177_04_100_2_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_45_D9_CTGGCATA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Anacardic acid	E177_04_100_2_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_46_D10_GAATCTGA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NCH-51	E177_04_100_2_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_47_D11_GACTAGTA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_04_100_2_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_48_D12_GAGCTGAA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_04_100_2_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_49_E1_GATAGACA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET-762	E177_04_100_2_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_50_E2_GCCACATA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG2833 (RGFP109)	E177_04_100_2_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_51_E3_GCGAGTAA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ME0328	E177_04_100_2_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_52_E4_GCTAACGA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Scriptaid	E177_04_100_2_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_53_E5_GCTCGGTA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Vorinostat (SAHA, MK0683)	E177_04_100_2_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_54_E6_GGAGAACA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC 0946	E177_04_100_2_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_55_E7_GGTGCGAA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Apicidin	E177_04_100_2_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_56_E8_GTACGCAA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-266	E177_04_100_2_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_57_E9_GTCGTAGA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM B2	E177_04_100_2_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_58_E10_GTCTGTCA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NSC-3852	E177_04_100_2_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_59_E11_GTGTTCTA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_04_100_2_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_60_E12_TAGGATGA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_04_100_2_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_61_F1_TATCAGCA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RGFP966	E177_04_100_2_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_62_F2_TCCGTCTA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RVX-208	E177_04_100_2_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_63_F3_TCTTCACA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nexturastat A	E177_04_100_2_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_64_F4_TGAAGAGA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A	E177_04_100_2_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_65_F5_TGGAACAA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM VX-680 (Tozasertib, MK-0457)	E177_04_100_2_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_66_F6_TGGCTTCA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC1215	E177_04_100_2_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_67_F7_TGGTGGTA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suberoyl bis-hydroxamic acid	E177_04_100_2_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_68_F8_TTCACGCA_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Piceatannol	E177_04_100_2_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_69_F9_AACTCACC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX-01294 3HCl	E177_04_100_2_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_70_F10_AAGAGATC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aminoresveratrol sulfate	E177_04_100_2_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_71_F11_AAGGACAC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_04_100_2_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_72_F12_AATCCGTC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_04_100_2_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_73_G1_AATGTTGC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Bromosporine	E177_04_100_2_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_74_G2_ACACGACC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34 HCl	E177_04_100_2_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_75_G3_ACAGATTC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Filgotinib (GLPG0634)	E177_04_100_2_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_76_G4_AGATGTAC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Lomeguatrib	E177_04_100_2_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_77_G5_AGCACCTC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entinostat (MS-275)	E177_04_100_2_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_78_G6_AGCCATGC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1208	E177_04_100_2_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_79_G7_AGGCTAAC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nullscript	E177_04_100_2_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_80_G8_ATAGCGAC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Fluoro-SAHA	E177_04_100_2_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_81_G9_ATCATTCC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Butyrolactone 3	E177_04_100_2_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_82_G10_ATTGGCTC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-281	E177_04_100_2_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_83_G11_CAAGGAGC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_04_100_2_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_84_G12_CACCTTAC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_04_100_2_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_85_H1_CCATCCTC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX1	E177_04_100_2_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_86_H2_CCGACAAC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CPI-203	E177_04_100_2_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_87_H3_CCTAATCC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rocilinostat (ACY-1215)	E177_04_100_2_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_88_H4_CCTCTATC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pacritinib (SB1518)	E177_04_100_2_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_89_H5_CGACACAC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Olaparib (AZD2281, Ku-0059436)	E177_04_100_2_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_90_H6_CGGATTGC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM (+)-JQ1	E177_04_100_2_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_91_H7_CTAAGGTC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Isonicotinamide	E177_04_100_2_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_92_H8_GAACAGGC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid hydroxamate	E177_04_100_2_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_93_H9_GACAGTGC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CTPB	E177_04_100_2_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_94_H10_GAGTTAGC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Triacetylresveratrol	E177_04_100_2_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_95_H11_GATGAATC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_04_100_2_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_96_H12_GCCAAGAC_100_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_05_100_3_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_1_A1_ACAAGCTA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Belinostat (PXD101)	E177_05_100_3_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_2_A2_AAACATCG_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Danusertib (PHA-739358)	E177_05_100_3_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_3_A3_ACATTGGC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SNS-314 Mesylate	E177_05_100_3_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_4_A4_ACCACTGT_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM JNJ-7706621	E177_05_100_3_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_5_A5_AACGTGAT_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT129202	E177_05_100_3_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_6_A6_CGCTGATC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-14361	E177_05_100_3_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_7_A7_CAGATCTG_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A HCl	E177_05_100_3_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_8_A8_ATGCCTAA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-907	E177_05_100_3_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_9_A9_CTGTAGCC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CI994 (Tacedinaline)	E177_05_100_3_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_10_A10_AGTACAAG_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entacapone	E177_05_100_3_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_11_A11_CATCAAGT_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_05_100_3_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_12_A12_AGTGGTCA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_05_100_3_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_13_B1_AACAACCA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Iniparib (BSI-201)	E177_05_100_3_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_14_B2_AACCGAGA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Mocetinostat (MGCD0103)	E177_05_100_3_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_15_B3_AACGCTTA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid sodium salt (Sodium valproate)	E177_05_100_3_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_16_B4_AAGACGGA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Ruxolitinib (INCB018424)	E177_05_100_3_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_17_B5_AAGGTACA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Hesperadin	E177_05_100_3_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_18_B6_ACACAGAA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM LY2784544	E177_05_100_3_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_19_B7_ACAGCAGA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NVP-BSK805 2HCl	E177_05_100_3_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_20_B8_ACCTCCAA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MK-5108 (VX-689)	E177_05_100_3_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_21_B9_ACGCTCGA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG108	E177_05_100_3_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_22_B10_ACGTATCA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sodium Phenylbutyrate	E177_05_100_3_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_23_B11_ACTATGCA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_05_100_3_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_24_B12_AGAGTCAA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_05_100_3_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_25_C1_AGATCGCA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-24781 (Abexinostat)	E177_05_100_3_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_26_C2_AGCAGGAA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SRT1720	E177_05_100_3_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_27_C3_AGTCACTA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYC116	E177_05_100_3_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_28_C4_ATCCTGTA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resveratrol	E177_05_100_3_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_29_C5_ATTGAGGA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EX 527 (Selisistat)	E177_05_100_3_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_30_C6_CAACCACA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1776 free base	E177_05_100_3_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_31_C7_CAAGACTA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101209	E177_05_100_3_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_32_C8_CAATGGAA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM M344	E177_05_100_3_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_33_C9_CACTTCGA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Baricitinib (LY3009104, INCB028050)	E177_05_100_3_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_34_C10_CAGCGTTA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine (2-PCPA) HCl	E177_05_100_3_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_35_C11_CATACCAA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_05_100_3_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_36_C12_CCAGTTCA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_05_100_3_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_37_D1_CCGAAGTA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM LAQ824 (Dacinostat)	E177_05_100_3_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_38_D2_CCGTGAGA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM INO-1001	E177_05_100_3_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_39_D3_CCTCCTGA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ENMD-2076	E177_05_100_3_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_40_D4_CGAACTTA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Droxinostat	E177_05_100_3_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_41_D5_CGACTGGA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Azacitidine	E177_05_100_3_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_42_D6_CGCATACA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZ 960	E177_05_100_3_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_43_D7_CTCAATGA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resminostat	E177_05_100_3_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_44_D8_CTGAGCCA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET151 (GSK1210151A)	E177_05_100_3_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_45_D9_CTGGCATA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM WHI-P154	E177_05_100_3_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_46_D10_GAATCTGA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Aminobenzamide	E177_05_100_3_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_47_D11_GACTAGTA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_05_100_3_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_48_D12_GAGCTGAA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_05_100_3_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_49_E1_GATAGACA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quisinostat (JNJ-26481585)	E177_05_100_3_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_50_E2_GCCACATA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Alisertib (MLN8237)	E177_05_100_3_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_51_E3_GCGAGTAA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-101	E177_05_100_3_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_52_E4_GCTAACGA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aurora A Inhibitor I	E177_05_100_3_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_53_E5_GCTCGGTA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-34051	E177_05_100_3_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_54_E6_GGAGAACA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYT387	E177_05_100_3_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_55_E7_GGTGCGAA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TAK-901	E177_05_100_3_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_56_E8_GTACGCAA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550,Tasocitinib)	E177_05_100_3_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_57_E9_GTCGTAGA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34	E177_05_100_3_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_58_E10_GTCTGTCA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Procainamide HCl	E177_05_100_3_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_59_E11_GTGTTCTA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_05_100_3_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_60_E12_TAGGATGA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_05_100_3_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_61_F1_TATCAGCA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rucaparib (AG-014699,PF-01367338)	E177_05_100_3_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_62_F2_TCCGTCTA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AT9283	E177_05_100_3_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_63_F3_TCTTCACA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Decitabine	E177_05_100_3_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_64_F4_TGAAGAGA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PHA-680632	E177_05_100_3_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_65_F5_TGGAACAA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM KW-2449	E177_05_100_3_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_66_F6_TGGCTTCA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubacin	E177_05_100_3_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_67_F7_TGGTGGTA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AMG-900	E177_05_100_3_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_68_F8_TTCACGCA_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM WP1066	E177_05_100_3_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_69_F9_AACTCACC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM S-Ruxolitinib (INCB018424)	E177_05_100_3_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_70_F10_AAGAGATC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550) Citrate	E177_05_100_3_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_71_F11_AAGGACAC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_05_100_3_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_72_F12_AATCCGTC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_05_100_3_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_73_G1_AATGTTGC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MLN8054	E177_05_100_3_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_74_G2_ACACGACC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-490 (Tyrphostin B42)	E177_05_100_3_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_75_G3_ACAGATTC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PFI-1 (PF-6405761)	E177_05_100_3_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_76_G4_AGATGTAC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC1568	E177_05_100_3_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_77_G5_AGCACCTC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1480	E177_05_100_3_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_78_G6_AGCCATGC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AR-42	E177_05_100_3_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_79_G7_AGGCTAAC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101348 (SAR302503)	E177_05_100_3_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_80_G8_ATAGCGAC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sirtinol	E177_05_100_3_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_81_G9_ATCATTCC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX2	E177_05_100_3_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_82_G10_ATTGGCTC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD2461	E177_05_100_3_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_83_G11_CAAGGAGC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_05_100_3_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_84_G12_CACCTTAC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_05_100_3_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_85_H1_CCATCCTC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 447439	E177_05_100_3_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_86_H2_CCGACAAC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Barasertib (AZD1152-HQPA)	E177_05_100_3_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_87_H3_CCTAATCC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2-Methoxyestradiol (2-MeOE2)	E177_05_100_3_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_88_H4_CCTCTATC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pracinostat (SB939)	E177_05_100_3_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_89_H5_CGACACAC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Givinostat (ITF2357)	E177_05_100_3_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_90_H6_CGGATTGC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quercetin	E177_05_100_3_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_91_H7_CTAAGGTC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT137690	E177_05_100_3_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_92_H8_GAACAGGC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CEP-33779	E177_05_100_3_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_93_H9_GACAGTGC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Romidepsin (FK228, Depsipeptide)	E177_05_100_3_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_94_H10_GAGTTAGC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM XL019	E177_05_100_3_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_95_H11_GATGAATC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_05_100_3_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_96_H12_GCCAAGAC_100_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_06_100_3_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_1_A1_ACAAGCTA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Zebularine	E177_06_100_3_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_2_A2_AAACATCG_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM OG-L002	E177_06_100_3_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_3_A3_ACATTGGC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TMP269	E177_06_100_3_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_4_A4_ACCACTGT_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 39923 HCl	E177_06_100_3_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_5_A5_AACGTGAT_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Veliparib (ABT-888)	E177_06_100_3_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_6_A6_CGCTGATC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CX-6258 HCl	E177_06_100_3_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_7_A7_CAGATCTG_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2,4-Pyridinedicarboxylic Acid	E177_06_100_3_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_8_A8_ATGCCTAA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ITSA-1	E177_06_100_3_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_9_A9_CTGTAGCC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AGK2	E177_06_100_3_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_10_A10_AGTACAAG_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Oxamflatin	E177_06_100_3_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_11_A11_CATCAAGT_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_06_100_3_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_12_A12_AGTGGTCA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_06_100_3_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_13_B1_AACAACCA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Deazaneplanocin A (DZNeP)	E177_06_100_3_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_14_B2_AACCGAGA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC-CBP30	E177_06_100_3_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_15_B3_AACGCTTA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ004777	E177_06_100_3_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_16_B4_AAGACGGA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SMI-4a	E177_06_100_3_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_17_B5_AAGGTACA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM FG-4592	E177_06_100_3_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_18_B6_ACACAGAA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BMN 673	E177_06_100_3_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_19_B7_ACAGCAGA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Garcinol	E177_06_100_3_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_20_B8_ACCTCCAA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine hemisulfate	E177_06_100_3_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_21_B9_ACGCTCGA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Salermide	E177_06_100_3_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_22_B10_ACGTATCA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suramin 6Na	E177_06_100_3_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_23_B11_ACTATGCA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_06_100_3_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_24_B12_AGAGTCAA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_06_100_3_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_25_C1_AGATCGCA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ-6438	E177_06_100_3_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_26_C2_AGCAGGAA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MM-102	E177_06_100_3_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_27_C3_AGTCACTA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM OTX015	E177_06_100_3_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_28_C4_ATCCTGTA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX 01294	E177_06_100_3_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_29_C5_ATTGAGGA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Panobinostat (LBH589)	E177_06_100_3_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_30_C6_CAACCACA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ5676	E177_06_100_3_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_31_C7_CAAGACTA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Splitomicin	E177_06_100_3_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_32_C8_CAATGGAA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid	E177_06_100_3_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_33_C9_CACTTCGA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC-1293	E177_06_100_3_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_34_C10_CAGCGTTA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-278	E177_06_100_3_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_35_C11_CATACCAA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_06_100_3_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_36_C12_CCAGTTCA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_06_100_3_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_37_D1_CCGAAGTA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM C646	E177_06_100_3_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_38_D2_CCGTGAGA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1027	E177_06_100_3_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_39_D3_CCTCCTGA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC669	E177_06_100_3_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_40_D4_CGAACTTA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UPF 1069	E177_06_100_3_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_41_D5_CGACTGGA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Trichostatin A (TSA)	E177_06_100_3_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_42_D6_CGCATACA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM GSK J4 HCl	E177_06_100_3_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_43_D7_CTCAATGA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-210	E177_06_100_3_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_44_D8_CTGAGCCA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nicotinamide	E177_06_100_3_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_45_D9_CTGGCATA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Anacardic acid	E177_06_100_3_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_46_D10_GAATCTGA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NCH-51	E177_06_100_3_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_47_D11_GACTAGTA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_06_100_3_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_48_D12_GAGCTGAA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_06_100_3_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_49_E1_GATAGACA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET-762	E177_06_100_3_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_50_E2_GCCACATA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG2833 (RGFP109)	E177_06_100_3_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_51_E3_GCGAGTAA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ME0328	E177_06_100_3_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_52_E4_GCTAACGA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Scriptaid	E177_06_100_3_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_53_E5_GCTCGGTA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Vorinostat (SAHA, MK0683)	E177_06_100_3_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_54_E6_GGAGAACA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC 0946	E177_06_100_3_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_55_E7_GGTGCGAA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Apicidin	E177_06_100_3_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_56_E8_GTACGCAA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-266	E177_06_100_3_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_57_E9_GTCGTAGA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM B2	E177_06_100_3_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_58_E10_GTCTGTCA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NSC-3852	E177_06_100_3_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_59_E11_GTGTTCTA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_06_100_3_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_60_E12_TAGGATGA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_06_100_3_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_61_F1_TATCAGCA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RGFP966	E177_06_100_3_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_62_F2_TCCGTCTA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RVX-208	E177_06_100_3_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_63_F3_TCTTCACA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nexturastat A	E177_06_100_3_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_64_F4_TGAAGAGA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A	E177_06_100_3_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_65_F5_TGGAACAA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM VX-680 (Tozasertib, MK-0457)	E177_06_100_3_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_66_F6_TGGCTTCA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC1215	E177_06_100_3_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_67_F7_TGGTGGTA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suberoyl bis-hydroxamic acid	E177_06_100_3_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_68_F8_TTCACGCA_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Piceatannol	E177_06_100_3_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_69_F9_AACTCACC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX-01294 3HCl	E177_06_100_3_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_70_F10_AAGAGATC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aminoresveratrol sulfate	E177_06_100_3_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_71_F11_AAGGACAC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_06_100_3_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_72_F12_AATCCGTC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_06_100_3_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_73_G1_AATGTTGC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Bromosporine	E177_06_100_3_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_74_G2_ACACGACC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34 HCl	E177_06_100_3_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_75_G3_ACAGATTC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Filgotinib (GLPG0634)	E177_06_100_3_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_76_G4_AGATGTAC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Lomeguatrib	E177_06_100_3_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_77_G5_AGCACCTC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entinostat (MS-275)	E177_06_100_3_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_78_G6_AGCCATGC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1208	E177_06_100_3_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_79_G7_AGGCTAAC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nullscript	E177_06_100_3_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_80_G8_ATAGCGAC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Fluoro-SAHA	E177_06_100_3_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_81_G9_ATCATTCC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Butyrolactone 3	E177_06_100_3_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_82_G10_ATTGGCTC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-281	E177_06_100_3_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_83_G11_CAAGGAGC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_06_100_3_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_84_G12_CACCTTAC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_06_100_3_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_85_H1_CCATCCTC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX1	E177_06_100_3_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_86_H2_CCGACAAC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CPI-203	E177_06_100_3_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_87_H3_CCTAATCC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rocilinostat (ACY-1215)	E177_06_100_3_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_88_H4_CCTCTATC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pacritinib (SB1518)	E177_06_100_3_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_89_H5_CGACACAC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Olaparib (AZD2281, Ku-0059436)	E177_06_100_3_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_90_H6_CGGATTGC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM (+)-JQ1	E177_06_100_3_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_91_H7_CTAAGGTC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Isonicotinamide	E177_06_100_3_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_92_H8_GAACAGGC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid hydroxamate	E177_06_100_3_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_93_H9_GACAGTGC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CTPB	E177_06_100_3_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_94_H10_GAGTTAGC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Triacetylresveratrol	E177_06_100_3_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_95_H11_GATGAATC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_06_100_3_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_96_H12_GCCAAGAC_100_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_07_1_1_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_1_A1_ACAAGCTA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Belinostat (PXD101)	E177_07_1_1_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_2_A2_AAACATCG_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Danusertib (PHA-739358)	E177_07_1_1_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_3_A3_ACATTGGC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SNS-314 Mesylate	E177_07_1_1_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_4_A4_ACCACTGT_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM JNJ-7706621	E177_07_1_1_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_5_A5_AACGTGAT_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT129202	E177_07_1_1_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_6_A6_CGCTGATC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-14361	E177_07_1_1_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_7_A7_CAGATCTG_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A HCl	E177_07_1_1_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_8_A8_ATGCCTAA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-907	E177_07_1_1_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_9_A9_CTGTAGCC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CI994 (Tacedinaline)	E177_07_1_1_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_10_A10_AGTACAAG_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Entacapone	E177_07_1_1_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_11_A11_CATCAAGT_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_07_1_1_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_12_A12_AGTGGTCA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_07_1_1_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_13_B1_AACAACCA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Iniparib (BSI-201)	E177_07_1_1_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_14_B2_AACCGAGA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mocetinostat (MGCD0103)	E177_07_1_1_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_15_B3_AACGCTTA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid sodium salt (Sodium valproate)	E177_07_1_1_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_16_B4_AAGACGGA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Ruxolitinib (INCB018424)	E177_07_1_1_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_17_B5_AAGGTACA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Hesperadin	E177_07_1_1_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_18_B6_ACACAGAA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM LY2784544	E177_07_1_1_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_19_B7_ACAGCAGA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NVP-BSK805 2HCl	E177_07_1_1_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_20_B8_ACCTCCAA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MK-5108 (VX-689)	E177_07_1_1_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_21_B9_ACGCTCGA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RG108	E177_07_1_1_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_22_B10_ACGTATCA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Sodium Phenylbutyrate	E177_07_1_1_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_23_B11_ACTATGCA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_07_1_1_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_24_B12_AGAGTCAA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_07_1_1_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_25_C1_AGATCGCA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-24781 (Abexinostat)	E177_07_1_1_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_26_C2_AGCAGGAA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SRT1720	E177_07_1_1_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_27_C3_AGTCACTA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CYC116	E177_07_1_1_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_28_C4_ATCCTGTA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Resveratrol	E177_07_1_1_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_29_C5_ATTGAGGA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EX 527 (Selisistat)	E177_07_1_1_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_30_C6_CAACCACA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1776 free base	E177_07_1_1_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_31_C7_CAAGACTA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101209	E177_07_1_1_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_32_C8_CAATGGAA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM M344	E177_07_1_1_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_33_C9_CACTTCGA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Baricitinib (LY3009104, INCB028050)	E177_07_1_1_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_34_C10_CAGCGTTA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine (2-PCPA) HCl	E177_07_1_1_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_35_C11_CATACCAA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_07_1_1_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_36_C12_CCAGTTCA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_07_1_1_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_37_D1_CCGAAGTA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM LAQ824 (Dacinostat)	E177_07_1_1_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_38_D2_CCGTGAGA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM INO-1001	E177_07_1_1_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_39_D3_CCTCCTGA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ENMD-2076	E177_07_1_1_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_40_D4_CGAACTTA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Droxinostat	E177_07_1_1_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_41_D5_CGACTGGA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Azacitidine	E177_07_1_1_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_42_D6_CGCATACA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZ 960	E177_07_1_1_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_43_D7_CTCAATGA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Resminostat	E177_07_1_1_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_44_D8_CTGAGCCA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET151 (GSK1210151A)	E177_07_1_1_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_45_D9_CTGGCATA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM WHI-P154	E177_07_1_1_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_46_D10_GAATCTGA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Aminobenzamide	E177_07_1_1_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_47_D11_GACTAGTA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_07_1_1_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_48_D12_GAGCTGAA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_07_1_1_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_49_E1_GATAGACA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Quisinostat (JNJ-26481585)	E177_07_1_1_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_50_E2_GCCACATA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Alisertib (MLN8237)	E177_07_1_1_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_51_E3_GCGAGTAA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-101	E177_07_1_1_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_52_E4_GCTAACGA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Aurora A Inhibitor I	E177_07_1_1_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_53_E5_GCTCGGTA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-34051	E177_07_1_1_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_54_E6_GGAGAACA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CYT387	E177_07_1_1_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_55_E7_GGTGCGAA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TAK-901	E177_07_1_1_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_56_E8_GTACGCAA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550,Tasocitinib)	E177_07_1_1_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_57_E9_GTCGTAGA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34	E177_07_1_1_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_58_E10_GTCTGTCA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Procainamide HCl	E177_07_1_1_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_59_E11_GTGTTCTA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_07_1_1_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_60_E12_TAGGATGA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_07_1_1_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_61_F1_TATCAGCA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Rucaparib (AG-014699,PF-01367338)	E177_07_1_1_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_62_F2_TCCGTCTA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AT9283	E177_07_1_1_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_63_F3_TCTTCACA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Decitabine	E177_07_1_1_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_64_F4_TGAAGAGA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PHA-680632	E177_07_1_1_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_65_F5_TGGAACAA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM KW-2449	E177_07_1_1_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_66_F6_TGGCTTCA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubacin	E177_07_1_1_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_67_F7_TGGTGGTA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AMG-900	E177_07_1_1_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_68_F8_TTCACGCA_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM WP1066	E177_07_1_1_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_69_F9_AACTCACC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM S-Ruxolitinib (INCB018424)	E177_07_1_1_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_70_F10_AAGAGATC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550) Citrate	E177_07_1_1_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_71_F11_AAGGACAC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_07_1_1_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_72_F12_AATCCGTC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_07_1_1_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_73_G1_AATGTTGC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MLN8054	E177_07_1_1_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_74_G2_ACACGACC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-490 (Tyrphostin B42)	E177_07_1_1_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_75_G3_ACAGATTC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PFI-1 (PF-6405761)	E177_07_1_1_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_76_G4_AGATGTAC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MC1568	E177_07_1_1_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_77_G5_AGCACCTC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1480	E177_07_1_1_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_78_G6_AGCCATGC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AR-42	E177_07_1_1_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_79_G7_AGGCTAAC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101348 (SAR302503)	E177_07_1_1_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_80_G8_ATAGCGAC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Sirtinol	E177_07_1_1_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_81_G9_ATCATTCC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX2	E177_07_1_1_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_82_G10_ATTGGCTC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD2461	E177_07_1_1_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_83_G11_CAAGGAGC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_07_1_1_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_84_G12_CACCTTAC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_07_1_1_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_85_H1_CCATCCTC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 447439	E177_07_1_1_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_86_H2_CCGACAAC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Barasertib (AZD1152-HQPA)	E177_07_1_1_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_87_H3_CCTAATCC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 2-Methoxyestradiol (2-MeOE2)	E177_07_1_1_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_88_H4_CCTCTATC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Pracinostat (SB939)	E177_07_1_1_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_89_H5_CGACACAC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Givinostat (ITF2357)	E177_07_1_1_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_90_H6_CGGATTGC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Quercetin	E177_07_1_1_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_91_H7_CTAAGGTC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT137690	E177_07_1_1_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_92_H8_GAACAGGC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CEP-33779	E177_07_1_1_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_93_H9_GACAGTGC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Romidepsin (FK228, Depsipeptide)	E177_07_1_1_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_94_H10_GAGTTAGC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM XL019	E177_07_1_1_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_95_H11_GATGAATC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_07_1_1_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_96_H12_GCCAAGAC_1_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_08_1_1_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_1_A1_ACAAGCTA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Zebularine	E177_08_1_1_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_2_A2_AAACATCG_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM OG-L002	E177_08_1_1_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_3_A3_ACATTGGC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TMP269	E177_08_1_1_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_4_A4_ACCACTGT_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 39923 HCl	E177_08_1_1_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_5_A5_AACGTGAT_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Veliparib (ABT-888)	E177_08_1_1_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_6_A6_CGCTGATC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CX-6258 HCl	E177_08_1_1_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_7_A7_CAGATCTG_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 2,4-Pyridinedicarboxylic Acid	E177_08_1_1_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_8_A8_ATGCCTAA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ITSA-1	E177_08_1_1_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_9_A9_CTGTAGCC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AGK2	E177_08_1_1_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_10_A10_AGTACAAG_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Oxamflatin	E177_08_1_1_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_11_A11_CATCAAGT_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_08_1_1_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_12_A12_AGTGGTCA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_08_1_1_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_13_B1_AACAACCA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Deazaneplanocin A (DZNeP)	E177_08_1_1_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_14_B2_AACCGAGA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC-CBP30	E177_08_1_1_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_15_B3_AACGCTTA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ004777	E177_08_1_1_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_16_B4_AAGACGGA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SMI-4a	E177_08_1_1_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_17_B5_AAGGTACA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM FG-4592	E177_08_1_1_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_18_B6_ACACAGAA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BMN 673	E177_08_1_1_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_19_B7_ACAGCAGA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Garcinol	E177_08_1_1_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_20_B8_ACCTCCAA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine hemisulfate	E177_08_1_1_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_21_B9_ACGCTCGA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Salermide	E177_08_1_1_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_22_B10_ACGTATCA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Suramin 6Na	E177_08_1_1_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_23_B11_ACTATGCA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_08_1_1_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_24_B12_AGAGTCAA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_08_1_1_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_25_C1_AGATCGCA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ-6438	E177_08_1_1_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_26_C2_AGCAGGAA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MM-102	E177_08_1_1_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_27_C3_AGTCACTA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM OTX015	E177_08_1_1_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_28_C4_ATCCTGTA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX 01294	E177_08_1_1_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_29_C5_ATTGAGGA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Panobinostat (LBH589)	E177_08_1_1_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_30_C6_CAACCACA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ5676	E177_08_1_1_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_31_C7_CAAGACTA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Splitomicin	E177_08_1_1_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_32_C8_CAATGGAA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid	E177_08_1_1_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_33_C9_CACTTCGA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MC-1293	E177_08_1_1_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_34_C10_CAGCGTTA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-278	E177_08_1_1_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_35_C11_CATACCAA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_08_1_1_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_36_C12_CCAGTTCA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_08_1_1_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_37_D1_CCGAAGTA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM C646	E177_08_1_1_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_38_D2_CCGTGAGA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1027	E177_08_1_1_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_39_D3_CCTCCTGA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC669	E177_08_1_1_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_40_D4_CGAACTTA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UPF 1069	E177_08_1_1_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_41_D5_CGACTGGA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Trichostatin A (TSA)	E177_08_1_1_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_42_D6_CGCATACA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM GSK J4 HCl	E177_08_1_1_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_43_D7_CTCAATGA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-210	E177_08_1_1_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_44_D8_CTGAGCCA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nicotinamide	E177_08_1_1_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_45_D9_CTGGCATA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Anacardic acid	E177_08_1_1_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_46_D10_GAATCTGA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NCH-51	E177_08_1_1_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_47_D11_GACTAGTA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_08_1_1_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_48_D12_GAGCTGAA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_08_1_1_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_49_E1_GATAGACA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET-762	E177_08_1_1_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_50_E2_GCCACATA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RG2833 (RGFP109)	E177_08_1_1_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_51_E3_GCGAGTAA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ME0328	E177_08_1_1_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_52_E4_GCTAACGA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Scriptaid	E177_08_1_1_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_53_E5_GCTCGGTA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Vorinostat (SAHA, MK0683)	E177_08_1_1_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_54_E6_GGAGAACA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC 0946	E177_08_1_1_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_55_E7_GGTGCGAA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Apicidin	E177_08_1_1_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_56_E8_GTACGCAA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-266	E177_08_1_1_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_57_E9_GTCGTAGA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM B2	E177_08_1_1_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_58_E10_GTCTGTCA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NSC-3852	E177_08_1_1_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_59_E11_GTGTTCTA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_08_1_1_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_60_E12_TAGGATGA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_08_1_1_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_61_F1_TATCAGCA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RGFP966	E177_08_1_1_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_62_F2_TCCGTCTA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RVX-208	E177_08_1_1_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_63_F3_TCTTCACA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nexturastat A	E177_08_1_1_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_64_F4_TGAAGAGA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A	E177_08_1_1_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_65_F5_TGGAACAA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM VX-680 (Tozasertib, MK-0457)	E177_08_1_1_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_66_F6_TGGCTTCA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC1215	E177_08_1_1_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_67_F7_TGGTGGTA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Suberoyl bis-hydroxamic acid	E177_08_1_1_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_68_F8_TTCACGCA_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Piceatannol	E177_08_1_1_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_69_F9_AACTCACC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX-01294 3HCl	E177_08_1_1_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_70_F10_AAGAGATC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Aminoresveratrol sulfate	E177_08_1_1_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_71_F11_AAGGACAC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_08_1_1_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_72_F12_AATCCGTC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_08_1_1_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_73_G1_AATGTTGC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Bromosporine	E177_08_1_1_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_74_G2_ACACGACC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34 HCl	E177_08_1_1_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_75_G3_ACAGATTC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Filgotinib (GLPG0634)	E177_08_1_1_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_76_G4_AGATGTAC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Lomeguatrib	E177_08_1_1_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_77_G5_AGCACCTC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Entinostat (MS-275)	E177_08_1_1_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_78_G6_AGCCATGC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1208	E177_08_1_1_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_79_G7_AGGCTAAC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nullscript	E177_08_1_1_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_80_G8_ATAGCGAC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Fluoro-SAHA	E177_08_1_1_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_81_G9_ATCATTCC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Butyrolactone 3	E177_08_1_1_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_82_G10_ATTGGCTC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-281	E177_08_1_1_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_83_G11_CAAGGAGC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_08_1_1_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_84_G12_CACCTTAC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_08_1_1_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_85_H1_CCATCCTC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX1	E177_08_1_1_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_86_H2_CCGACAAC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CPI-203	E177_08_1_1_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_87_H3_CCTAATCC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Rocilinostat (ACY-1215)	E177_08_1_1_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_88_H4_CCTCTATC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Pacritinib (SB1518)	E177_08_1_1_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_89_H5_CGACACAC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Olaparib (AZD2281, Ku-0059436)	E177_08_1_1_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_90_H6_CGGATTGC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM (+)-JQ1	E177_08_1_1_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_91_H7_CTAAGGTC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Isonicotinamide	E177_08_1_1_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_92_H8_GAACAGGC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid hydroxamate	E177_08_1_1_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_93_H9_GACAGTGC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CTPB	E177_08_1_1_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_94_H10_GAGTTAGC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Triacetylresveratrol	E177_08_1_1_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_95_H11_GATGAATC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_08_1_1_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_96_H12_GCCAAGAC_1_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_09_1_2_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_1_A1_ACAAGCTA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Belinostat (PXD101)	E177_09_1_2_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_2_A2_AAACATCG_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Danusertib (PHA-739358)	E177_09_1_2_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_3_A3_ACATTGGC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SNS-314 Mesylate	E177_09_1_2_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_4_A4_ACCACTGT_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM JNJ-7706621	E177_09_1_2_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_5_A5_AACGTGAT_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT129202	E177_09_1_2_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_6_A6_CGCTGATC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-14361	E177_09_1_2_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_7_A7_CAGATCTG_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A HCl	E177_09_1_2_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_8_A8_ATGCCTAA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-907	E177_09_1_2_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_9_A9_CTGTAGCC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CI994 (Tacedinaline)	E177_09_1_2_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_10_A10_AGTACAAG_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Entacapone	E177_09_1_2_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_11_A11_CATCAAGT_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_09_1_2_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_12_A12_AGTGGTCA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_09_1_2_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_13_B1_AACAACCA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Iniparib (BSI-201)	E177_09_1_2_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_14_B2_AACCGAGA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mocetinostat (MGCD0103)	E177_09_1_2_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_15_B3_AACGCTTA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid sodium salt (Sodium valproate)	E177_09_1_2_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_16_B4_AAGACGGA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Ruxolitinib (INCB018424)	E177_09_1_2_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_17_B5_AAGGTACA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Hesperadin	E177_09_1_2_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_18_B6_ACACAGAA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM LY2784544	E177_09_1_2_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_19_B7_ACAGCAGA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NVP-BSK805 2HCl	E177_09_1_2_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_20_B8_ACCTCCAA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MK-5108 (VX-689)	E177_09_1_2_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_21_B9_ACGCTCGA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RG108	E177_09_1_2_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_22_B10_ACGTATCA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Sodium Phenylbutyrate	E177_09_1_2_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_23_B11_ACTATGCA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_09_1_2_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_24_B12_AGAGTCAA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_09_1_2_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_25_C1_AGATCGCA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-24781 (Abexinostat)	E177_09_1_2_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_26_C2_AGCAGGAA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SRT1720	E177_09_1_2_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_27_C3_AGTCACTA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CYC116	E177_09_1_2_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_28_C4_ATCCTGTA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Resveratrol	E177_09_1_2_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_29_C5_ATTGAGGA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EX 527 (Selisistat)	E177_09_1_2_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_30_C6_CAACCACA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1776 free base	E177_09_1_2_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_31_C7_CAAGACTA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101209	E177_09_1_2_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_32_C8_CAATGGAA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM M344	E177_09_1_2_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_33_C9_CACTTCGA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Baricitinib (LY3009104, INCB028050)	E177_09_1_2_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_34_C10_CAGCGTTA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine (2-PCPA) HCl	E177_09_1_2_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_35_C11_CATACCAA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_09_1_2_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_36_C12_CCAGTTCA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_09_1_2_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_37_D1_CCGAAGTA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM LAQ824 (Dacinostat)	E177_09_1_2_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_38_D2_CCGTGAGA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM INO-1001	E177_09_1_2_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_39_D3_CCTCCTGA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ENMD-2076	E177_09_1_2_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_40_D4_CGAACTTA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Droxinostat	E177_09_1_2_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_41_D5_CGACTGGA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Azacitidine	E177_09_1_2_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_42_D6_CGCATACA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZ 960	E177_09_1_2_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_43_D7_CTCAATGA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Resminostat	E177_09_1_2_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_44_D8_CTGAGCCA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET151 (GSK1210151A)	E177_09_1_2_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_45_D9_CTGGCATA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM WHI-P154	E177_09_1_2_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_46_D10_GAATCTGA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Aminobenzamide	E177_09_1_2_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_47_D11_GACTAGTA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_09_1_2_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_48_D12_GAGCTGAA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_09_1_2_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_49_E1_GATAGACA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Quisinostat (JNJ-26481585)	E177_09_1_2_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_50_E2_GCCACATA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Alisertib (MLN8237)	E177_09_1_2_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_51_E3_GCGAGTAA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-101	E177_09_1_2_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_52_E4_GCTAACGA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Aurora A Inhibitor I	E177_09_1_2_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_53_E5_GCTCGGTA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-34051	E177_09_1_2_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_54_E6_GGAGAACA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CYT387	E177_09_1_2_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_55_E7_GGTGCGAA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TAK-901	E177_09_1_2_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_56_E8_GTACGCAA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550,Tasocitinib)	E177_09_1_2_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_57_E9_GTCGTAGA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34	E177_09_1_2_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_58_E10_GTCTGTCA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Procainamide HCl	E177_09_1_2_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_59_E11_GTGTTCTA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_09_1_2_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_60_E12_TAGGATGA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_09_1_2_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_61_F1_TATCAGCA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Rucaparib (AG-014699,PF-01367338)	E177_09_1_2_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_62_F2_TCCGTCTA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AT9283	E177_09_1_2_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_63_F3_TCTTCACA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Decitabine	E177_09_1_2_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_64_F4_TGAAGAGA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PHA-680632	E177_09_1_2_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_65_F5_TGGAACAA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM KW-2449	E177_09_1_2_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_66_F6_TGGCTTCA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubacin	E177_09_1_2_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_67_F7_TGGTGGTA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AMG-900	E177_09_1_2_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_68_F8_TTCACGCA_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM WP1066	E177_09_1_2_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_69_F9_AACTCACC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM S-Ruxolitinib (INCB018424)	E177_09_1_2_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_70_F10_AAGAGATC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550) Citrate	E177_09_1_2_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_71_F11_AAGGACAC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_09_1_2_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_72_F12_AATCCGTC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_09_1_2_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_73_G1_AATGTTGC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MLN8054	E177_09_1_2_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_74_G2_ACACGACC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-490 (Tyrphostin B42)	E177_09_1_2_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_75_G3_ACAGATTC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PFI-1 (PF-6405761)	E177_09_1_2_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_76_G4_AGATGTAC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MC1568	E177_09_1_2_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_77_G5_AGCACCTC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1480	E177_09_1_2_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_78_G6_AGCCATGC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AR-42	E177_09_1_2_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_79_G7_AGGCTAAC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101348 (SAR302503)	E177_09_1_2_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_80_G8_ATAGCGAC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Sirtinol	E177_09_1_2_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_81_G9_ATCATTCC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX2	E177_09_1_2_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_82_G10_ATTGGCTC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD2461	E177_09_1_2_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_83_G11_CAAGGAGC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_09_1_2_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_84_G12_CACCTTAC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_09_1_2_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_85_H1_CCATCCTC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 447439	E177_09_1_2_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_86_H2_CCGACAAC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Barasertib (AZD1152-HQPA)	E177_09_1_2_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_87_H3_CCTAATCC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 2-Methoxyestradiol (2-MeOE2)	E177_09_1_2_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_88_H4_CCTCTATC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Pracinostat (SB939)	E177_09_1_2_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_89_H5_CGACACAC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Givinostat (ITF2357)	E177_09_1_2_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_90_H6_CGGATTGC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Quercetin	E177_09_1_2_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_91_H7_CTAAGGTC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT137690	E177_09_1_2_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_92_H8_GAACAGGC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CEP-33779	E177_09_1_2_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_93_H9_GACAGTGC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Romidepsin (FK228, Depsipeptide)	E177_09_1_2_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_94_H10_GAGTTAGC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM XL019	E177_09_1_2_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_95_H11_GATGAATC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_09_1_2_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_96_H12_GCCAAGAC_1_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_10_1_2_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_1_A1_ACAAGCTA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Zebularine	E177_10_1_2_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_2_A2_AAACATCG_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM OG-L002	E177_10_1_2_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_3_A3_ACATTGGC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TMP269	E177_10_1_2_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_4_A4_ACCACTGT_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 39923 HCl	E177_10_1_2_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_5_A5_AACGTGAT_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Veliparib (ABT-888)	E177_10_1_2_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_6_A6_CGCTGATC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CX-6258 HCl	E177_10_1_2_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_7_A7_CAGATCTG_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 2,4-Pyridinedicarboxylic Acid	E177_10_1_2_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_8_A8_ATGCCTAA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ITSA-1	E177_10_1_2_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_9_A9_CTGTAGCC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AGK2	E177_10_1_2_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_10_A10_AGTACAAG_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Oxamflatin	E177_10_1_2_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_11_A11_CATCAAGT_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_10_1_2_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_12_A12_AGTGGTCA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_10_1_2_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_13_B1_AACAACCA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Deazaneplanocin A (DZNeP)	E177_10_1_2_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_14_B2_AACCGAGA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC-CBP30	E177_10_1_2_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_15_B3_AACGCTTA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ004777	E177_10_1_2_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_16_B4_AAGACGGA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SMI-4a	E177_10_1_2_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_17_B5_AAGGTACA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM FG-4592	E177_10_1_2_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_18_B6_ACACAGAA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BMN 673	E177_10_1_2_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_19_B7_ACAGCAGA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Garcinol	E177_10_1_2_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_20_B8_ACCTCCAA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine hemisulfate	E177_10_1_2_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_21_B9_ACGCTCGA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Salermide	E177_10_1_2_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_22_B10_ACGTATCA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Suramin 6Na	E177_10_1_2_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_23_B11_ACTATGCA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_10_1_2_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_24_B12_AGAGTCAA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_10_1_2_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_25_C1_AGATCGCA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ-6438	E177_10_1_2_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_26_C2_AGCAGGAA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MM-102	E177_10_1_2_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_27_C3_AGTCACTA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM OTX015	E177_10_1_2_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_28_C4_ATCCTGTA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX 01294	E177_10_1_2_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_29_C5_ATTGAGGA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Panobinostat (LBH589)	E177_10_1_2_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_30_C6_CAACCACA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ5676	E177_10_1_2_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_31_C7_CAAGACTA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Splitomicin	E177_10_1_2_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_32_C8_CAATGGAA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid	E177_10_1_2_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_33_C9_CACTTCGA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MC-1293	E177_10_1_2_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_34_C10_CAGCGTTA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-278	E177_10_1_2_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_35_C11_CATACCAA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_10_1_2_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_36_C12_CCAGTTCA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_10_1_2_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_37_D1_CCGAAGTA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM C646	E177_10_1_2_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_38_D2_CCGTGAGA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1027	E177_10_1_2_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_39_D3_CCTCCTGA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC669	E177_10_1_2_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_40_D4_CGAACTTA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UPF 1069	E177_10_1_2_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_41_D5_CGACTGGA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Trichostatin A (TSA)	E177_10_1_2_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_42_D6_CGCATACA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM GSK J4 HCl	E177_10_1_2_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_43_D7_CTCAATGA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-210	E177_10_1_2_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_44_D8_CTGAGCCA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nicotinamide	E177_10_1_2_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_45_D9_CTGGCATA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Anacardic acid	E177_10_1_2_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_46_D10_GAATCTGA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NCH-51	E177_10_1_2_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_47_D11_GACTAGTA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_10_1_2_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_48_D12_GAGCTGAA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_10_1_2_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_49_E1_GATAGACA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET-762	E177_10_1_2_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_50_E2_GCCACATA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RG2833 (RGFP109)	E177_10_1_2_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_51_E3_GCGAGTAA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ME0328	E177_10_1_2_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_52_E4_GCTAACGA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Scriptaid	E177_10_1_2_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_53_E5_GCTCGGTA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Vorinostat (SAHA, MK0683)	E177_10_1_2_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_54_E6_GGAGAACA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC 0946	E177_10_1_2_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_55_E7_GGTGCGAA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Apicidin	E177_10_1_2_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_56_E8_GTACGCAA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-266	E177_10_1_2_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_57_E9_GTCGTAGA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM B2	E177_10_1_2_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_58_E10_GTCTGTCA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NSC-3852	E177_10_1_2_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_59_E11_GTGTTCTA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_10_1_2_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_60_E12_TAGGATGA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_10_1_2_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_61_F1_TATCAGCA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RGFP966	E177_10_1_2_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_62_F2_TCCGTCTA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RVX-208	E177_10_1_2_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_63_F3_TCTTCACA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nexturastat A	E177_10_1_2_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_64_F4_TGAAGAGA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A	E177_10_1_2_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_65_F5_TGGAACAA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM VX-680 (Tozasertib, MK-0457)	E177_10_1_2_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_66_F6_TGGCTTCA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC1215	E177_10_1_2_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_67_F7_TGGTGGTA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Suberoyl bis-hydroxamic acid	E177_10_1_2_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_68_F8_TTCACGCA_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Piceatannol	E177_10_1_2_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_69_F9_AACTCACC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX-01294 3HCl	E177_10_1_2_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_70_F10_AAGAGATC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Aminoresveratrol sulfate	E177_10_1_2_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_71_F11_AAGGACAC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_10_1_2_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_72_F12_AATCCGTC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_10_1_2_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_73_G1_AATGTTGC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Bromosporine	E177_10_1_2_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_74_G2_ACACGACC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34 HCl	E177_10_1_2_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_75_G3_ACAGATTC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Filgotinib (GLPG0634)	E177_10_1_2_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_76_G4_AGATGTAC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Lomeguatrib	E177_10_1_2_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_77_G5_AGCACCTC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Entinostat (MS-275)	E177_10_1_2_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_78_G6_AGCCATGC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1208	E177_10_1_2_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_79_G7_AGGCTAAC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nullscript	E177_10_1_2_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_80_G8_ATAGCGAC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Fluoro-SAHA	E177_10_1_2_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_81_G9_ATCATTCC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Butyrolactone 3	E177_10_1_2_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_82_G10_ATTGGCTC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-281	E177_10_1_2_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_83_G11_CAAGGAGC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_10_1_2_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_84_G12_CACCTTAC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_10_1_2_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_85_H1_CCATCCTC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX1	E177_10_1_2_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_86_H2_CCGACAAC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CPI-203	E177_10_1_2_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_87_H3_CCTAATCC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Rocilinostat (ACY-1215)	E177_10_1_2_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_88_H4_CCTCTATC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Pacritinib (SB1518)	E177_10_1_2_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_89_H5_CGACACAC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Olaparib (AZD2281, Ku-0059436)	E177_10_1_2_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_90_H6_CGGATTGC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM (+)-JQ1	E177_10_1_2_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_91_H7_CTAAGGTC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Isonicotinamide	E177_10_1_2_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_92_H8_GAACAGGC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid hydroxamate	E177_10_1_2_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_93_H9_GACAGTGC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CTPB	E177_10_1_2_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_94_H10_GAGTTAGC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Triacetylresveratrol	E177_10_1_2_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_95_H11_GATGAATC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_10_1_2_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_96_H12_GCCAAGAC_1_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_11_1_3_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_1_A1_ACAAGCTA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Belinostat (PXD101)	E177_11_1_3_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_2_A2_AAACATCG_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Danusertib (PHA-739358)	E177_11_1_3_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_3_A3_ACATTGGC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SNS-314 Mesylate	E177_11_1_3_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_4_A4_ACCACTGT_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM JNJ-7706621	E177_11_1_3_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_5_A5_AACGTGAT_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT129202	E177_11_1_3_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_6_A6_CGCTGATC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-14361	E177_11_1_3_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_7_A7_CAGATCTG_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A HCl	E177_11_1_3_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_8_A8_ATGCCTAA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-907	E177_11_1_3_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_9_A9_CTGTAGCC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CI994 (Tacedinaline)	E177_11_1_3_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_10_A10_AGTACAAG_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Entacapone	E177_11_1_3_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_11_A11_CATCAAGT_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_11_1_3_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_12_A12_AGTGGTCA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_11_1_3_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_13_B1_AACAACCA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Iniparib (BSI-201)	E177_11_1_3_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_14_B2_AACCGAGA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mocetinostat (MGCD0103)	E177_11_1_3_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_15_B3_AACGCTTA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid sodium salt (Sodium valproate)	E177_11_1_3_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_16_B4_AAGACGGA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Ruxolitinib (INCB018424)	E177_11_1_3_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_17_B5_AAGGTACA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Hesperadin	E177_11_1_3_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_18_B6_ACACAGAA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM LY2784544	E177_11_1_3_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_19_B7_ACAGCAGA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NVP-BSK805 2HCl	E177_11_1_3_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_20_B8_ACCTCCAA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MK-5108 (VX-689)	E177_11_1_3_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_21_B9_ACGCTCGA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RG108	E177_11_1_3_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_22_B10_ACGTATCA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Sodium Phenylbutyrate	E177_11_1_3_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_23_B11_ACTATGCA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_11_1_3_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_24_B12_AGAGTCAA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_11_1_3_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_25_C1_AGATCGCA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-24781 (Abexinostat)	E177_11_1_3_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_26_C2_AGCAGGAA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SRT1720	E177_11_1_3_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_27_C3_AGTCACTA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CYC116	E177_11_1_3_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_28_C4_ATCCTGTA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Resveratrol	E177_11_1_3_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_29_C5_ATTGAGGA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EX 527 (Selisistat)	E177_11_1_3_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_30_C6_CAACCACA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1776 free base	E177_11_1_3_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_31_C7_CAAGACTA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101209	E177_11_1_3_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_32_C8_CAATGGAA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM M344	E177_11_1_3_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_33_C9_CACTTCGA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Baricitinib (LY3009104, INCB028050)	E177_11_1_3_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_34_C10_CAGCGTTA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine (2-PCPA) HCl	E177_11_1_3_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_35_C11_CATACCAA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_11_1_3_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_36_C12_CCAGTTCA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_11_1_3_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_37_D1_CCGAAGTA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM LAQ824 (Dacinostat)	E177_11_1_3_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_38_D2_CCGTGAGA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM INO-1001	E177_11_1_3_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_39_D3_CCTCCTGA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ENMD-2076	E177_11_1_3_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_40_D4_CGAACTTA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Droxinostat	E177_11_1_3_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_41_D5_CGACTGGA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Azacitidine	E177_11_1_3_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_42_D6_CGCATACA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZ 960	E177_11_1_3_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_43_D7_CTCAATGA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Resminostat	E177_11_1_3_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_44_D8_CTGAGCCA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET151 (GSK1210151A)	E177_11_1_3_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_45_D9_CTGGCATA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM WHI-P154	E177_11_1_3_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_46_D10_GAATCTGA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Aminobenzamide	E177_11_1_3_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_47_D11_GACTAGTA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_11_1_3_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_48_D12_GAGCTGAA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_11_1_3_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_49_E1_GATAGACA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Quisinostat (JNJ-26481585)	E177_11_1_3_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_50_E2_GCCACATA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Alisertib (MLN8237)	E177_11_1_3_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_51_E3_GCGAGTAA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-101	E177_11_1_3_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_52_E4_GCTAACGA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Aurora A Inhibitor I	E177_11_1_3_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_53_E5_GCTCGGTA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-34051	E177_11_1_3_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_54_E6_GGAGAACA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CYT387	E177_11_1_3_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_55_E7_GGTGCGAA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TAK-901	E177_11_1_3_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_56_E8_GTACGCAA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550,Tasocitinib)	E177_11_1_3_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_57_E9_GTCGTAGA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34	E177_11_1_3_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_58_E10_GTCTGTCA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Procainamide HCl	E177_11_1_3_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_59_E11_GTGTTCTA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_11_1_3_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_60_E12_TAGGATGA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_11_1_3_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_61_F1_TATCAGCA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Rucaparib (AG-014699,PF-01367338)	E177_11_1_3_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_62_F2_TCCGTCTA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AT9283	E177_11_1_3_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_63_F3_TCTTCACA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Decitabine	E177_11_1_3_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_64_F4_TGAAGAGA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PHA-680632	E177_11_1_3_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_65_F5_TGGAACAA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM KW-2449	E177_11_1_3_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_66_F6_TGGCTTCA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubacin	E177_11_1_3_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_67_F7_TGGTGGTA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AMG-900	E177_11_1_3_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_68_F8_TTCACGCA_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM WP1066	E177_11_1_3_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_69_F9_AACTCACC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM S-Ruxolitinib (INCB018424)	E177_11_1_3_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_70_F10_AAGAGATC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550) Citrate	E177_11_1_3_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_71_F11_AAGGACAC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_11_1_3_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_72_F12_AATCCGTC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_11_1_3_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_73_G1_AATGTTGC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MLN8054	E177_11_1_3_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_74_G2_ACACGACC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-490 (Tyrphostin B42)	E177_11_1_3_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_75_G3_ACAGATTC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PFI-1 (PF-6405761)	E177_11_1_3_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_76_G4_AGATGTAC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MC1568	E177_11_1_3_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_77_G5_AGCACCTC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1480	E177_11_1_3_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_78_G6_AGCCATGC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AR-42	E177_11_1_3_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_79_G7_AGGCTAAC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101348 (SAR302503)	E177_11_1_3_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_80_G8_ATAGCGAC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Sirtinol	E177_11_1_3_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_81_G9_ATCATTCC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX2	E177_11_1_3_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_82_G10_ATTGGCTC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD2461	E177_11_1_3_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_83_G11_CAAGGAGC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_11_1_3_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_84_G12_CACCTTAC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_11_1_3_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_85_H1_CCATCCTC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 447439	E177_11_1_3_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_86_H2_CCGACAAC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Barasertib (AZD1152-HQPA)	E177_11_1_3_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_87_H3_CCTAATCC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 2-Methoxyestradiol (2-MeOE2)	E177_11_1_3_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_88_H4_CCTCTATC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Pracinostat (SB939)	E177_11_1_3_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_89_H5_CGACACAC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Givinostat (ITF2357)	E177_11_1_3_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_90_H6_CGGATTGC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Quercetin	E177_11_1_3_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_91_H7_CTAAGGTC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT137690	E177_11_1_3_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_92_H8_GAACAGGC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CEP-33779	E177_11_1_3_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_93_H9_GACAGTGC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Romidepsin (FK228, Depsipeptide)	E177_11_1_3_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_94_H10_GAGTTAGC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM XL019	E177_11_1_3_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_95_H11_GATGAATC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_11_1_3_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_96_H12_GCCAAGAC_1_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_12_1_3_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_1_A1_ACAAGCTA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Zebularine	E177_12_1_3_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_2_A2_AAACATCG_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM OG-L002	E177_12_1_3_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_3_A3_ACATTGGC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TMP269	E177_12_1_3_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_4_A4_ACCACTGT_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 39923 HCl	E177_12_1_3_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_5_A5_AACGTGAT_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Veliparib (ABT-888)	E177_12_1_3_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_6_A6_CGCTGATC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CX-6258 HCl	E177_12_1_3_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_7_A7_CAGATCTG_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 2,4-Pyridinedicarboxylic Acid	E177_12_1_3_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_8_A8_ATGCCTAA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ITSA-1	E177_12_1_3_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_9_A9_CTGTAGCC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AGK2	E177_12_1_3_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_10_A10_AGTACAAG_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Oxamflatin	E177_12_1_3_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_11_A11_CATCAAGT_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_12_1_3_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_12_A12_AGTGGTCA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_12_1_3_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_13_B1_AACAACCA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Deazaneplanocin A (DZNeP)	E177_12_1_3_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_14_B2_AACCGAGA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC-CBP30	E177_12_1_3_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_15_B3_AACGCTTA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ004777	E177_12_1_3_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_16_B4_AAGACGGA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SMI-4a	E177_12_1_3_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_17_B5_AAGGTACA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM FG-4592	E177_12_1_3_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_18_B6_ACACAGAA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BMN 673	E177_12_1_3_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_19_B7_ACAGCAGA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Garcinol	E177_12_1_3_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_20_B8_ACCTCCAA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine hemisulfate	E177_12_1_3_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_21_B9_ACGCTCGA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Salermide	E177_12_1_3_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_22_B10_ACGTATCA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Suramin 6Na	E177_12_1_3_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_23_B11_ACTATGCA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_12_1_3_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_24_B12_AGAGTCAA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_12_1_3_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_25_C1_AGATCGCA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ-6438	E177_12_1_3_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_26_C2_AGCAGGAA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MM-102	E177_12_1_3_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_27_C3_AGTCACTA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM OTX015	E177_12_1_3_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_28_C4_ATCCTGTA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX 01294	E177_12_1_3_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_29_C5_ATTGAGGA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Panobinostat (LBH589)	E177_12_1_3_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_30_C6_CAACCACA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ5676	E177_12_1_3_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_31_C7_CAAGACTA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Splitomicin	E177_12_1_3_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_32_C8_CAATGGAA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid	E177_12_1_3_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_33_C9_CACTTCGA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MC-1293	E177_12_1_3_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_34_C10_CAGCGTTA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-278	E177_12_1_3_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_35_C11_CATACCAA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_12_1_3_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_36_C12_CCAGTTCA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_12_1_3_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_37_D1_CCGAAGTA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM C646	E177_12_1_3_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_38_D2_CCGTGAGA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1027	E177_12_1_3_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_39_D3_CCTCCTGA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC669	E177_12_1_3_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_40_D4_CGAACTTA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UPF 1069	E177_12_1_3_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_41_D5_CGACTGGA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Trichostatin A (TSA)	E177_12_1_3_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_42_D6_CGCATACA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM GSK J4 HCl	E177_12_1_3_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_43_D7_CTCAATGA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-210	E177_12_1_3_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_44_D8_CTGAGCCA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nicotinamide	E177_12_1_3_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_45_D9_CTGGCATA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Anacardic acid	E177_12_1_3_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_46_D10_GAATCTGA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NCH-51	E177_12_1_3_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_47_D11_GACTAGTA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_12_1_3_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_48_D12_GAGCTGAA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_12_1_3_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_49_E1_GATAGACA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET-762	E177_12_1_3_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_50_E2_GCCACATA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RG2833 (RGFP109)	E177_12_1_3_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_51_E3_GCGAGTAA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ME0328	E177_12_1_3_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_52_E4_GCTAACGA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Scriptaid	E177_12_1_3_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_53_E5_GCTCGGTA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Vorinostat (SAHA, MK0683)	E177_12_1_3_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_54_E6_GGAGAACA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC 0946	E177_12_1_3_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_55_E7_GGTGCGAA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Apicidin	E177_12_1_3_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_56_E8_GTACGCAA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-266	E177_12_1_3_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_57_E9_GTCGTAGA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM B2	E177_12_1_3_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_58_E10_GTCTGTCA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NSC-3852	E177_12_1_3_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_59_E11_GTGTTCTA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_12_1_3_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_60_E12_TAGGATGA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_12_1_3_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_61_F1_TATCAGCA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RGFP966	E177_12_1_3_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_62_F2_TCCGTCTA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RVX-208	E177_12_1_3_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_63_F3_TCTTCACA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nexturastat A	E177_12_1_3_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_64_F4_TGAAGAGA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A	E177_12_1_3_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_65_F5_TGGAACAA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM VX-680 (Tozasertib, MK-0457)	E177_12_1_3_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_66_F6_TGGCTTCA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC1215	E177_12_1_3_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_67_F7_TGGTGGTA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Suberoyl bis-hydroxamic acid	E177_12_1_3_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_68_F8_TTCACGCA_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Piceatannol	E177_12_1_3_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_69_F9_AACTCACC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX-01294 3HCl	E177_12_1_3_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_70_F10_AAGAGATC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Aminoresveratrol sulfate	E177_12_1_3_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_71_F11_AAGGACAC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_12_1_3_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_72_F12_AATCCGTC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_12_1_3_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_73_G1_AATGTTGC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Bromosporine	E177_12_1_3_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_74_G2_ACACGACC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34 HCl	E177_12_1_3_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_75_G3_ACAGATTC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Filgotinib (GLPG0634)	E177_12_1_3_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_76_G4_AGATGTAC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Lomeguatrib	E177_12_1_3_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_77_G5_AGCACCTC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Entinostat (MS-275)	E177_12_1_3_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_78_G6_AGCCATGC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1208	E177_12_1_3_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_79_G7_AGGCTAAC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nullscript	E177_12_1_3_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_80_G8_ATAGCGAC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Fluoro-SAHA	E177_12_1_3_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_81_G9_ATCATTCC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Butyrolactone 3	E177_12_1_3_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_82_G10_ATTGGCTC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-281	E177_12_1_3_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_83_G11_CAAGGAGC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_12_1_3_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_84_G12_CACCTTAC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_12_1_3_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_85_H1_CCATCCTC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX1	E177_12_1_3_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_86_H2_CCGACAAC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CPI-203	E177_12_1_3_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_87_H3_CCTAATCC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Rocilinostat (ACY-1215)	E177_12_1_3_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_88_H4_CCTCTATC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Pacritinib (SB1518)	E177_12_1_3_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_89_H5_CGACACAC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Olaparib (AZD2281, Ku-0059436)	E177_12_1_3_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_90_H6_CGGATTGC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM (+)-JQ1	E177_12_1_3_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_91_H7_CTAAGGTC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Isonicotinamide	E177_12_1_3_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_92_H8_GAACAGGC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid hydroxamate	E177_12_1_3_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_93_H9_GACAGTGC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CTPB	E177_12_1_3_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_94_H10_GAGTTAGC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Triacetylresveratrol	E177_12_1_3_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_95_H11_GATGAATC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_12_1_3_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_96_H12_GCCAAGAC_1_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_13_10_1_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_1_A1_ACAAGCTA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Belinostat (PXD101)	E177_13_10_1_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_2_A2_AAACATCG_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Danusertib (PHA-739358)	E177_13_10_1_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_3_A3_ACATTGGC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SNS-314 Mesylate	E177_13_10_1_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_4_A4_ACCACTGT_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM JNJ-7706621	E177_13_10_1_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_5_A5_AACGTGAT_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CCT129202	E177_13_10_1_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_6_A6_CGCTGATC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AG-14361	E177_13_10_1_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_7_A7_CAGATCTG_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubastatin A HCl	E177_13_10_1_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_8_A8_ATGCCTAA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CUDC-907	E177_13_10_1_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_9_A9_CTGTAGCC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CI994 (Tacedinaline)	E177_13_10_1_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_10_A10_AGTACAAG_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Entacapone	E177_13_10_1_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_11_A11_CATCAAGT_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_13_10_1_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_12_A12_AGTGGTCA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_13_10_1_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_13_B1_AACAACCA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Iniparib (BSI-201)	E177_13_10_1_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_14_B2_AACCGAGA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Mocetinostat (MGCD0103)	E177_13_10_1_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_15_B3_AACGCTTA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid sodium salt (Sodium valproate)	E177_13_10_1_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_16_B4_AAGACGGA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Ruxolitinib (INCB018424)	E177_13_10_1_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_17_B5_AAGGTACA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Hesperadin	E177_13_10_1_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_18_B6_ACACAGAA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM LY2784544	E177_13_10_1_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_19_B7_ACAGCAGA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM NVP-BSK805 2HCl	E177_13_10_1_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_20_B8_ACCTCCAA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MK-5108 (VX-689)	E177_13_10_1_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_21_B9_ACGCTCGA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RG108	E177_13_10_1_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_22_B10_ACGTATCA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Sodium Phenylbutyrate	E177_13_10_1_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_23_B11_ACTATGCA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_13_10_1_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_24_B12_AGAGTCAA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_13_10_1_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_25_C1_AGATCGCA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PCI-24781 (Abexinostat)	E177_13_10_1_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_26_C2_AGCAGGAA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SRT1720	E177_13_10_1_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_27_C3_AGTCACTA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CYC116	E177_13_10_1_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_28_C4_ATCCTGTA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Resveratrol	E177_13_10_1_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_29_C5_ATTGAGGA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EX 527 (Selisistat)	E177_13_10_1_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_30_C6_CAACCACA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGI-1776 free base	E177_13_10_1_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_31_C7_CAAGACTA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TG101209	E177_13_10_1_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_32_C8_CAATGGAA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM M344	E177_13_10_1_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_33_C9_CACTTCGA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Baricitinib (LY3009104, INCB028050)	E177_13_10_1_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_34_C10_CAGCGTTA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tranylcypromine (2-PCPA) HCl	E177_13_10_1_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_35_C11_CATACCAA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_13_10_1_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_36_C12_CCAGTTCA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_13_10_1_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_37_D1_CCGAAGTA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM LAQ824 (Dacinostat)	E177_13_10_1_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_38_D2_CCGTGAGA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM INO-1001	E177_13_10_1_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_39_D3_CCTCCTGA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ENMD-2076	E177_13_10_1_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_40_D4_CGAACTTA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Droxinostat	E177_13_10_1_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_41_D5_CGACTGGA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Azacitidine	E177_13_10_1_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_42_D6_CGCATACA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZ 960	E177_13_10_1_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_43_D7_CTCAATGA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Resminostat	E177_13_10_1_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_44_D8_CTGAGCCA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM I-BET151 (GSK1210151A)	E177_13_10_1_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_45_D9_CTGGCATA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM WHI-P154	E177_13_10_1_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_46_D10_GAATCTGA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 3-Aminobenzamide	E177_13_10_1_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_47_D11_GACTAGTA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_13_10_1_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_48_D12_GAGCTGAA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_13_10_1_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_49_E1_GATAGACA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Quisinostat (JNJ-26481585)	E177_13_10_1_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_50_E2_GCCACATA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Alisertib (MLN8237)	E177_13_10_1_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_51_E3_GCGAGTAA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CUDC-101	E177_13_10_1_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_52_E4_GCTAACGA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Aurora A Inhibitor I	E177_13_10_1_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_53_E5_GCTCGGTA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PCI-34051	E177_13_10_1_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_54_E6_GGAGAACA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CYT387	E177_13_10_1_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_55_E7_GGTGCGAA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TAK-901	E177_13_10_1_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_56_E8_GTACGCAA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tofacitinib (CP-690550,Tasocitinib)	E177_13_10_1_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_57_E9_GTCGTAGA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PJ34	E177_13_10_1_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_58_E10_GTCTGTCA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Procainamide HCl	E177_13_10_1_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_59_E11_GTGTTCTA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_13_10_1_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_60_E12_TAGGATGA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_13_10_1_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_61_F1_TATCAGCA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Rucaparib (AG-014699,PF-01367338)	E177_13_10_1_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_62_F2_TCCGTCTA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AT9283	E177_13_10_1_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_63_F3_TCTTCACA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Decitabine	E177_13_10_1_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_64_F4_TGAAGAGA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PHA-680632	E177_13_10_1_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_65_F5_TGGAACAA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM KW-2449	E177_13_10_1_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_66_F6_TGGCTTCA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubacin	E177_13_10_1_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_67_F7_TGGTGGTA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AMG-900	E177_13_10_1_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_68_F8_TTCACGCA_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM WP1066	E177_13_10_1_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_69_F9_AACTCACC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM S-Ruxolitinib (INCB018424)	E177_13_10_1_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_70_F10_AAGAGATC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tofacitinib (CP-690550) Citrate	E177_13_10_1_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_71_F11_AAGGACAC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_13_10_1_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_72_F12_AATCCGTC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_13_10_1_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_73_G1_AATGTTGC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MLN8054	E177_13_10_1_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_74_G2_ACACGACC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AG-490 (Tyrphostin B42)	E177_13_10_1_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_75_G3_ACAGATTC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PFI-1 (PF-6405761)	E177_13_10_1_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_76_G4_AGATGTAC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MC1568	E177_13_10_1_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_77_G5_AGCACCTC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD1480	E177_13_10_1_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_78_G6_AGCCATGC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AR-42	E177_13_10_1_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_79_G7_AGGCTAAC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TG101348 (SAR302503)	E177_13_10_1_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_80_G8_ATAGCGAC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Sirtinol	E177_13_10_1_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_81_G9_ATCATTCC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM IOX2	E177_13_10_1_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_82_G10_ATTGGCTC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD2461	E177_13_10_1_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_83_G11_CAAGGAGC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_13_10_1_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_84_G12_CACCTTAC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_13_10_1_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_85_H1_CCATCCTC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ZM 447439	E177_13_10_1_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_86_H2_CCGACAAC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Barasertib (AZD1152-HQPA)	E177_13_10_1_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_87_H3_CCTAATCC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 2-Methoxyestradiol (2-MeOE2)	E177_13_10_1_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_88_H4_CCTCTATC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Pracinostat (SB939)	E177_13_10_1_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_89_H5_CGACACAC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Givinostat (ITF2357)	E177_13_10_1_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_90_H6_CGGATTGC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Quercetin	E177_13_10_1_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_91_H7_CTAAGGTC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CCT137690	E177_13_10_1_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_92_H8_GAACAGGC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CEP-33779	E177_13_10_1_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_93_H9_GACAGTGC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Romidepsin (FK228, Depsipeptide)	E177_13_10_1_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_94_H10_GAGTTAGC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM XL019	E177_13_10_1_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_95_H11_GATGAATC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_13_10_1_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_96_H12_GCCAAGAC_10_1_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_14_10_1_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_1_A1_ACAAGCTA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Zebularine	E177_14_10_1_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_2_A2_AAACATCG_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM OG-L002	E177_14_10_1_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_3_A3_ACATTGGC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TMP269	E177_14_10_1_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_4_A4_ACCACTGT_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ZM 39923 HCl	E177_14_10_1_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_5_A5_AACGTGAT_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Veliparib (ABT-888)	E177_14_10_1_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_6_A6_CGCTGATC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CX-6258 HCl	E177_14_10_1_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_7_A7_CAGATCTG_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 2,4-Pyridinedicarboxylic Acid	E177_14_10_1_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_8_A8_ATGCCTAA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ITSA-1	E177_14_10_1_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_9_A9_CTGTAGCC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AGK2	E177_14_10_1_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_10_A10_AGTACAAG_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Oxamflatin	E177_14_10_1_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_11_A11_CATCAAGT_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_14_10_1_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_12_A12_AGTGGTCA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_14_10_1_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_13_B1_AACAACCA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 3-Deazaneplanocin A (DZNeP)	E177_14_10_1_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_14_B2_AACCGAGA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGC-CBP30	E177_14_10_1_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_15_B3_AACGCTTA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ004777	E177_14_10_1_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_16_B4_AAGACGGA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SMI-4a	E177_14_10_1_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_17_B5_AAGGTACA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM FG-4592	E177_14_10_1_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_18_B6_ACACAGAA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BMN 673	E177_14_10_1_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_19_B7_ACAGCAGA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Garcinol	E177_14_10_1_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_20_B8_ACCTCCAA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tranylcypromine hemisulfate	E177_14_10_1_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_21_B9_ACGCTCGA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Salermide	E177_14_10_1_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_22_B10_ACGTATCA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Suramin 6Na	E177_14_10_1_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_23_B11_ACTATGCA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_14_10_1_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_24_B12_AGAGTCAA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_14_10_1_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_25_C1_AGATCGCA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ-6438	E177_14_10_1_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_26_C2_AGCAGGAA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MM-102	E177_14_10_1_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_27_C3_AGTCACTA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM OTX015	E177_14_10_1_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_28_C4_ATCCTGTA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BIX 01294	E177_14_10_1_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_29_C5_ATTGAGGA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Panobinostat (LBH589)	E177_14_10_1_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_30_C6_CAACCACA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ5676	E177_14_10_1_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_31_C7_CAAGACTA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Splitomicin	E177_14_10_1_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_32_C8_CAATGGAA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid	E177_14_10_1_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_33_C9_CACTTCGA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MC-1293	E177_14_10_1_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_34_C10_CAGCGTTA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-278	E177_14_10_1_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_35_C11_CATACCAA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_14_10_1_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_36_C12_CCAGTTCA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_14_10_1_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_37_D1_CCGAAGTA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM C646	E177_14_10_1_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_38_D2_CCGTGAGA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGI-1027	E177_14_10_1_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_39_D3_CCTCCTGA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM UNC669	E177_14_10_1_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_40_D4_CGAACTTA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM UPF 1069	E177_14_10_1_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_41_D5_CGACTGGA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Trichostatin A (TSA)	E177_14_10_1_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_42_D6_CGCATACA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM GSK J4 HCl	E177_14_10_1_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_43_D7_CTCAATGA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-210	E177_14_10_1_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_44_D8_CTGAGCCA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nicotinamide	E177_14_10_1_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_45_D9_CTGGCATA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Anacardic acid	E177_14_10_1_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_46_D10_GAATCTGA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM NCH-51	E177_14_10_1_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_47_D11_GACTAGTA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_14_10_1_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_48_D12_GAGCTGAA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_14_10_1_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_49_E1_GATAGACA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM I-BET-762	E177_14_10_1_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_50_E2_GCCACATA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RG2833 (RGFP109)	E177_14_10_1_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_51_E3_GCGAGTAA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ME0328	E177_14_10_1_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_52_E4_GCTAACGA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Scriptaid	E177_14_10_1_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_53_E5_GCTCGGTA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Vorinostat (SAHA, MK0683)	E177_14_10_1_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_54_E6_GGAGAACA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGC 0946	E177_14_10_1_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_55_E7_GGTGCGAA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Apicidin	E177_14_10_1_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_56_E8_GTACGCAA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-266	E177_14_10_1_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_57_E9_GTCGTAGA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM B2	E177_14_10_1_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_58_E10_GTCTGTCA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM NSC-3852	E177_14_10_1_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_59_E11_GTGTTCTA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_14_10_1_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_60_E12_TAGGATGA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_14_10_1_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_61_F1_TATCAGCA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RGFP966	E177_14_10_1_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_62_F2_TCCGTCTA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RVX-208	E177_14_10_1_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_63_F3_TCTTCACA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nexturastat A	E177_14_10_1_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_64_F4_TGAAGAGA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubastatin A	E177_14_10_1_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_65_F5_TGGAACAA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM VX-680 (Tozasertib, MK-0457)	E177_14_10_1_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_66_F6_TGGCTTCA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM UNC1215	E177_14_10_1_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_67_F7_TGGTGGTA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Suberoyl bis-hydroxamic acid	E177_14_10_1_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_68_F8_TTCACGCA_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Piceatannol	E177_14_10_1_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_69_F9_AACTCACC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BIX-01294 3HCl	E177_14_10_1_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_70_F10_AAGAGATC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Aminoresveratrol sulfate	E177_14_10_1_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_71_F11_AAGGACAC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_14_10_1_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_72_F12_AATCCGTC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_14_10_1_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_73_G1_AATGTTGC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Bromosporine	E177_14_10_1_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_74_G2_ACACGACC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PJ34 HCl	E177_14_10_1_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_75_G3_ACAGATTC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Filgotinib (GLPG0634)	E177_14_10_1_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_76_G4_AGATGTAC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Lomeguatrib	E177_14_10_1_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_77_G5_AGCACCTC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Entinostat (MS-275)	E177_14_10_1_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_78_G6_AGCCATGC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD1208	E177_14_10_1_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_79_G7_AGGCTAAC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nullscript	E177_14_10_1_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_80_G8_ATAGCGAC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Fluoro-SAHA	E177_14_10_1_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_81_G9_ATCATTCC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Butyrolactone 3	E177_14_10_1_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_82_G10_ATTGGCTC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-281	E177_14_10_1_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_83_G11_CAAGGAGC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_14_10_1_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_84_G12_CACCTTAC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_14_10_1_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_85_H1_CCATCCTC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM IOX1	E177_14_10_1_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_86_H2_CCGACAAC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CPI-203	E177_14_10_1_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_87_H3_CCTAATCC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Rocilinostat (ACY-1215)	E177_14_10_1_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_88_H4_CCTCTATC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Pacritinib (SB1518)	E177_14_10_1_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_89_H5_CGACACAC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Olaparib (AZD2281, Ku-0059436)	E177_14_10_1_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_90_H6_CGGATTGC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM (+)-JQ1	E177_14_10_1_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_91_H7_CTAAGGTC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Isonicotinamide	E177_14_10_1_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_92_H8_GAACAGGC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid hydroxamate	E177_14_10_1_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_93_H9_GACAGTGC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CTPB	E177_14_10_1_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_94_H10_GAGTTAGC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Triacetylresveratrol	E177_14_10_1_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_95_H11_GATGAATC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_14_10_1_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_96_H12_GCCAAGAC_10_1_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_15_10_2_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_1_A1_ACAAGCTA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Belinostat (PXD101)	E177_15_10_2_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_2_A2_AAACATCG_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Danusertib (PHA-739358)	E177_15_10_2_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_3_A3_ACATTGGC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SNS-314 Mesylate	E177_15_10_2_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_4_A4_ACCACTGT_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM JNJ-7706621	E177_15_10_2_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_5_A5_AACGTGAT_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CCT129202	E177_15_10_2_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_6_A6_CGCTGATC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AG-14361	E177_15_10_2_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_7_A7_CAGATCTG_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubastatin A HCl	E177_15_10_2_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_8_A8_ATGCCTAA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CUDC-907	E177_15_10_2_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_9_A9_CTGTAGCC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CI994 (Tacedinaline)	E177_15_10_2_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_10_A10_AGTACAAG_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Entacapone	E177_15_10_2_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_11_A11_CATCAAGT_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_15_10_2_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_12_A12_AGTGGTCA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_15_10_2_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_13_B1_AACAACCA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Iniparib (BSI-201)	E177_15_10_2_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_14_B2_AACCGAGA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Mocetinostat (MGCD0103)	E177_15_10_2_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_15_B3_AACGCTTA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid sodium salt (Sodium valproate)	E177_15_10_2_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_16_B4_AAGACGGA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Ruxolitinib (INCB018424)	E177_15_10_2_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_17_B5_AAGGTACA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Hesperadin	E177_15_10_2_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_18_B6_ACACAGAA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM LY2784544	E177_15_10_2_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_19_B7_ACAGCAGA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM NVP-BSK805 2HCl	E177_15_10_2_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_20_B8_ACCTCCAA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MK-5108 (VX-689)	E177_15_10_2_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_21_B9_ACGCTCGA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RG108	E177_15_10_2_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_22_B10_ACGTATCA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Sodium Phenylbutyrate	E177_15_10_2_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_23_B11_ACTATGCA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_15_10_2_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_24_B12_AGAGTCAA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_15_10_2_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_25_C1_AGATCGCA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PCI-24781 (Abexinostat)	E177_15_10_2_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_26_C2_AGCAGGAA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SRT1720	E177_15_10_2_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_27_C3_AGTCACTA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CYC116	E177_15_10_2_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_28_C4_ATCCTGTA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Resveratrol	E177_15_10_2_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_29_C5_ATTGAGGA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EX 527 (Selisistat)	E177_15_10_2_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_30_C6_CAACCACA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGI-1776 free base	E177_15_10_2_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_31_C7_CAAGACTA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TG101209	E177_15_10_2_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_32_C8_CAATGGAA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM M344	E177_15_10_2_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_33_C9_CACTTCGA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Baricitinib (LY3009104, INCB028050)	E177_15_10_2_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_34_C10_CAGCGTTA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tranylcypromine (2-PCPA) HCl	E177_15_10_2_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_35_C11_CATACCAA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_15_10_2_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_36_C12_CCAGTTCA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_15_10_2_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_37_D1_CCGAAGTA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM LAQ824 (Dacinostat)	E177_15_10_2_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_38_D2_CCGTGAGA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM INO-1001	E177_15_10_2_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_39_D3_CCTCCTGA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ENMD-2076	E177_15_10_2_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_40_D4_CGAACTTA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Droxinostat	E177_15_10_2_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_41_D5_CGACTGGA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Azacitidine	E177_15_10_2_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_42_D6_CGCATACA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZ 960	E177_15_10_2_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_43_D7_CTCAATGA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Resminostat	E177_15_10_2_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_44_D8_CTGAGCCA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM I-BET151 (GSK1210151A)	E177_15_10_2_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_45_D9_CTGGCATA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM WHI-P154	E177_15_10_2_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_46_D10_GAATCTGA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 3-Aminobenzamide	E177_15_10_2_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_47_D11_GACTAGTA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_15_10_2_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_48_D12_GAGCTGAA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_15_10_2_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_49_E1_GATAGACA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Quisinostat (JNJ-26481585)	E177_15_10_2_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_50_E2_GCCACATA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Alisertib (MLN8237)	E177_15_10_2_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_51_E3_GCGAGTAA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CUDC-101	E177_15_10_2_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_52_E4_GCTAACGA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Aurora A Inhibitor I	E177_15_10_2_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_53_E5_GCTCGGTA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PCI-34051	E177_15_10_2_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_54_E6_GGAGAACA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CYT387	E177_15_10_2_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_55_E7_GGTGCGAA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TAK-901	E177_15_10_2_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_56_E8_GTACGCAA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tofacitinib (CP-690550,Tasocitinib)	E177_15_10_2_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_57_E9_GTCGTAGA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PJ34	E177_15_10_2_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_58_E10_GTCTGTCA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Procainamide HCl	E177_15_10_2_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_59_E11_GTGTTCTA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_15_10_2_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_60_E12_TAGGATGA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_15_10_2_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_61_F1_TATCAGCA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Rucaparib (AG-014699,PF-01367338)	E177_15_10_2_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_62_F2_TCCGTCTA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AT9283	E177_15_10_2_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_63_F3_TCTTCACA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Decitabine	E177_15_10_2_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_64_F4_TGAAGAGA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PHA-680632	E177_15_10_2_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_65_F5_TGGAACAA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM KW-2449	E177_15_10_2_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_66_F6_TGGCTTCA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubacin	E177_15_10_2_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_67_F7_TGGTGGTA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AMG-900	E177_15_10_2_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_68_F8_TTCACGCA_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM WP1066	E177_15_10_2_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_69_F9_AACTCACC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM S-Ruxolitinib (INCB018424)	E177_15_10_2_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_70_F10_AAGAGATC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tofacitinib (CP-690550) Citrate	E177_15_10_2_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_71_F11_AAGGACAC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_15_10_2_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_72_F12_AATCCGTC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_15_10_2_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_73_G1_AATGTTGC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MLN8054	E177_15_10_2_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_74_G2_ACACGACC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AG-490 (Tyrphostin B42)	E177_15_10_2_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_75_G3_ACAGATTC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PFI-1 (PF-6405761)	E177_15_10_2_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_76_G4_AGATGTAC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MC1568	E177_15_10_2_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_77_G5_AGCACCTC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD1480	E177_15_10_2_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_78_G6_AGCCATGC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AR-42	E177_15_10_2_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_79_G7_AGGCTAAC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TG101348 (SAR302503)	E177_15_10_2_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_80_G8_ATAGCGAC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Sirtinol	E177_15_10_2_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_81_G9_ATCATTCC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM IOX2	E177_15_10_2_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_82_G10_ATTGGCTC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD2461	E177_15_10_2_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_83_G11_CAAGGAGC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_15_10_2_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_84_G12_CACCTTAC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_15_10_2_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_85_H1_CCATCCTC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ZM 447439	E177_15_10_2_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_86_H2_CCGACAAC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Barasertib (AZD1152-HQPA)	E177_15_10_2_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_87_H3_CCTAATCC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 2-Methoxyestradiol (2-MeOE2)	E177_15_10_2_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_88_H4_CCTCTATC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Pracinostat (SB939)	E177_15_10_2_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_89_H5_CGACACAC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Givinostat (ITF2357)	E177_15_10_2_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_90_H6_CGGATTGC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Quercetin	E177_15_10_2_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_91_H7_CTAAGGTC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CCT137690	E177_15_10_2_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_92_H8_GAACAGGC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CEP-33779	E177_15_10_2_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_93_H9_GACAGTGC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Romidepsin (FK228, Depsipeptide)	E177_15_10_2_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_94_H10_GAGTTAGC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM XL019	E177_15_10_2_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_95_H11_GATGAATC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_15_10_2_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_96_H12_GCCAAGAC_10_2_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_16_10_2_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_1_A1_ACAAGCTA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Zebularine	E177_16_10_2_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_2_A2_AAACATCG_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM OG-L002	E177_16_10_2_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_3_A3_ACATTGGC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TMP269	E177_16_10_2_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_4_A4_ACCACTGT_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ZM 39923 HCl	E177_16_10_2_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_5_A5_AACGTGAT_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Veliparib (ABT-888)	E177_16_10_2_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_6_A6_CGCTGATC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CX-6258 HCl	E177_16_10_2_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_7_A7_CAGATCTG_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 2,4-Pyridinedicarboxylic Acid	E177_16_10_2_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_8_A8_ATGCCTAA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ITSA-1	E177_16_10_2_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_9_A9_CTGTAGCC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AGK2	E177_16_10_2_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_10_A10_AGTACAAG_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Oxamflatin	E177_16_10_2_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_11_A11_CATCAAGT_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_16_10_2_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_12_A12_AGTGGTCA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_16_10_2_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_13_B1_AACAACCA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 3-Deazaneplanocin A (DZNeP)	E177_16_10_2_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_14_B2_AACCGAGA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGC-CBP30	E177_16_10_2_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_15_B3_AACGCTTA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ004777	E177_16_10_2_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_16_B4_AAGACGGA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SMI-4a	E177_16_10_2_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_17_B5_AAGGTACA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM FG-4592	E177_16_10_2_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_18_B6_ACACAGAA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BMN 673	E177_16_10_2_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_19_B7_ACAGCAGA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Garcinol	E177_16_10_2_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_20_B8_ACCTCCAA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tranylcypromine hemisulfate	E177_16_10_2_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_21_B9_ACGCTCGA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Salermide	E177_16_10_2_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_22_B10_ACGTATCA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Suramin 6Na	E177_16_10_2_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_23_B11_ACTATGCA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_16_10_2_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_24_B12_AGAGTCAA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_16_10_2_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_25_C1_AGATCGCA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ-6438	E177_16_10_2_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_26_C2_AGCAGGAA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MM-102	E177_16_10_2_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_27_C3_AGTCACTA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM OTX015	E177_16_10_2_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_28_C4_ATCCTGTA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BIX 01294	E177_16_10_2_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_29_C5_ATTGAGGA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Panobinostat (LBH589)	E177_16_10_2_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_30_C6_CAACCACA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ5676	E177_16_10_2_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_31_C7_CAAGACTA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Splitomicin	E177_16_10_2_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_32_C8_CAATGGAA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid	E177_16_10_2_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_33_C9_CACTTCGA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MC-1293	E177_16_10_2_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_34_C10_CAGCGTTA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-278	E177_16_10_2_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_35_C11_CATACCAA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_16_10_2_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_36_C12_CCAGTTCA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_16_10_2_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_37_D1_CCGAAGTA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM C646	E177_16_10_2_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_38_D2_CCGTGAGA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGI-1027	E177_16_10_2_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_39_D3_CCTCCTGA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM UNC669	E177_16_10_2_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_40_D4_CGAACTTA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM UPF 1069	E177_16_10_2_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_41_D5_CGACTGGA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Trichostatin A (TSA)	E177_16_10_2_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_42_D6_CGCATACA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM GSK J4 HCl	E177_16_10_2_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_43_D7_CTCAATGA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-210	E177_16_10_2_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_44_D8_CTGAGCCA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nicotinamide	E177_16_10_2_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_45_D9_CTGGCATA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Anacardic acid	E177_16_10_2_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_46_D10_GAATCTGA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM NCH-51	E177_16_10_2_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_47_D11_GACTAGTA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_16_10_2_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_48_D12_GAGCTGAA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_16_10_2_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_49_E1_GATAGACA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM I-BET-762	E177_16_10_2_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_50_E2_GCCACATA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RG2833 (RGFP109)	E177_16_10_2_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_51_E3_GCGAGTAA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ME0328	E177_16_10_2_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_52_E4_GCTAACGA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Scriptaid	E177_16_10_2_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_53_E5_GCTCGGTA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Vorinostat (SAHA, MK0683)	E177_16_10_2_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_54_E6_GGAGAACA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGC 0946	E177_16_10_2_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_55_E7_GGTGCGAA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Apicidin	E177_16_10_2_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_56_E8_GTACGCAA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-266	E177_16_10_2_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_57_E9_GTCGTAGA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM B2	E177_16_10_2_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_58_E10_GTCTGTCA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM NSC-3852	E177_16_10_2_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_59_E11_GTGTTCTA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_16_10_2_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_60_E12_TAGGATGA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_16_10_2_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_61_F1_TATCAGCA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RGFP966	E177_16_10_2_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_62_F2_TCCGTCTA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RVX-208	E177_16_10_2_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_63_F3_TCTTCACA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nexturastat A	E177_16_10_2_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_64_F4_TGAAGAGA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubastatin A	E177_16_10_2_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_65_F5_TGGAACAA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM VX-680 (Tozasertib, MK-0457)	E177_16_10_2_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_66_F6_TGGCTTCA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM UNC1215	E177_16_10_2_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_67_F7_TGGTGGTA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Suberoyl bis-hydroxamic acid	E177_16_10_2_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_68_F8_TTCACGCA_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Piceatannol	E177_16_10_2_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_69_F9_AACTCACC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BIX-01294 3HCl	E177_16_10_2_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_70_F10_AAGAGATC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Aminoresveratrol sulfate	E177_16_10_2_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_71_F11_AAGGACAC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_16_10_2_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_72_F12_AATCCGTC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_16_10_2_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_73_G1_AATGTTGC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Bromosporine	E177_16_10_2_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_74_G2_ACACGACC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PJ34 HCl	E177_16_10_2_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_75_G3_ACAGATTC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Filgotinib (GLPG0634)	E177_16_10_2_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_76_G4_AGATGTAC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Lomeguatrib	E177_16_10_2_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_77_G5_AGCACCTC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Entinostat (MS-275)	E177_16_10_2_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_78_G6_AGCCATGC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD1208	E177_16_10_2_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_79_G7_AGGCTAAC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nullscript	E177_16_10_2_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_80_G8_ATAGCGAC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Fluoro-SAHA	E177_16_10_2_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_81_G9_ATCATTCC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Butyrolactone 3	E177_16_10_2_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_82_G10_ATTGGCTC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-281	E177_16_10_2_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_83_G11_CAAGGAGC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_16_10_2_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_84_G12_CACCTTAC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_16_10_2_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_85_H1_CCATCCTC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM IOX1	E177_16_10_2_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_86_H2_CCGACAAC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CPI-203	E177_16_10_2_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_87_H3_CCTAATCC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Rocilinostat (ACY-1215)	E177_16_10_2_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_88_H4_CCTCTATC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Pacritinib (SB1518)	E177_16_10_2_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_89_H5_CGACACAC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Olaparib (AZD2281, Ku-0059436)	E177_16_10_2_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_90_H6_CGGATTGC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM (+)-JQ1	E177_16_10_2_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_91_H7_CTAAGGTC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Isonicotinamide	E177_16_10_2_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_92_H8_GAACAGGC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid hydroxamate	E177_16_10_2_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_93_H9_GACAGTGC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CTPB	E177_16_10_2_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_94_H10_GAGTTAGC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Triacetylresveratrol	E177_16_10_2_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_95_H11_GATGAATC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_16_10_2_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_96_H12_GCCAAGAC_10_2_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_17_10_3_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_1_A1_ACAAGCTA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Belinostat (PXD101)	E177_17_10_3_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_2_A2_AAACATCG_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Danusertib (PHA-739358)	E177_17_10_3_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_3_A3_ACATTGGC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SNS-314 Mesylate	E177_17_10_3_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_4_A4_ACCACTGT_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM JNJ-7706621	E177_17_10_3_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_5_A5_AACGTGAT_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CCT129202	E177_17_10_3_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_6_A6_CGCTGATC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AG-14361	E177_17_10_3_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_7_A7_CAGATCTG_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubastatin A HCl	E177_17_10_3_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_8_A8_ATGCCTAA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CUDC-907	E177_17_10_3_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_9_A9_CTGTAGCC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CI994 (Tacedinaline)	E177_17_10_3_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_10_A10_AGTACAAG_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Entacapone	E177_17_10_3_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_11_A11_CATCAAGT_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_17_10_3_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_12_A12_AGTGGTCA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_17_10_3_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_13_B1_AACAACCA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Iniparib (BSI-201)	E177_17_10_3_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_14_B2_AACCGAGA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Mocetinostat (MGCD0103)	E177_17_10_3_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_15_B3_AACGCTTA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid sodium salt (Sodium valproate)	E177_17_10_3_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_16_B4_AAGACGGA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Ruxolitinib (INCB018424)	E177_17_10_3_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_17_B5_AAGGTACA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Hesperadin	E177_17_10_3_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_18_B6_ACACAGAA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM LY2784544	E177_17_10_3_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_19_B7_ACAGCAGA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM NVP-BSK805 2HCl	E177_17_10_3_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_20_B8_ACCTCCAA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MK-5108 (VX-689)	E177_17_10_3_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_21_B9_ACGCTCGA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RG108	E177_17_10_3_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_22_B10_ACGTATCA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Sodium Phenylbutyrate	E177_17_10_3_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_23_B11_ACTATGCA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_17_10_3_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_24_B12_AGAGTCAA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_17_10_3_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_25_C1_AGATCGCA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PCI-24781 (Abexinostat)	E177_17_10_3_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_26_C2_AGCAGGAA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SRT1720	E177_17_10_3_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_27_C3_AGTCACTA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CYC116	E177_17_10_3_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_28_C4_ATCCTGTA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Resveratrol	E177_17_10_3_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_29_C5_ATTGAGGA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EX 527 (Selisistat)	E177_17_10_3_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_30_C6_CAACCACA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGI-1776 free base	E177_17_10_3_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_31_C7_CAAGACTA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TG101209	E177_17_10_3_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_32_C8_CAATGGAA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM M344	E177_17_10_3_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_33_C9_CACTTCGA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Baricitinib (LY3009104, INCB028050)	E177_17_10_3_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_34_C10_CAGCGTTA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tranylcypromine (2-PCPA) HCl	E177_17_10_3_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_35_C11_CATACCAA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_17_10_3_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_36_C12_CCAGTTCA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_17_10_3_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_37_D1_CCGAAGTA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM LAQ824 (Dacinostat)	E177_17_10_3_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_38_D2_CCGTGAGA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM INO-1001	E177_17_10_3_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_39_D3_CCTCCTGA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ENMD-2076	E177_17_10_3_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_40_D4_CGAACTTA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Droxinostat	E177_17_10_3_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_41_D5_CGACTGGA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Azacitidine	E177_17_10_3_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_42_D6_CGCATACA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZ 960	E177_17_10_3_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_43_D7_CTCAATGA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Resminostat	E177_17_10_3_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_44_D8_CTGAGCCA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM I-BET151 (GSK1210151A)	E177_17_10_3_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_45_D9_CTGGCATA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM WHI-P154	E177_17_10_3_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_46_D10_GAATCTGA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 3-Aminobenzamide	E177_17_10_3_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_47_D11_GACTAGTA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_17_10_3_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_48_D12_GAGCTGAA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_17_10_3_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_49_E1_GATAGACA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Quisinostat (JNJ-26481585)	E177_17_10_3_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_50_E2_GCCACATA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Alisertib (MLN8237)	E177_17_10_3_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_51_E3_GCGAGTAA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CUDC-101	E177_17_10_3_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_52_E4_GCTAACGA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Aurora A Inhibitor I	E177_17_10_3_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_53_E5_GCTCGGTA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PCI-34051	E177_17_10_3_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_54_E6_GGAGAACA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CYT387	E177_17_10_3_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_55_E7_GGTGCGAA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TAK-901	E177_17_10_3_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_56_E8_GTACGCAA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tofacitinib (CP-690550,Tasocitinib)	E177_17_10_3_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_57_E9_GTCGTAGA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PJ34	E177_17_10_3_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_58_E10_GTCTGTCA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Procainamide HCl	E177_17_10_3_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_59_E11_GTGTTCTA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_17_10_3_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_60_E12_TAGGATGA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_17_10_3_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_61_F1_TATCAGCA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Rucaparib (AG-014699,PF-01367338)	E177_17_10_3_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_62_F2_TCCGTCTA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AT9283	E177_17_10_3_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_63_F3_TCTTCACA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Decitabine	E177_17_10_3_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_64_F4_TGAAGAGA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PHA-680632	E177_17_10_3_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_65_F5_TGGAACAA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM KW-2449	E177_17_10_3_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_66_F6_TGGCTTCA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubacin	E177_17_10_3_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_67_F7_TGGTGGTA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AMG-900	E177_17_10_3_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_68_F8_TTCACGCA_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM WP1066	E177_17_10_3_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_69_F9_AACTCACC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM S-Ruxolitinib (INCB018424)	E177_17_10_3_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_70_F10_AAGAGATC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tofacitinib (CP-690550) Citrate	E177_17_10_3_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_71_F11_AAGGACAC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_17_10_3_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_72_F12_AATCCGTC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_17_10_3_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_73_G1_AATGTTGC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MLN8054	E177_17_10_3_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_74_G2_ACACGACC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AG-490 (Tyrphostin B42)	E177_17_10_3_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_75_G3_ACAGATTC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PFI-1 (PF-6405761)	E177_17_10_3_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_76_G4_AGATGTAC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MC1568	E177_17_10_3_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_77_G5_AGCACCTC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD1480	E177_17_10_3_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_78_G6_AGCCATGC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AR-42	E177_17_10_3_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_79_G7_AGGCTAAC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TG101348 (SAR302503)	E177_17_10_3_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_80_G8_ATAGCGAC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Sirtinol	E177_17_10_3_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_81_G9_ATCATTCC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM IOX2	E177_17_10_3_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_82_G10_ATTGGCTC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD2461	E177_17_10_3_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_83_G11_CAAGGAGC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_17_10_3_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_84_G12_CACCTTAC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_17_10_3_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_85_H1_CCATCCTC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ZM 447439	E177_17_10_3_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_86_H2_CCGACAAC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Barasertib (AZD1152-HQPA)	E177_17_10_3_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_87_H3_CCTAATCC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 2-Methoxyestradiol (2-MeOE2)	E177_17_10_3_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_88_H4_CCTCTATC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Pracinostat (SB939)	E177_17_10_3_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_89_H5_CGACACAC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Givinostat (ITF2357)	E177_17_10_3_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_90_H6_CGGATTGC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Quercetin	E177_17_10_3_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_91_H7_CTAAGGTC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CCT137690	E177_17_10_3_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_92_H8_GAACAGGC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CEP-33779	E177_17_10_3_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_93_H9_GACAGTGC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Romidepsin (FK228, Depsipeptide)	E177_17_10_3_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_94_H10_GAGTTAGC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM XL019	E177_17_10_3_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_95_H11_GATGAATC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_17_10_3_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_96_H12_GCCAAGAC_10_3_1_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_18_10_3_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_1_A1_ACAAGCTA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Zebularine	E177_18_10_3_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_2_A2_AAACATCG_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM OG-L002	E177_18_10_3_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_3_A3_ACATTGGC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM TMP269	E177_18_10_3_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_4_A4_ACCACTGT_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ZM 39923 HCl	E177_18_10_3_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_5_A5_AACGTGAT_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Veliparib (ABT-888)	E177_18_10_3_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_6_A6_CGCTGATC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CX-6258 HCl	E177_18_10_3_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_7_A7_CAGATCTG_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 2,4-Pyridinedicarboxylic Acid	E177_18_10_3_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_8_A8_ATGCCTAA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ITSA-1	E177_18_10_3_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_9_A9_CTGTAGCC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AGK2	E177_18_10_3_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_10_A10_AGTACAAG_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Oxamflatin	E177_18_10_3_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_11_A11_CATCAAGT_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_18_10_3_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_12_A12_AGTGGTCA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_18_10_3_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_13_B1_AACAACCA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM 3-Deazaneplanocin A (DZNeP)	E177_18_10_3_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_14_B2_AACCGAGA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGC-CBP30	E177_18_10_3_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_15_B3_AACGCTTA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ004777	E177_18_10_3_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_16_B4_AAGACGGA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SMI-4a	E177_18_10_3_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_17_B5_AAGGTACA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM FG-4592	E177_18_10_3_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_18_B6_ACACAGAA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BMN 673	E177_18_10_3_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_19_B7_ACAGCAGA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Garcinol	E177_18_10_3_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_20_B8_ACCTCCAA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tranylcypromine hemisulfate	E177_18_10_3_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_21_B9_ACGCTCGA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Salermide	E177_18_10_3_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_22_B10_ACGTATCA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Suramin 6Na	E177_18_10_3_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_23_B11_ACTATGCA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_18_10_3_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_24_B12_AGAGTCAA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_18_10_3_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_25_C1_AGATCGCA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ-6438	E177_18_10_3_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_26_C2_AGCAGGAA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MM-102	E177_18_10_3_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_27_C3_AGTCACTA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM OTX015	E177_18_10_3_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_28_C4_ATCCTGTA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BIX 01294	E177_18_10_3_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_29_C5_ATTGAGGA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Panobinostat (LBH589)	E177_18_10_3_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_30_C6_CAACCACA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ5676	E177_18_10_3_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_31_C7_CAAGACTA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Splitomicin	E177_18_10_3_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_32_C8_CAATGGAA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid	E177_18_10_3_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_33_C9_CACTTCGA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM MC-1293	E177_18_10_3_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_34_C10_CAGCGTTA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-278	E177_18_10_3_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_35_C11_CATACCAA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_18_10_3_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_36_C12_CCAGTTCA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_18_10_3_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_37_D1_CCGAAGTA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM C646	E177_18_10_3_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_38_D2_CCGTGAGA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGI-1027	E177_18_10_3_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_39_D3_CCTCCTGA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM UNC669	E177_18_10_3_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_40_D4_CGAACTTA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM UPF 1069	E177_18_10_3_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_41_D5_CGACTGGA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Trichostatin A (TSA)	E177_18_10_3_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_42_D6_CGCATACA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM GSK J4 HCl	E177_18_10_3_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_43_D7_CTCAATGA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-210	E177_18_10_3_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_44_D8_CTGAGCCA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nicotinamide	E177_18_10_3_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_45_D9_CTGGCATA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Anacardic acid	E177_18_10_3_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_46_D10_GAATCTGA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM NCH-51	E177_18_10_3_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_47_D11_GACTAGTA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_18_10_3_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_48_D12_GAGCTGAA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_18_10_3_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_49_E1_GATAGACA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM I-BET-762	E177_18_10_3_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_50_E2_GCCACATA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RG2833 (RGFP109)	E177_18_10_3_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_51_E3_GCGAGTAA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM ME0328	E177_18_10_3_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_52_E4_GCTAACGA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Scriptaid	E177_18_10_3_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_53_E5_GCTCGGTA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Vorinostat (SAHA, MK0683)	E177_18_10_3_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_54_E6_GGAGAACA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGC 0946	E177_18_10_3_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_55_E7_GGTGCGAA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Apicidin	E177_18_10_3_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_56_E8_GTACGCAA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-266	E177_18_10_3_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_57_E9_GTCGTAGA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM B2	E177_18_10_3_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_58_E10_GTCTGTCA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM NSC-3852	E177_18_10_3_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_59_E11_GTGTTCTA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E177_18_10_3_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_60_E12_TAGGATGA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_18_10_3_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_61_F1_TATCAGCA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RGFP966	E177_18_10_3_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_62_F2_TCCGTCTA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM RVX-208	E177_18_10_3_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_63_F3_TCTTCACA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nexturastat A	E177_18_10_3_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_64_F4_TGAAGAGA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubastatin A	E177_18_10_3_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_65_F5_TGGAACAA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM VX-680 (Tozasertib, MK-0457)	E177_18_10_3_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_66_F6_TGGCTTCA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM UNC1215	E177_18_10_3_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_67_F7_TGGTGGTA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Suberoyl bis-hydroxamic acid	E177_18_10_3_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_68_F8_TTCACGCA_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Piceatannol	E177_18_10_3_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_69_F9_AACTCACC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BIX-01294 3HCl	E177_18_10_3_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_70_F10_AAGAGATC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Aminoresveratrol sulfate	E177_18_10_3_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_71_F11_AAGGACAC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E177_18_10_3_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_72_F12_AATCCGTC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_18_10_3_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_73_G1_AATGTTGC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Bromosporine	E177_18_10_3_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_74_G2_ACACGACC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM PJ34 HCl	E177_18_10_3_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_75_G3_ACAGATTC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Filgotinib (GLPG0634)	E177_18_10_3_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_76_G4_AGATGTAC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Lomeguatrib	E177_18_10_3_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_77_G5_AGCACCTC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Entinostat (MS-275)	E177_18_10_3_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_78_G6_AGCCATGC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD1208	E177_18_10_3_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_79_G7_AGGCTAAC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nullscript	E177_18_10_3_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_80_G8_ATAGCGAC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Fluoro-SAHA	E177_18_10_3_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_81_G9_ATCATTCC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Butyrolactone 3	E177_18_10_3_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_82_G10_ATTGGCTC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-281	E177_18_10_3_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_83_G11_CAAGGAGC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E177_18_10_3_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_84_G12_CACCTTAC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_18_10_3_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_85_H1_CCATCCTC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM IOX1	E177_18_10_3_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_86_H2_CCGACAAC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CPI-203	E177_18_10_3_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_87_H3_CCTAATCC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Rocilinostat (ACY-1215)	E177_18_10_3_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_88_H4_CCTCTATC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Pacritinib (SB1518)	E177_18_10_3_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_89_H5_CGACACAC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Olaparib (AZD2281, Ku-0059436)	E177_18_10_3_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_90_H6_CGGATTGC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM (+)-JQ1	E177_18_10_3_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_91_H7_CTAAGGTC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Isonicotinamide	E177_18_10_3_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_92_H8_GAACAGGC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid hydroxamate	E177_18_10_3_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_93_H9_GACAGTGC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM CTPB	E177_18_10_3_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_94_H10_GAGTTAGC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 10 uM Triacetylresveratrol	E177_18_10_3_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 10 µM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_95_H11_GATGAATC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E177_18_10_3_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	Illumina MiSeq	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	5280_96_H12_GCCAAGAC_10_3_2_R1.fq.gz
K562 ddCas9 RSTP2 pools treated with DMSO	HDACi_rep1_E1650_A_RSTP2_pools_LBR2_DMSO_-_72_run1	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen in position treated with  DMSO	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP pools treated with Vorinostat or DMSO (equal volume), 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6543_3_HDACi_rep1_E1650_A_RSTP2_LBR2_DMSO_AACGCTTA_S4_R1_001.fastq.gz
K562 ddCas9 RSTP2 pools treated with Vorinostat	HDACi_rep1_E1650_A_RSTP2_pools_LBR2_Vorinostat_-_72_run1	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen in position treated with  Vorinostat	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP pools treated with Vorinostat or DMSO (equal volume), 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6543_4_HDACi_rep1_E1650_A_RSTP2_LBR2_Vorinostat_AAGACGGA_S8_R1_001.fastq.gz
K562 ddCas9 RSTP2 pools treated with DMSO	HDACi_rep1_E1650_B_RSTP2_pools_LBR2_DMSO_-_72_run1	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen in position treated with  DMSO	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP pools treated with Vorinostat or DMSO (equal volume), 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6543_7_HDACi_rep1_E1650_B_RSTP2_LBR2_DMSO_ACAGCAGA_S12_R1_001.fastq.gz
K562 ddCas9 RSTP2 pools treated with Vorinostat	HDACi_rep1_E1650_B_RSTP2_pools_LBR2_Vorinostat_-_72_run1	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen in position treated with  Vorinostat	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP pools treated with Vorinostat or DMSO (equal volume), 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6543_8_HDACi_rep1_E1650_B_RSTP2_LBR2_Vorinostat_ACCTCCAA_S14_R1_001.fastq.gz
K562 ddCas9 RSTP2 pools treated with DMSO	HDACi_rep2_E1650_A_RSTP2_pools_LBR2_DMSO_-_72_run1	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen in position treated with  DMSO	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP pools treated with Vorinostat or DMSO (equal volume), 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6543_11_HDACi_rep2_E1650_A_RSTP2_LBR2_DMSO_ACTATGCA_S18_R1_001.fastq.gz
K562 ddCas9 RSTP2 pools treated with Vorinostat	HDACi_rep2_E1650_A_RSTP2_pools_LBR2_Vorinostat_-_72_run1	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen in position treated with  Vorinostat	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP pools treated with Vorinostat or DMSO (equal volume), 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6543_12_HDACi_rep2_E1650_A_RSTP2_LBR2_Vorinostat_AGAGTCAA_S17_R1_001.fastq.gz
K562 ddCas9 RSTP2 pools treated with DMSO	HDACi_rep2_E1650_B_RSTP2_pools_LBR2_DMSO_-_72_run1	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen in position treated with  DMSO	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP pools treated with Vorinostat or DMSO (equal volume), 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6543_15_HDACi_rep2_E1650_B_RSTP2_LBR2_DMSO_AGTCACTA_S16_R1_001.fastq.gz
K562 ddCas9 RSTP2 pools treated with Vorinostat	HDACi_rep2_E1650_B_RSTP2_pools_LBR2_Vorinostat_-_72_run1	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen in position treated with  Vorinostat	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP pools treated with Vorinostat or DMSO (equal volume), 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6543_16_HDACi_rep2_E1650_B_RSTP2_LBR2_Vorinostat_ATCCTGTA_S6_R1_001.fastq.gz
K562 ddCas9 RSTP2 pools treated with DMSO	HDACi_rep3_E1650_A_RSTP2_pools_LBR2_DMSO_-_72_run1	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen in position treated with  DMSO	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP pools treated with Vorinostat or DMSO (equal volume), 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6543_19_HDACi_rep3_E1650_A_RSTP2_LBR2_DMSO_CAAGACTA_S20_R1_001.fastq.gz
K562 ddCas9 RSTP2 pools treated with Vorinostat	HDACi_rep3_E1650_A_RSTP2_pools_LBR2_Vorinostat_-_72_run1	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen in position treated with  Vorinostat	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP pools treated with Vorinostat or DMSO (equal volume), 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6543_20_HDACi_rep3_E1650_A_RSTP2_LBR2_Vorinostat_CAATGGAA_S15_R1_001.fastq.gz
K562 ddCas9 RSTP2 pools treated with DMSO	HDACi_rep3_E1650_B_RSTP2_pools_LBR2_DMSO_-_72_run1	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen in position treated with  DMSO	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP pools treated with Vorinostat or DMSO (equal volume), 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6543_23_HDACi_rep3_E1650_B_RSTP2_LBR2_DMSO_CATACCAA_S23_R1_001.fastq.gz
K562 ddCas9 RSTP2 pools treated with Vorinostat	HDACi_rep3_E1650_B_RSTP2_pools_LBR2_Vorinostat_-_72_run1	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen in position treated with  Vorinostat	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP pools treated with Vorinostat or DMSO (equal volume), 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6543_24_HDACi_rep3_E1650_B_RSTP2_LBR2_Vorinostat_CCAGTTCA_S24_R1_001.fastq.gz
